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SUMMARY 127 
Phosphoribosyl diphosphate (PRPP) is an important intermediate in cellular 128 
metabolism. PRPP, synthesized by PRPP synthase: ribose 5-phosphate + ATP → 129 
PRPP + AMP, is ubiquitously found in living organisms, and is used in substitution 130 
reactions with the formation of glycosidic bonds. PRPP is utilized in the biosynthesis 131 
of purine and pyrimidine nucleotides, the amino acids histidine and tryptophan, the 132 
co-factors NAD and tetrahydromethanopterin, arabinosyl monophosphodecaprenol 133 
and certain aminoglycoside antibiotics. The participation of PRPP in each of these 134 
metabolic pathways is reviewed. Central to the metabolism of PRPP is PRPP 135 
synthase, which has been studied from all kingdoms of life by classical mechanistic 136 
procedures. The results of these analyses are unified with recent progress in molecular 137 
enzymology and the elucidation of the three-dimensional structure of PRPP synthases 138 
from eubacteria, archaea, and humans. Structure and mechanism of catalysis of the 139 
five diphosphoryltransferases are compared, as are those of selected enzymes of 140 
diphosphoryltransfer, phosphoryltransfer and nucleotidyltransfer reactions. PRPP is 141 
used as a substrate by a large number phosphoribosyltransferases. The protein 142 
structure and reaction mechanism of these phosphoribosyltransferases vary and 143 
demonstrate the versatility of PRPP as an intermediate in cellular physiology. PRPP 144 
synthases appears to originate from a phosphoribosyltransferase during evolution as 145 
demonstrated by phylogenetic analysis. PRPP furthermore is an effector molecule of 146 
purine and pyrimidine nucleotide biosynthesis either by binding to PurR or PyrR 147 
regulatory proteins or as allosteric activator of carbamoylphosphate synthetase. 148 
Genetic analysis have disclosed a number of mutants altered in the PRPP synthase-149 
specifying-genes in humans as well as bacterial species. 150 
 151 
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INTRODUCTION 152 
The compound 5-phospho-D-ribosyl-α-1-diphosphate (PRPP) is an important 153 
metabolite required in the biosynthesis of purine and pyrimidine nucleotides, the 154 
amino acids histidine and tryptophan, and the co-factors NAD and NADP (1-3). 155 
Furthermore, PRPP is utilized in the biosynthesis of methanopterin in certain archaeal 156 
species (4), and in the biosynthesis of polyprenylphosphate-pentoses in 157 
Mycobacterium tuberculosis (5). By far, the most abundant class of reactions using 158 
PRPP as a substrate results in the formation of N-glycosidic bonds, whereas a few 159 
reactions result in the formation of O- and C-glycosidic bonds. Kornberg and co-160 
workers discovered PRPP in the mid 1950s, while searching for a reaction that 161 
converted orotate to uridylate as well as the enzymes catalyzing these reactions (6, 7). 162 
The enzyme catalyzing the synthesis of PRPP, PRPP synthase (ATP:D-ribose 5-163 
phosphate diphosphotransferase, EC 2.7.6.1) is ubiquitous among free living 164 
organisms. Thus, only certain obligate intracellular parasites such as some Chlamydia 165 
and Rickettsia species lack a gene encoding PRPP synthase. Therefore, in general an 166 
organism contains at least one gene specifying PRPP synthase. A few bacterial 167 
species contain more than one prs gene. In contrast, many eukaryotic organisms 168 
contain more than one PRPP synthase-specifying gene. The yeasts Saccharomyces 169 
cerevisiae and Schizosaccharomyces pombe appear to contain five and three PRPP 170 
synthase orthologs, respectively (8-10), mammals (humans and rat) contain three 171 
PRPP synthase-encoding genes (11-13), and the plants Spinacea oleracea and 172 
Arabidopsis thaliana contain four and five PRPP synthase genes, respectively (14-173 
16). 174 
 Although prs is believed to be an essential gene (17), a number of prs mutants 175 
have been isolated, primarily in Escherichia coli and Salmonella enterica serovar 176 
 9
Typhimurium, that are conditional or specify mutant variants of PRPP synthase with 177 
altered enzymatic properties. Additionally, a few knockout mutations (Δprs) have 178 
been constructed in vitro. Insertion of these Δprs alleles into strains with a specific 179 
genetic background revealed that an organism can be viable in the absence of PRPP 180 
synthase activity. Also, a number of naturally occurring variant PRPP synthases have 181 
been identified among patients with gout or uric acid overproduction (18). 182 
 The present review deals with all aspects of PRPP metabolism with emphasis on 183 
biochemical, genetic and physiological aspects of PRPP synthase and the utilization 184 
of PRPP in biosynthesis, primarily in microorganisms. The elucidation of high-185 
resolution structures of PRPP synthase from a number of organisms makes this review 186 
timely. Previously, a few reviews have been published on PRPP synthase of microbial 187 
(1, 19), and of mammalian origin (18, 20). These reviews are complemented by the 188 
present. 189 
 Sequence analysis was performed with BLAST (21), the program packages of the 190 
Integrated Microbial Genomes web-site (http://img.jgi.doe.gov/) (22), and the 191 
National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/) (23), 192 
whereas amino acid sequence analysis and alignments were performed with Multalin 193 
(http://multalin.toulouse.inra.fr/multalin/) and DNA Strider (24, 25). Figures of three-194 
dimensional structures were prepared with the Pymol Molecular Viewer 195 
(http://www.pymol.org) (26). 196 
 197 
CHEMISTRY OF PRPP 198 
PRPP is synthesized by transfer, in a single step, of the β,γ-diphosphoryl group of 199 
ATP to the C-1 hydroxyl of α-D-ribosyl 5-phosphate with the simultaneous formation 200 
of AMP by the following deceptively simple reaction: ribose 5-phosphate + ATP → 201 
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PRPP + AMP (Fig. 1). The reaction is catalyzed by PRPP synthase (6, 7), encoded by 202 
a prs, prsA or PRPS gene (13, 27, 28). PRPP may be regarded as an activated form of 203 
ribose 5-phosphate. Essentially all of the reactions utilizing PRPP as a substrate are 204 
substitutions, where usually nitrogen-containing aromatic bases replace the 205 
diphosphoryl group with simultaneous inversion of configuration at C1 of the ribosyl 206 
moiety (Fig. 1). In the majority of these reactions a ribonucleoside 5’-monophosphate 207 
is formed. Thus, ”all” that has happened in reactions such as those shown in Fig. 1 is 208 
an attachment of the nitrogenous compound to the ribosyl moiety and the formation of 209 
diphosphate (PPi). PPi, i.e. phosphoric acid anhydride with a high negative free energy 210 
of hydrolysis, in turn is hydrolyzed to phosphate (Pi), which makes the 211 
phosphoribosyl transfer reaction thermodynamically irreversible. 212 
 Immediately after its discovery, it was noted that PRPP was a stable compound as 213 
long as it was stored in the cold at neutral pH, whereas acidic or basic conditions and 214 
heating readily decomposed the compound. Divalent ions such as Mg2+, Mn2+ and 215 
Ba2+ encouraged decomposition. The degradation of PRPP, presumably by hydrolysis, 216 
appears to follow either of three pathways: (a) PRPP + H2O → ribose 5-phosphate + 217 
PPi, (b) PRPP + H2O → 5-phosphoribosyl 1,2-cyclic phosphate + Pi (6, 7, 29), or (c) 218 
PRPP + H2O → ribosyl 1,5-cyclic phosphate + PPi with (a) and (b) representing the 219 
major pathways (30, 31). Degradation through pathway (b) may furthermore continue 220 
according to the scheme 5-phosphoribosyl 1,2-cyclic phosphate → ribosyl 1-221 
phosphate → ribose (32). The binding of divalent ions to PRPP is conveniently 222 
measured by 31P nuclear magnetic resonance, and revealed that Mg2+ binds to both the 223 
5-phosphate and the 1-diphosphate moieties of PRPP (33). 224 
 The standard free energy (ΔG°’) for the hydrolysis of PRPP (PRPP + H2O → 225 
ribose 5-phosphate + PPi) has been calculated as approximately -35 kJ mol-1. This 226 
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value should be compared to -47 kJ mol-1 for the hydrolysis of the α,β-227 
phosphoanhydride bond of ATP (34). Consistently, the equilibrium constant for the 228 
diphosphoryltransfer reaction of PRPP synthase was determined as 29 (35). 229 
 In spite of the lability of PRPP, procedures have been developed for the 230 
quantitative isolation of the compound. These include extraction of PRPP from cells 231 
with cold formic acid (36-38), cold perchloric acid (39), or boiling followed by 232 
immediate cooling (40), followed by chromatography or phosphoribosyltransferase-233 
catalyzed conversion of PRPP to ribonucleoside 5’-monophospate. 234 
 A chemically stable analog of PRPP has been synthesized for use as ligand to 235 
various PRPP-binding proteins: 1-α-diphosphoryl-2,3-α-dihydroxy-4-β-cyclopentane-236 
methanol 5-phosphate (cPRPP) (41, 42). Although an inhibitor of PRPP synthase 237 
activity, the compound has proven valuable as a PRPP analog in X-ray analyses of 238 
PRPP synthase. 239 
 240 
BIOSYNTHESIS OF PRPP 241 
PRPP synthase and Phosphoribosyl Bisphosphate Phosphokinase 242 
The synthesis of PRPP is catalyzed by two enzymes, PRPP synthase and 243 
phosphoribosyl bisphosphate phosphokinase. On a quantitative basis, PRPP synthase 244 
is by far the most important. Phosphoribosyl bisphosphate phosphokinase is a 245 
component of the phosphonate catabolic pathway, and is present only in cells that 246 
thrive on phosphonate as Pi source. We shall deal first with PRPP synthase, and with 247 
phosphoribosyl bisphosphate phosphokinase in a later section. 248 
 249 
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Alignment of the amino acid sequences from a variety of organisms revealed a high 251 
similarity among PRPP synthases. For example, the overall identity of PRPP synthase 252 
amino acid sequences of E. coli and humans is 47% (20), that of PRPP synthases of E. 253 
coli and the Gram-positive organism Bacillus subtilis is 51% (43). In addition, a 15-254 
amino acid sequence is highly conserved among PRPP synthase and adenine 255 
phosphoribosyltransferase (44, 45). The latter enzyme catalyzes the reaction adenine 256 
+ PRPP → AMP + PPi. This 15-amino acid sequence of adenine 257 
phosphoribosyltransferase was designated the PRPP binding site, and later, the ribose 258 
5-phosphate binding loop in PRPP synthase. Subsequently, studies of cDNA libraries 259 
of the plants S. oleracea and A. thaliana revealed the presence of four genes that 260 
specify PRPP synthase. Two of these enzymes (isozyme 1 and 2) had primary 261 
structures similar to those of E. coli and humans, whereas two (isozyme 3 and 4) had 262 
primary structures quite different from those of E. coli and humans. The amino acid 263 
sequence identity of S. oleracea isozyme 1 and 2 is 88% and that of isozyme 3 and 4 264 
is 75%. In contrast, the amino acid sequence identity of isozyme 1 or 2 to isozymes 3 265 
or 4 is modest, 22 to 25%. This deviation of amino acid sequence identity of S. 266 
oleracea PRPP synthase isozymes 3 and 4 from isozymes 1 and 2 and other 267 
“classical” PRPP synthases was also reflected in their physico-chemical properties, as 268 
further described below. It was therefore suggested that two different classes of PRPP 269 
synthases exist, class I and II (46, 47). Additionally, PRPP synthases of archaeal 270 
origin show low amino acid sequence identity with class I or class II PRPP synthases. 271 
Thus, the amino acid sequence identity of B. subtilis and the thermophilic, 272 
methanogenic archaeon Methanocaldococcus jannaschii, the thermoacidophilic 273 
archaeon Sulfolobus solfataricus or the thermoacidophilic, facultatively anaerobic, 274 
organotrophic archeaon Thermoplasma volcanium PRPP synthases is 26 to 28%. 275 
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Analysis of PRPP synthase of M. jannaschii revealed biochemical properties that 276 
appeared to be a mixture of the properties of class I and II PRPP synthases, and it was 277 
suggested to belong to a novel class III PRPP synthases (48). In the present review we 278 
shall instead designate these class III enzymes as “archaeal PRPP synthases”. An 279 
alignment of representatives of PRPP synthases of class I (B. subtilis), class II (S. 280 
oleracea isozyme 4), and archaea (M. jannaschii) is shown in Fig. 2. Overall, 36 281 
amino acid residues are identical among the three sequences, i.e. an amino acid 282 
sequence identity of 13% or less. The inclusion of additional 26 conserved amino acid 283 
residues results in a similarity of approximately 21%. As we shall see below, the 284 
conservation of amino acid residues identified as responsible for catalysis is very 285 
high, whereas amino acid residues involved in allosteric regulation of activity of B. 286 
subtilis PRPP synthase are non-conserved among the three classes, consistent with the 287 
fact that only class I PRPP synthases are allosterically regulated. 288 
 289 
Class I PRPP Synthases 290 
The classical PRPP synthases, i.e. class I, are by far the most widely phylogenetically 291 
distributed PRPP synthases. These enzymes contain approximately 315 amino acid 292 
residues. PRPP synthase of the bacterial species S. enterica, E. coli and B. subtilis, as 293 
well as those of humans and rat are the best studied PRPP synthases. Among the class 294 
I enzymes, B. subtilis and E. coli PRPP synthase and human PRPP synthase isozyme 295 
1 have been crystallized and high-resolution structures have been determined (49-52). 296 
A three-dimensional structure has been determined also of PRPP synthase from the 297 
Gram-negative bacterium Burkholderia (Pseudomonas) pseudomallei strain 1710b 298 
(PDB code 3dah) (53). However, there are no biochemical data available for the latter 299 
enzyme. The crystal forms of PRPP synthase from the various organisms are 300 
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summarized in Table 1. Some kinetic properties of PRPP synthases of various 301 
organisms are listed in Table 2. 302 
 Eubacterial PRPP synthases. In this section we shall treat the properties of 303 
PRPP synthase of the bacterial species B. subtilis, S. enterica, E. coli, and M. 304 
tuberculosis. Among these, a three-dimensional structure has been determined of B. 305 
subtilis and E. coli PRPP synthase. The biochemical properties of B. subtilis PRPP 306 
synthase is much less studied compared to those of S. enterica and E. coli PRPP 307 
synthases. The latter two enzymes are identical except for two conservative amino 308 
acid substitutions (E. coli PRPP synthase serines 278 and 283 are threonine and 309 
alanine, respectively, in the S. enterica enzyme). Furthermore, the S. enterica and E. 310 
coli PRPP synthase amino acid sequences are 51% identical to that of the B. subtilis 311 
enzyme. It is therefore very likely that these three enzymes share identical three-312 
dimensional structures, biochemical properties, and catalytic and regulatory 313 
properties. Below, we describe the three-dimensional structure of B. subtilis PRPP 314 
synthase and, when applicable, the properties of the enterobacterial PRPP synthases 315 
with reference to the structure of the B. subtilis enzyme. 316 
 (i) Three-dimensional structure of B. subtilis PRPP synthase. A number of 317 
crystal forms, summarized in Table 1, are utilized for the description of the structure 318 
and catalysis of B. subtilis PRPP synthase. (a) SO42--PRPP synthase with one SO42- 319 
bound in the active site at the position corresponding to the phosphate moiety of 320 
ribose 5-phosphate and a second SO42- bound at the position corresponding to the the 321 
α-phosphate of ADP at the regulatory site. No divalent metal ion was present, and the 322 
structure was determind to 2.3 Å resolution (PDB code 1dkr); (b) mADP-PRPP 323 
synthase with methylene ADP bound at the active and regulatory sites. As before no 324 
divalent metal ion was present, and the structure was determined to 2.2 Å resolution 325 
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(PDB code 1dku) (49); (c) Cd2+-PRPP synthase with two Cd2+ bound in each 326 
monomer presumably at the two Mg2+ sites, AMP bound at the active site, and SO42- 327 
bound in place of the phosphate moiety at the ribose 5-phosphate site. The structure 328 
was resolved to 2.8 Å resolution (PDB code 1ibs) (50); (d) AlF3-PRPP synthase. This 329 
crystal form contained in the active site an analog of ATP pieced together by three 330 
molecules: (i) AMP representing the AMP moiety of ATP, (ii) AlF3 with Al3+ 331 
representing the β-phosphorus and the three F- representing the three oxygens of ATP, 332 
and (iii) a second AMP molecule whose phosphate represented the γ-phosphate of 333 
ATP. The remaining adenosyl moiety of the latter AMP molecule protruded into an 334 
“empty space” between two subunits. Furthermore, the crystal form contained two 335 
Mg2+ (one ligated to the “triphosphate chain”), one ribose 5-phosphate at the active 336 
site and one SO42- located at the position of the α-phosphate of ADP in the allosteric 337 
site. This structure was resolved to 2.8 Å resolution. Altogether this complex is 338 
thought to resemble the transition state of PRPP synthase; (e) mADP/R5P-PRPP 339 
synthase with one methylene ADP representing the ADP moiety of ATP as well one 340 
ribose 5-phosphate in the active site, two Mg2+ and one SO42 representing the α-341 
phosphate of ADP at the allosteric site in each monomer. This structure was resolved 342 
to 2.1 Å (54). The structure of the active site is described in more detail including 343 
stereo views in the forthcoming section “Mechanism of Catalysis”. Two additional 344 
crystal forms (GDP-PRPP synthase and mGDP-PRPP synthase) have been 345 
determined and have been particularly useful in elucidating the mechanism of 346 
allosteric regulation and will be further described below. 347 
 (a) Tertiary structure. The PRPP synthase monomer is composed of two domains 348 
in a head to tail arrangement. The tertiary structures of the two domains are 349 
remarkably similar, although the amino acid sequence identity of the two domains 350 
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(amino acid residues 1 to 150 and 152 to 292) is only 11% with additional 10% 351 
similar amino acid residues. Thus, the similarity in tertiary structure of the two 352 
domains is not at all predictable from their primary structure. Each domain possesses 353 
an α/β structure with a five-stranded parallel β-sheet at the center surrounded by four 354 
α-helices as well as one 310-helix in the N-terminal domain (Fig. 3A). Additionally, 355 
short antiparallel β-sheets, designated flag regions, flank both domains. This structure 356 
resembles that of type I phosphoribosyltransferases. It is likely, therefore, that type I 357 
phosphoribosyltransferases and PRPP synthase originate from the same ancestral 358 
gene, and that “modern” PRPP synthases may have evolved from duplication of that 359 
ancestral gene of half the size of the contemporary prs gene (54). 360 
 A number of regions along the amino acid sequence have been highlighted on the 361 
basis of their functions. These are called the regulatory flexible loop (Tyr97-Thr113), 362 
the diphosphate (PP) loop (Asp174-Gly177), the catalytic flexible loop (Lys197-363 
Met208) the ribose 5-phosphate binding loop (previously called the PRPP binding 364 
site) (Gly216-Thr231) (49, 50, 54) (Fig. 2). 365 
 There are two types of subunit interactions in PRPP synthase. First, interactions 366 
of the α3N and α4N helices of the N-terminal domain result in the formation of a bent 367 
head to head arrangement of two subunits, referred to as the bent dimer (Fig. 3B). The 368 
relevent amino acid residues involved in this interaction are Asn69, Glu70, Ile 72, 369 
Met73, Leu76, Ile77 (α3N) and Leu116 and Leu120 (α4N), many of which are highly 370 
conserved and listed in Table 3 (left-hand column). Second, a subunit is aligned in a 371 
parallel manner with a neighboring subunit in an arrangement involving residues from 372 
both the N- and the C-terminal domains (Fig. 3B). These interactions include 373 
hydrophobic interactions and salt bridges of the α1C helix and the flag region of the 374 
C-terminal domain as well as interactions of the 310 helices and salt bridges of the N-375 
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terminal domain. Important residues in the formation of this type of dimer, referred to 376 
hereafter as the parallel dimer, are Lys115, Gln138, Ile139, Phe142, Asp144, Val178, 377 
Asp186, Ile192, Ala193, Ile194, Arg198 and Val211 and are listed in Table 3 (left-378 
hand column) (49). The two types of subunit interactions are shown in Fig. 3B, and it 379 
is easy to see how this “trimer” may be formally assembled to the hexameric, 380 
propeller like structure shown in Fig. 3C. The enzyme, thus, consist of a trimer of 381 
dimers with all of the N-terminal domains forming an inner circle and the C-terminal 382 
domains forming the propeller blades at the outside resulting in a three-fold symmetry 383 
axis with perpendicular two-fold axes (49). 384 
 (b) The active site. The active site must accommodate the substrates ribose 5-385 
phosphate and MgATP. In addition, an overwhelming volume of research data has 386 
shown that an additional so-called free Mg2+ is required for activity, because maximal 387 
activity is only obtained when Mg2+ is added to the reaction in excess of the MgATP 388 
concentration with both bacterial (35, 45, 55-58), and mammalian PRPP synthases 389 
(59, 60). Furthermore, most PRPP synthases may accept other divalent metalions in 390 
place of Mg2+, and, thus, Mg2+ may be regarded as a pseudosubstrate (45, 56, 58, 61). 391 
In contrast, Ca2+ is an inhibitor of PRPP synthase activity, even in the presence of 392 
Mg2+ (45). In the crystal structure one Mg2+ (the MG1 site) coordinates to Asp174, a 393 
highly conserved residue of the C-terminal domain, to the oxygens of the hydroxyls of 394 
C1, C2 and C3 of ribose 5-phosphate, to an oxygen of the γ-phosphate of ATP and to 395 
a water molecule, which forms hydrogen bonds to Asp174 and Asp223. This Mg2+ 396 
thus ligates to both of the substrates. A second Mg2+ (MG2) coordinates to His135 of 397 
the N-terminal domain, to oxygens of the α-, β- and γ-phosphates of ATP and to two 398 
water molecules, which form hydrogen bonds to the side chains of Asp103 and 399 
Arg104 and the carbonyl oxygen of Arg101. The effect of this intricate binding is a 400 
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perfect alignment of ribose 5-phosphate and ATP for an in-line attack of the hydroxyl 401 
of C1 of ribose 5-phosphate at the β-phosphorus of ATP (54), as described in detail in 402 
the section “Mechanism of Catalysis”. 403 
 As described above, the two active site Mg2+ ligate to Asp174 of the C-terminal 404 
domain and His135 of the N-terminal domain. Similarly, the ATP binding site is 405 
located at the interface of the N- and C-terminal domains of each subunit, but with 406 
contributions of amino acid residues of the N-terminal domain of a neighbor subunit 407 
of the parallel dimer, for example, subunit A and subunit D (Fig. 3B). The specific 408 
amino acid residues that are important in the binding of ATP in B. subtilis PRPP 409 
synthase are listed in Table S1 (left-hand column). In contrast, the ribose 5-phosphate 410 
binding site is located within the C-terminal domain and is formed exclusively by 411 
amino acid residues of this domain. A subset of amino acid residues of the ribose 5-412 
phosphate binding site, Gly216-Thr231, have been shown to directly interact with the 413 
hydroxyls 2 and 3 (Asp223 and Asp224), or the phosphate moiety (Asp227, Thr228, 414 
Ala229, Thr2321 and Ile232) (50, 54), also listed in Table S1 (left-hand column). 415 
 Chemical modification studies have confirmed the importance of some of the 416 
amino acid residues mentioned above. Thus, chemical modification of S. enterica 417 
PRPP synthase with 5’-(4-fluorosulfonylbenzoyl)adenosine completely inactivated 418 
the enzyme in a one to one molar ratio. ATP protected the enzyme against 419 
inactivation, and the site of modification was His130, which corresponds to His135 in 420 
B. subtilis PRPP synthase (62), providing evidence for the importance of this residue. 421 
Similarly, affinity labelling of E. coli PRPP synthase has been performed with the 422 
ATP analog 2’,3’-dialdehyde ATP. Three lysine residues were labeled, Lys181, 423 
Lys193 and Lys230. Only Lys193 is conserved and corresponds to Lys197 of B. 424 
subtilis PRPP synthase (63). As we shall see, this Lys197 residue plays a very 425 
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important role in the catalysis of PRPP synthase. Chemical modification with 426 
sulfhydryl reagents has been reported to cause inactivation of PRPP synthase that is 427 
protected by the presence of ATP and Pi (64, 65), but cysteine residues have not been 428 
identified from the structural studies to be important in catalysis, which suggests that 429 
these treatments resulted in nonspecific inactivation of the enzyme.. 430 
 The geometry of the two Mg2+ binding sites confirms a wealth of information on 431 
the binding properties of divalent cations to PRPP synthases of particularly S. enterica 432 
and E. coli. Firstly, kinetic analysis of the S. enterica enzyme revealed the binding of 433 
both MgATP and free, i.e. enzyme-bound, Mg2+ (56). It was proposed that the 434 
enzyme-bound Mg2+ ligates to the α-phosphate of ATP, provided to the enzyme as 435 
β,γ-MgATP (58, 66). However, according to the crystal structure of B. subtilis PRPP 436 
synthase, the true substrate of the enzyme is the α,β,γ-tridentate complex of MgATP, 437 
which is consistent with the MG2 site described above. Additionally, analysis of E. 438 
coli PRPP synthase altered in the ribose 5-phosphate binding site (Asp220Glu, 439 
Asp220Phe and Asp221Ala) revealed that the effects on the values for Vapp and KM for 440 
ribose 5-phosphate were dependent on the divalent cation present suggesting that the 441 
binding of ribose 5-phosphate also occurs by interaction with Mg2+ (61), which is 442 
consistent with the MG1 site described above. The crystal structure furthermore 443 
completes nuclear magnetic resonance analyses that attempted to elucidate the 444 
conformation of ATP at the active site of S. enterica PRPP synthase. Thus, 445 
paramagnetic line broadening of the C-1 proton or of 31P of ribose 5-phosphate by 446 
Cr(III) bound to ATP as the exchange-stable αsβsγ-tridentate complex estimated the 447 
distances from the Cr atom (and presumably Mg2+) to the two atoms as 6.7 to 8.0 Å. 448 
This is consistent with proximity of the ribose 5-phosphate C1 hydroxyl and the β-449 
phosphorus of ATP to the enzyme-bound divalent cation (67). 450 
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 Steady state kinetic analysis of the inhibition of S. enterica or E. coli PRPP 451 
synthase by substrate analogs revealed an ordered Bi-Bi mechanism with binding of 452 
Mg2+ first followed by MgATP and then ribose 5-phosphate (41, 56, 57). The ordered 453 
kinetic mechanism was further confirmed by equilibrium dialysis. Thus, radioactive 454 
ATP and the inactive analog α,β-methylene ATP bound well to the free enzyme with 455 
dissociation constants in the micromolar range, whereas ribose 5-phosphate binding 456 
could not be detected unless α,β-methylene ATP was also included (68). Kinetic 457 
parameters of PRPP synthases from various bacilli and enteric organisms are listed in 458 
Table 2. 459 
 (c) The allosteric site. In addition to the crystal forms SO42--PRPP synthase and 460 
mADP-PRPP synthase described above, two additional crystal forms have been useful 461 
in elucidating the structure of the allosteric site. (f) GDP-PRPP synthase (with four 462 
Mg2+, one Ca2+, one GDP, one GTP, two α,β-methylene ATP and two ribose 5-463 
phosphates bound per assymetric unit) resolved to 1.8 Å resolution; (g) mGDP-PRPP 464 
synthase (with five Mg2+, one methylene GDP, three α,β-methylene ATP and two 465 
ribose 5-phosphate bound per assymetric unit) resolved to 1.9 Å resolution (54). The 466 
allosteric site of B. subtilis PRPP synthase is composed of amino acid residues 467 
contributed by three subunits such as A, B and D (Fig. 3B) (49). The amino acid 468 
residues involved in the binding of the β-phosphate and the adenyl moiety of ADP are 469 
provided by subunit D (Ser52, Arg54, Ala85 and Ser86) and subunit B (Ser310, 470 
Val311, Ser312 and Phe315). Subunit B also provides amino acids for the so-called 471 
hydrophobic pocket (Leu134, Ile139, Gln140, Asp148 and His149). Finally, subunit 472 
A contains the regulatory flexible loop (Lys105, Ala106, Arg107, Ser108 and 473 
Arg109) (49, 54). These amino acid residues are listed in Table S2. A stereo view of 474 
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the allosteric site is shown in Fig. 4. We shall return to the mechanism of allosteric 475 
regulation below in the section “Regulation of PRPP Synthase Activity”. 476 
 In general, the activity of class I PRPP synthases is regulated by the presence of 477 
ribonucleoside diphosphates, primarily ADP, which inhibits the enzyme in 478 
competition with ATP as well as by binding to a second, allosteric site. In some cases 479 
GDP is also an inhibitor, although GDP only binds to the allosteric site. Thus, a dual 480 
mechanism, competitive and allosteric inhibition, appears to control the activity of 481 
class I PRPP synthases. The complex inhibition pattern by ADP of the enzyme from 482 
S. enterica has been studied in particular detail. Kinetic analysis revealed that ADP 483 
competes with ATP at subsaturating ribose 5-phosphate concentrations, and that ADP 484 
causes substrate inhibition by ribose 5-phosphate due to the binding at a site different 485 
from the active site (69). Direct binding was demonstrated by equlibrium dialysis. 486 
Thus, in the absence of ribose 5-phosphate ADP binds to the same site as ATP, 487 
whereas in the presence of ribose 5-phosphate, ADP binds to two sites per monomer 488 
(68). Presumably, these are the active and allosteric sites, respectively. Similarly, 489 
PRPP synthases from E. coli (45), B. subtilis, and mammalian sources have been 490 
shown to be subject to allosteric regulation by ADP, the enzymes from B. subtilis, 491 
Bacillus caldolyticus, and mammals are also inhibited by GDP (55, 70-72). 492 
 As metioned above, the activity of class I PRPP synthases requires the presence 493 
of Pi. In some cases sulfate may substitute for Pi although a ten-fold higher 494 
concentration of sulfate is required (49, 71, 73). Removal of Pi from E. coli and S. 495 
enterica PRPP synthase causes irrevisible inactivation or aggregation (35, 45, 74), 496 
although the presence of MgATP or MgPRPP stabilizes the enzyme from E. coli or S. 497 
enterica, respectively (35, 75). B. subtilis and mammalian PRPP synthases are stable 498 
but inactive upon Pi-removal (49, 71, 73). Indeed, Pi and ADP have been shown to 499 
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compete for the same binding site in B. subtilis and human PRPP synthases, with Pi 500 
acting as an allosteric activator and ADP an allosteric inhibitor. Thus, certain mutant 501 
variants of PRPP synthase desensitized in inhibition by ribonucleoside diphosphates 502 
are reciprocally activated at lower concentrations of Pi (72), and the antitumor agent 503 
aminopyrimidopyrimidine ribonucleoside 5’-phosphate binds to the allosteric site of 504 
human PRPP synthase isozyme 1 and 2. The concentration needed for half-maximal 505 
binding increases with increasing Pi concentrations (76). Finally, a sulfate ion was 506 
found in the B. subtilis SO42--PRPP synthase structure. Superimposition of the SO42--507 
PRPP synthase and mADP-PRPP structures revealed that the sulfate ion was located 508 
similarly to the β-phosphate of the methylene ADP molecule of the regulatory or 509 
allosteric ADP binding site (49). Altogether, the data demonstrate that Pi and ADP 510 
compete for binding to the same site. Steady state kinetic analysis revealed that Pi 511 
binds randomly to E. coli PRPP synthase, i.e. either before or after the ordered 512 
binding of Mg2+, MgATP and ribose 5-phosphate. Similarly, ADP may bind to PRPP 513 
synthase in a random fashion, however, with significantly different rate constants 514 
constituting the equlibria, so that the pathway where Mg2+, MgATP and ribose 5-515 
phosphate bind in the absence of Pi is much slower than when Pi is bound first. This 516 
phenomenon provokes what is termed kinetic cooperativity and thus the sigmoid 517 
saturation curves frequently obtained for Pi activation with class I PRPP synthases 518 
(75). 519 
 As expected from the 51% identity of the amino acid sequences of B. subtilis and 520 
E. coli PRPP synthases, the amino acid residues involved in the formation of dimers 521 
as well as the the active site and the allosteric site (Tables 3, S1 and S2) are highly 522 
conserved.. The identity of this subset of amino acids is 61%. These data are 523 
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furthermore confirmed by analysis of the three-dimensional structure of E. coli PRPP 524 
synthase (52). 525 
 (ii) M. tuberculosis PRPP synthase. Some attention has been devoted to studies 526 
of PRPP synthase of M. tuberculosis in searching for possible targets for drug 527 
treatment of tuberculosis. Three research groups have characterized this enzyme (77-528 
79). All three groups agree that the quaternary structure of the active enzyme is a 529 
hexamer, and that allosteric inhibition is exhibited by the ribonucleoside diphosphates 530 
ADP and GDP, whereas there is some disagreement about the kinetic properties 531 
(Table 2). In addition, one research group established GTP, UTP and CTP as 532 
diphosphoryl donors with kcat/KM values of 3.8, 3.0 and 2.5 M-1 s-1, respectively, 533 
compared to the value 26 M-1 s-1 for ATP (78). Interestingly, analytical 534 
utracentrifugation revealed that the apo-enzyme existed as a trimer as well as a 535 
hexamer. The presence of ADP greatly shifted the oligomeric state toward the 536 
hexamer, whereas the presence of ATP had no effect on the oligomerization state 537 
(79). A comparison of the amino acid residues involved in dimer formation, bent as 538 
well as parallel dimers, of M. tuberculosis and B. subtilis PRPP synthases is shown in 539 
Table 3. It is evident that essentially all of the amino acids involved in dimer 540 
formation of B. subtilis PRPP synthase are retained in the M. tuberculosis enzyme. 541 
Additionally, a comparison of the amino acid residues involved in the binding of the 542 
substrates MgATP, ribose 5-phosphate and Mg2+ of the two enzymes reveals a high 543 
degree of conservation as does a comparison of the amino acid residues involved in 544 
the formation of the allosteric site between the two enzymes. All of these data are 545 
consistent with the identification of the M. tuberculosis enzyme as a class I PRPP 546 
synthase. The amino acids involved in the binding of GTP and the pyrimidine 547 
ribonucleoside 5’-triphosphates CTP and UTP as substrates for PRPP synthase have 548 
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not been mapped, so the propensity of M. tuberculosis PRPP synthase to utilize these 549 
latter ribonucleoside 5’-triphosphates remains unexplained. Other class I PRPP 550 
synthases do not utilize GTP, CTP or UTP. 551 
 (iii) Other bacterial PRPP synthases. Although most prokaryotic species 552 
contain a single gene encoding PRPP synthase, the genomes of almost 100 species 553 
have been annotated as containing two PRPP synthase orthologs. Biochemical data 554 
for PRPP synthase are available for only a few of these organisms. One of these is 555 
Lactococcus lactis, which contains two PRPP synthase-encoding orthologs, prsA and 556 
prsB, and for which some physiologic data excist. The two genes are separated by 557 
approximately 300 kBp. The sequence identities of the prsA- and prsB-specified 558 
amino acid sequences with that of B. subtilis PRPP synthase are 65 % (L. lactis PrsA), 559 
and 52% (L. lactis PrsB), whereas the amino acid sequence identity between the the 560 
two L. lactis Prs sequences is 49 %. Comparison of amino acid sequence of L. lactis 561 
prsA- and prsB-specified gene products and the established active site amino acid 562 
residues of B. subtilis PRPP synthase reveals that PrsA and B. subtilis PRPP synthase 563 
are nearly identical, whereas in PrsB the amino acid residues of the catalytic flexible 564 
loop vary considerably from those of B. subtilis PRPP synthase. Specifically, the 565 
catalytically important Lys197 and Arg199 residues of B. subtilis PRPP synthase are 566 
replaced by Tyr198 and Asp200 in L. lactis PrsB (Table S3). Complementation 567 
analysis revealed that L. lactis prsA complements an E. coli prs allele, whereas prsB 568 
does not, which demonstrate that prsA encodes a functional PRPP synthase. The 569 
function of the prsB gene product remains to be established (P. Bennedsen and J. M., 570 
The Technical University of Denmark, unpublished results). 571 
 A few bacterial species have three annotated PRPP synthase orthologs. In 572 
Roseiflexus castenholzii (DSM 13941) one amino acid sequence has a histidine 573 
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residue corresponding to B. subtilis Arg199 as well as additional six amino acid 574 
residues in the catalytic flexible loop, and 43% amino acid sequence identity with B. 575 
subtilis PRPP synthase. The other two amino acid sequences have 42 and 51% amino 576 
acid sequence identity with B. subtilis PRPP synthase. Similarly, in Sphingobium 577 
japonicum strain UT26S one sequence has an aspartate at the position of the B. 578 
subtilis Lys197 and there is a nine amino acid-insertion in the catalytic flexible loop. 579 
In Pseudomonas stutzeri strain A 1501 the amino acid sequence identity with B. 580 
subtilis PRPP synthase varies between 23 and 49%, in Clostridium beijerinckii strain 581 
NCIMB 8052 these values are 27 and 62%, whereas in Rhodoferax ferrireducens 582 
strain T118 these values are 24 and 54%. No biochemical studies of any of these 583 
putative PRPP synthases are currently available. 584 
 Yeast PRPP synthases. Among yeast species PRPP synthase has been analyzed 585 
only in S. cerevisiae and S. pombe, but presumably many of the physiologic properties 586 
of PRPP metabolism of these two species are similar to those of other yeast species. 587 
Although yeast PRPP synthases share typical class I properties, they also contain 588 
properties different from the PRPP synthases described so far. 589 
 (i) S. cerevisiae. S. cerevisiae contains five PRPP synthase-specifying orthologs, 590 
PRS1 to 5 (8, 9). Inspection of the amino acid sequences reveals that PRS2, PRS3 and 591 
PRS4 appear to encode typical class I enzymes. Also, PRS1 and PRS5 may encode 592 
class I enzymes, but PRS1- and PRS5-specified amino acid sequences contain so-593 
called non-homologous regions (NHRs), which are insertions relative to the sequences 594 
specified by PRS2, PRS3 or PRS4 (Fig. 5). Prs1 contains a single NHR (NHR1) of 595 
105 amino acids in length, whereas Prs5 contains two NHRs of 110 amino acids 596 
(NHR5-1) and 63 amino acids (NHR5-2). With Prs1 immunochemical analysis has 597 
confirmed that the NHR1 is actually present in the polypeptide found in yeast cells (8, 598 
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80, 81). The Prs1 NHR1 is inserted after Ser199, whereas the Prs5 NHR5-2 is inserted 599 
after Ser306. These two positions, Ser199 and Ser306, correspond to Arg202 of the B. 600 
subtilis PRPP synthase, and, thus the NHRs are inserted in the catalytic flexible loop. 601 
In contrast, the Prs5 NHR5-1 sequence is inserted after Pro100, which corresponds to 602 
Asp103 of the B. subtilis PRPP synthase, and, thus the NHR5-2 is inserted in the 603 
regulatory flexible loop. The identity of the amino acid sequences specified by PRS2, 604 
PRS3 and PRS4 with that of B. subtilis PRPP synthase is 42-46%, whereas these 605 
values for the PRS1- and PRS5-specified sequences are 29 and 24%, respectively. 606 
After removal of the NHR amino acid sequences in silico, the latter values increase to 607 
41 % (Prs1 ΔNHR1) and 39 % (Prs5 ΔNHR5-1 ΔNHR5-2). 608 
 (a) Interaction of PRS gene products. Unlike most other cloned prs genes, the 609 
gene products of each of the five S. cerevisiae PRS genes have no PRPP synthase 610 
activity in vivo, when their genes are harbored and expressed individually in an E. 611 
coli host strain (82). In contrast, the formation of active PRPP synthase requires the 612 
expression of two or more PRS genes, as established by deletion analysis of PRS 613 
genes in S. cerevisiae or by expression of PRS genes in E. coli. A single knockout 614 
mutation in PRS1, PRS2, PRS3, PRS4 or PRS5 results in viable phenotypes (80, 83). 615 
Additionally, all 10 combinations of two PRS gene knockouts result in viable 616 
phenotypes except the Δprs1 Δprs5 and Δprs3 Δprs5 double knockouts, both of 617 
which are lethal (83). The latter double mutant, Δprs3 Δprs5, is lethal because the 618 
Prs1 polypeptide is unstable in a Δprs3 genetic background. Thus, strains with the 619 
genotype Δprs3 Δprs5 are phenotypically prs1 prs3 prs5 (84). Among the five 620 
possible combinations of deletion of three PRS genes only Δprs1 Δprs2 Δprs3, Δprs1 621 
Δprs3 Δprs4 and Δprs2 Δprs4 Δprs5 deletants are viable, whereas Δprs1 Δprs2 Δprs4 622 
and Δprs2 Δprs3 Δprs4 are lethal, and, thus, S. cerevisiae cannot exist with only a 623 
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single PRS gene. These results were confirmed by analysis of complementation by 624 
relevant combinations of PRS genes of an E. coli Δprs allele. This analysis 625 
furthermore showed that the simultaneous expression of PRS1 and PRS2 or the 626 
simultaneous expression of PRS1 and PRS4 resulted in PRPP synthase with very low 627 
activity in vivo, presumably too low to promote growth of S. cerevisia Δprs3 Δprs4 628 
Δprs5 or Δprs2 Δprs3 Δprs5 deletants. Although complementation of the E. coli Δprs 629 
allele by combinations of two PRS genes revealed the production of active PRPP 630 
synthase in vivo, in vitro PRPP synthase activity could be detected only in cell extract 631 
of the strain that expressed both PRS1 and PRS3 (82). The conclusions from this 632 
analysis are that active PRPP synthase requires either PRS1 or PRS5 in addition to at 633 
least one more PRS gene product, but not just any PRS gene product. Thus, an active 634 
enzyme consists of the PRS1 and PRS3 gene products, or an active enzyme consists of 635 
the PRS5 PRS2, the PRS5 PRS4, or the PRS5 PRS2 PRS4 gene products (83). 636 
 Physical interaction of Prs polypeptides was furthermore demonstrated by yeast 637 
two-hybrid analysis. The results of this analysis showed interaction between Prs1 and 638 
Prs3, between Prs1 and Prs2 and between Prs1 and Prs4. These interactions were 639 
demonstrated in a reciprocal manner, i.e. with each PRS gene fused to the binding 640 
domain as well as to the activating domain. Additional, some non-reciprocal 641 
interactions were also observed between Prs5 and Prs2 and between Prs5 and Prs4 642 
(83). Studies of synthetic lethality of combinations of prs-deletions also demonstrated 643 
interaction between Prs1 and Prs3 and between Prs1 and Prs5 (84, 85). These Prs-644 
polypeptide interactions, demonstrated by genetic and physical analysis after 645 
manually manipulating the relevant DNA molecules, have been by and large 646 
confirmed by high-throughput analyses with two-hybrid analysis (86-88), protein-647 
fragment complementation (89, 90), or affinity-capture mass spectrometry (91, 92). 648 
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 The protein-protein interaction analyses reveal an extensive interaction between 649 
the various PRS gene products. Evidently, all of the Prs-polypeptides interact with one 650 
another. Presumably, each Prs-polypeptide may be able to form a hexameric structure 651 
like that of B. subtilis PRPP synthase, as well as mixed hetero-hexamers and 652 
eventually larger molecular structures similar to those described for mammalian PRPP 653 
synthases (see below). 654 
 (b) Enzyme structure. S. cerevisiae PRPP synthase appears to be a large enzyme. 655 
PRPP synthase activity of wild-type S. cerevisiae strain YN94-2 eluted as a single 656 
symmetrical peak corresponding to a molecular mass of at least 900 kDa by exclusion 657 
chromatography (Fig. S1A). Also, the enzyme eluted as a single peak by ion exchange 658 
chromatography (Fig. S1B). These results may indicate the presence of a single 659 
enzyme form containing all five PRS gene products, although the existence of 660 
multiple forms with nearly identical size and charge properties cannot be excluded. 661 
Additionally, PRPP synthase activity of extracts of Δprs2, Δprs3 or Δprs4 strains 662 
eluted with molecular mass identical to that of the wild-type, whereas no PRPP 663 
synthase activity could be determined in the exclusion chromatography-eluates of 664 
either a Δprs1 or a Δprs5 strain, even though activity could be easily determined in 665 
the cell extracts before loading them to the column (Fig. S1A). Thus, PRPP synthase 666 
lacking either of the Prs1 and Prs5 polypeptides may be unstable to the conditions of 667 
exclusion chromatography conditions, and the presence of additional PRS gene 668 
product(s) apparently stabilizes the enzyme complex (93). 669 
 Amino acid residues important in active site formation, i.e. residues involved in 670 
the binding of the adenyl moiety and the triphosphate chain of ATP as well as binding 671 
of ribose 5-phosphate, and the catalytic flexible loop of B. subtilis PRPP synthase are 672 
compared to those of each of the five S. cerevisiae PRS specified amino acid 673 
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sequences (Table S3). The similarity of these selected B. subtilis PRPP synthase 674 
amino acid residues with each of those of S. cerevisiae is 71% (PRS1-specified amino 675 
acid residues), 88% (PRS2-, PRS3- and PRS4-specified amino acid residues), or 50% 676 
(PRS5-specified amino acid residues). Little is known of the enzymatic properties of 677 
S. cerevisiae PRPP synthase activity. Some activity remains following dialysis of an 678 
S. cerevisiae crude extract against Pi-free buffer and in assay under Pi-free conditions 679 
and only 18% of the activity remained when the enzyme was assayed in the presence 680 
of 2 mM ADP relative to 100% in the absence of ADP (82). These properties differ 681 
from those of bacterial PRPP synthases. 682 
 (c) Physiological function. The complexity of S. cerevisiae PRPP synthase 683 
polypeptides may reflect their physiological function. Evidence for involvement of 684 
PRS-specified polypeptides in processes other than catalysis of PRPP synthesis 685 
originates from characterization of (i) prs mutants, (ii) mutants defective in other 686 
processes and from analyses of (iii) protein-protein interactions with PRS-specified 687 
polypeptides. First, Δprs3 mutant strains are highly pleiotropic and it was concluded 688 
that PRS3 is required for cell wall integrity, cell cycle arrest following deprivation of 689 
nutrient, proper ion homeostasis, and proper actin cytoskeleton-organization, and cell 690 
size homeostasis (94-96). The cell wall integrity signaling pathway includes protein 691 
Slt2 and the transcription factor Rlm1 of the protein kinase C (Pkc1) mitogen-692 
activated protein kinase cascade (97). Strains with prs lesions are sensitive to the 693 
purine analog 1,3,7-trimethylxanthine (caffeine), which interferes with Pkc-1 694 
activated cell wall integrity signaling and the mitogen-activated protein kinase 695 
cascade (98), providing evidence for Prs polypeptides being involved in the cell wall 696 
integrity signaling (99). Second, the pps1-1 lesion of S. cerevisiae, isolated after 697 
screening for an elongated cell morphology, is an allele of PRS1 (100). Third, 698 
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evidence of Prs polypeptides being involved in the stress and cell wall integrity 699 
signaling pathway comes from yeast two-hybrid analysis of Prs polypeptides with 700 
Slt2 (85, 101, 102). 701 
 A number of other protein-protein interactions with Prs polypeptides as partners 702 
have been identified. Rim11, a homolog of mammalian glycogen synthase kinase-3β 703 
interacts with Prs2, Prs3 and Prs5 as shown by affinity-capture mass spectrometry 704 
(103), and confirmed by manual yeast two-hybrid analysis with the RIM11 gene and 705 
each of the PRS genes (104). High through-put analyses revealed a number of protein-706 
protein interactions of Prs polypeptides with other polypeptides (86, 88), although 707 
their physiological function has not been established (102). Interestingly, the 708 
interaction of the protein kinase Rim11 with Prs5 may be responsible for the 709 
phosphorylation of the latter protein (104). Phosphoproteome analysis by mass 710 
spectrometry revealed three phosphorylation sites in Prs5, 361-KTTpSTSpSTpSS-711 
370, where p indicates phosphorylation of the following serine residues (105). This 712 
sequence is located within NHR5-2. 713 
 From the data given above it appears very likely that yeast PRS specified 714 
polypeptides share functions in addition to the catalysis of PRPP formation. Further 715 
investigations are necessary to establish the detailed mechanisms of this behaviour. 716 
 (d) Function of NHR. The function of the NHRs has been studied to some extent. 717 
Deletion of NHR1 prevented the interaction with Slt2 (84). It is therefore possible that 718 
yeast PRPP synthase may be a bifunctional enzyme involved in nucleotide and amino 719 
acid biosynthesis as well as in maintaining cell wall integrity, the latter function 720 
involving the NHR1 (84, 85, 101, 102). 721 
 Finally, the deletion of NHR5-1 resulted in a polypeptide with altered interaction 722 
with other Prs polypeptides. The simultaneous expression in an E. coli Δprs host 723 
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strain of PRS3 and prs5 ΔNHR5-1 or of PRS3 and prs5 ΔNHR5-1 ΔNHR5-2 resulted 724 
in complementation of the E. coli Δprs allele, and, thus, production of active PRPP 725 
synthase, whereas no complementation was observed by the simultaneous expression 726 
of the wild-type alleles PRS3 and PRS5. This result may indicate that the NHR5-1 727 
prevents the formation of an active enzyme rather than preventing interaction of Prs3 728 
and Prs5, as interaction of these polypeptides has been previously established (89, 729 
106) (B.H.-J., unpublished result). 730 
 (e) Ribonucleotide pool sizes and PRPP synthase activity. The apparent 731 
interaction of Prs polypeptides with proteins of other cellular processes suggests an 732 
involvement of Prs polypeptides in linking metabolism to various stress situations. It 733 
remains to be established, however, if other physiological phenomena, such as 734 
perturbation of the pool sizes of ribonucleotides or PRPP, are also involved in the 735 
transmission of these metabolic effects. Single PRS knock-outs are either unaffected 736 
in growth rate (μ) as observed for Δprs2, Δprs4 and Δprs5 harboring strains or 737 
reduced in growth rate as observed for Δprs1 and Δprs3 harboring strains (8, 81, 106). 738 
Along with reduced growth rates, the pool sizes of adenylate nucleotides (AMP, ADP 739 
and ATP) were reduced to approximately 50 % of those of wild-type strains in Δprs1 740 
and Δprs3 strains, whereas less reduced adenylate nucleotide pool sizes were observed 741 
in Δprs2, Δprs4 and Δprs5 strains (106). Correspondingly, PRPP synthase activity 742 
was lower in Δprs1 or Δprs3 strains than in Δprs2 or Δprs4 strains (81). A Δprs1 743 
Δprs3 strain (i.e. synthesizing Prs2, Prs4 and Prs5) contained approximately 40 % of 744 
the adenylate nucleotides and 2-3 % of the PRPP synthase activity compared to the 745 
values of the wild-type strain. A Δprs2 Δprs4 Δprs5 strain (i.e. synthesizing Prs1 and 746 
Prs3) had almost normal growth rate, 90 % adenylate nucleotide pools and 16 % 747 
PRPP synthase activity compared to the values of the wild-type strain (83). The 748 
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relatively low PRPP synthase activities determined in the various mutant strains may 749 
indicate that non-optimal assay conditions were employed or that PRPP synthase may 750 
unstable in vitro when one or more PRS gene products are absent, and thus may not 751 
accurately reflect PRPP synthase activity in vivo. Altogether, a hierarchy exists 752 
among prs lesions. Thus, Δprs3 or Δprs1 deletants appear to be more severely 753 
affected than Δprs3, Δprs4 or Δprs5 deletants. 754 
 In summary, much focus has been devoted to the analysis of Prs polypeptide 755 
interactions with one another as well as with other polypeptides. However, the 756 
enzymology of yeast PRPP synthase is far from solved. The characterization in the 757 
future of a few mutants suggested from studies of the well characterized bacterial 758 
PRPP synthases might contribute significantly to our understanding of the 759 
oligomerization of this enzyme. The B. subtilis PRPP synthase amino acid residues 760 
His135, Asp174 and Lys197 are all very important for catalysis. These amino acid 761 
residues are identical in the five yeast Prs polypeptides except for Prs1, which has 762 
Asn171 and Arg196 rather than aspartate and lysine residues, respectively, found in B. 763 
subtilis PRPP synthase (Table S3). Thus, a replacement of the Lys197 analogs with 764 
alanine followed by complementation and enzyme activity analysis might prove 765 
valuable in establishing which Prs polypeptide, i.e. PRPP synthase subunit, is 766 
important for enzyme activity. It is generally believed that an active PRPP synthase is 767 
composed of Prs1 and Prs3 or of Prs2 Prs4 and Prs5 (83). It is furthermore very likely 768 
that these polypeptides form a propeller-like hexameric structure similar to that of B. 769 
subtilis PRPP synthase. It would therefore be of interest to analyze variants such as 770 
Prs2Lys197Ala Prs4 Prs5, Prs2 Prs4Lys197Ala, Prs2 Prs4 Prs5Lys308Ala, Prs1Arg196Ala Prs3 or 771 
Prs1 Prs3Lys196Ala as well as some double variants for complementation and enzymatic 772 
properties. Indeed, the multiple, heterologous-subunits composition of yeast PRPP 773 
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synthase provides a unique system to study alterations in a single subunit of the 774 
hexameric enzyme, which is not possible with other PRPP synthases, which are also 775 
hexamers, but composed of a single species of subunit. 776 
 S. cerevisiae PRPP synthase is an intriguing enzyme. The expression of more 777 
than one ortholog necessary for PRPP synthase activity. Also the presence of HNRs 778 
imposes interesting questions about the structure and function of PRPP synthase. Do 779 
NHRs have ordered structures or are they intrinsically disordered regions? Could they 780 
confer Hub-protein character to PRPP synthase, thus facilitating heterologous protein 781 
interactions such as those described above? 782 
 (ii) S. pombe. S. pombe contains three PRPP synthase orthologs, PRS1, PRS2 and 783 
PRS3, presumably specifying class I PRPP synthases, as judged from their deduced 784 
amino acid sequences. The three genes are unlinked with PRS1 located in 785 
chromosome I, PRS2 in chromosome II, and PRS3 in chromosome III. As PRS-786 
specified polypeptides of S. cerevisiae, two of the PRS-specified polypeptides of S. 787 
pombe contain NHRs (Fig. 5). Similar to the NHRs of S. cerevisiae Prs1 and Prs5, the 788 
NHRs of S. pombe are located within the catalytic flexible loop (Prs1 NHR1) or 789 
within the regulatory flexible loop (Prs2 NHR2). Amino acid sequence alignments 790 
with B. subtilis PRPP synthase and S. pombe PRS specified amino acid sequences 791 
reveal an identity for Prs1 of 29% (37% when the NHR1 is removed), for Prs2 of 39% 792 
(42% when the NHR2 is removed), and for Prs3 45%. A comparison of amino acid 793 
residues presumed to be important for active site formation and catalysis is included 794 
in Table S3. Specifically, these amino acid residues of Prs3 are highly conserved, 88 795 
%, compared to 63 and 75 % of those of Prs1 and Prs2, respectively. In addition, only 796 
Prs2 and Prs3 contain both of the important lysine and arginine residues of the 797 
catalytic flexible loop. 798 
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 The three S. pombe PRS genes have been cloned in a plasmid vector and 799 
expressed in an E. coli Δprs strain for complementation analysis (Table S4). The 800 
results showed that neither PRS1, PRS2 nor PRS3 alone complemented the prs null 801 
allele. In contrast, simultaneous expression of PRS3 and PRS1 or PRS2 resulted in 802 
complementation, whereas simultaneous expression of PRS1 with PRS2 did not result 803 
in complementation. Furthermore, very low PRPP synthase activity could be 804 
measured in extracts of cells harboring PRS1 PRS3 or PRS2 PRS3. The activity, 805 
however, increased more than 10-fold in extracts of cells harboring PRS1 PRS3 in one 806 
plasmid and PRS2 in a second compatible plasmid or, vice versa, PRS2 PRS3 in one 807 
plasmid and PRS1 in a second compatible plasmid. These data suggest that the 808 
presence of all three PRS gene products may have a stabilizing effect on the enzyme 809 
activity (BH-J, unpublished data). 810 
 Heterozygous diploid deletion mutations have been constructed for essentially all 811 
of the genes of S. pombe. Strains containing deletion mutations in PRS1 (also 812 
designated SPAC4A8.14) or PRS2 (also designated SPBC3D6.06c) are viable. In 813 
contrast, the PRS3 (also designated SPCC1620.06c) is essential (107). Additionally, 814 
two amino acids, Tyr168 and Ser172, of the PRS3 specified amino acid sequence 815 
were shown to be phosphorylated (108). Ser172 corresponds to Ser172 of B. subtilis 816 
PRPP synthase, a fairly conserved amino acid residue. It remains to be established, if 817 
phosphorylation affects the activity of PRPP synthase. 818 
 The combined conclusion of the complementation and deletion analyses is that 819 
PRPP synthase activity requires the PRS3 gene product as well as the gene product of 820 
either PRS1 or PRS2. 821 
 (iii) PRPP synthase of other fungi. The association of multiple PRPP synthase 822 
subunits occurs in other species of fungi as well. The filamentous fungus Aspergillus 823 
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nidulans contains a mycelium of multinucleate cells that are partitioned by septa 824 
(reviewed by Harris (109)). Briefly, the formation of septa is regulated by a protein 825 
kinase cascade, which involves a sepH-specified protein kinase, which is a positive 826 
regulator of the septation initiation network. Thus, a phenotype of sepH mutations is a 827 
reduction or lack of septation. A number of suppressors of sepH mutation has been 828 
isolated and characterized, among which are altered levels of PRPP synthase activity. 829 
The authors offered a somewhat speculative model, in which competition of PRPP 830 
synthase and SepH for ATP might be the trigger of septation (110). 831 
 A. nidulans contains three PRPP synthase orthologs, PRS1 (located on 832 
chromosome I), PRS2 (chromosome VI) and PRS3 (chromosome VII). Prs1 (Genbank 833 
CBF69369.1) (489 amino acid residues) resembles S. cerevisiae Prs1 as there is an 834 
addition of 169 amino acid residues inserted within the catalytic flexible loop, Prs2 835 
(435 amino acid residues) (Genbank CBF83270.1) has an insertion of 116 amino acid 836 
residues at position 115, i.e. far from the catalytic flexible loop, and Prs2 may 837 
represent a new variant of PRPP synthases, and Prs3 (320 amino acid residues) 838 
(Genbank CBF85908.1) appears to be a “normal” PRPP synthase polypeptide. Each 839 
of the three amino acid sequences reveals all of the characteristic features for class I 840 
PRPP synthases, i.e. amino acids involved in subunit-subunit interactions, substrate 841 
binding and catalysis, and allosteric regulation. Yeast two hybrid analysis revealed 842 
interaction of Prs1 with Prs2, Prs1 with Prs3, and Prs2 with Prs3. Thus, the enzyme 843 
may contain all three polypeptides in an unknown stoichiometry (110). 844 
 The filamentous fungus Eremothecium (Ashbya) gossypii contains four PRPP 845 
synthase-specifying orthologs (111, 112). Two of these genes, both located on 846 
chromosome VII, have been analyzed: Agl080c (accession NP_986586), a homolog 847 
of S. cerevisiae PRS2 or PRS4, and Agr371c (accession NP_987037) a homolog of S. 848 
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cerevisiae PRS3. The two other orthologs are homologs of S. cerevisiae PRS1 849 
(accession NP_984943) and PRS5 (accession NP_984410). Both of these E. gossypii 850 
gene products have NHRs at positions similar to those of S. cerevisiae Prs1 and Prs5 851 
although their length varies. All four E. gossypii genes may specify typical class I 852 
PRPP synthases (112). Similar to the situation in S. cerevisiae, the knockout of the 853 
PRS3 homolog had more dramatic effects on various growth parameters than that of 854 
the knockout of the PRS2/PRS4 homolog. The presence of only four PRS orthologs in 855 
E. gossypii contrary to five in S. cerevisiae may indicate some redundancy in the 856 
PRS2 and PRS4 genes of S. cerevisiae, as only one of these is present in E. gossypii. It 857 
was furthermore shown that introduction of the amino acid alteration Leu133Ile or 858 
Leu132Ile into the PRS2/PRS4 or the PRS3 homolog, respectively, resulted in 859 
reduction of feed-back inhibition of PRPP synthase activity. Similar effects were 860 
observed by His196Gln or His195Gln alterations of the PRS2/PRS4 or the PRS3 861 
homolog, respectively. These amino acid alterations of PRPP synthase were 862 
introduced to desensitize the pathway for riboflavin biosynthesis for which purine 863 
nucleotides, and, thus, PRPP are precursors (112). We shall return to explain the 864 
effect of the amino acid alterations on PRPP synthase activity in the section 865 
“Regulation of PRPP Synthase Activity”. 866 
 It is obvious from the description above that the physiology of yeast PRPP 867 
synthase differs from that of bacteria. Although also belonging to the class I PRPP 868 
synthases, major differences exist such as the presence of the amino acid sequences 869 
NHR, the requirement of heteromeric oligomerization, and the involvement of PRS-870 
specified polypeptides in cellular processes other than PRPP synthesis. 871 
 Mammalian PRPP synthase and PRPP synthase associated proteins. As 872 
described above, yeasts contain PRPP synthase-specifying homologs with NHRs 873 
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inserted at specific positions as well as “ordinary” PRPP synthase-specifying 874 
homologs without these insertions. Similar proteins are found in mammalian 875 
organisms, where apparent PRPP synthases have insertions similar to the yeast NHRs. 876 
In mammals a PRPP synthase polypeptide with an insertion has been designated 877 
PRPP synthase-associated protein or PAP. The description below of each type, PRPP 878 
synthase and PAP, complements previously published reviews (18, 20).  879 
 (i) PRPP synthase. Among PRPP synthases of mammalian origin, only those of 880 
humans and rat have been characterized. Both organisms contain three genes, PRPS1-881 
3 encoding PRPP synthase isozymes 1-3. PRPS1 and PRPS2 are located on the X-882 
chromosome, whereas PRPS3 is located on chromosome 7. The latter gene is 883 
expressed only in testes, whereas both of the former genes are expressed in all the 884 
tissues examined (11). 885 
 (a) Enzyme characteristics. Human and rat PRPP synthases also belong to class I, 886 
and as such their properties resemble the microbial class I PRPP synthases with 887 
respect to their restricted diphosphoryl donor capacity (ATP and dATP) and allosteric 888 
regulation by Pi and ADP (18, 20). The amino acid sequence identity among the three 889 
human PRPP synthase isozymes is 91-95 %, whereas the identities of B. subtilis 890 
PRPP synthase and the three human isozymes are 45 or 46 %. Exclusion 891 
chromatography of PRPP synthase activity isolated from rat liver revealed a protein 892 
complex with a molecular mass of 1000 kDa or more. The protein complex consisted 893 
of four different polypeptides, the two catalytic PRPP synthase isozymes 1 and 2 as 894 
well as the two so-called PAP-39 and PAP-41 estimated to contain 20 molecules of 895 
isozyme 1, five of isozyme 2, eight and one of PAP-39 and PAP-41, respectively 896 
(113). Previous characterization of human PRPP synthase may have been performed 897 
on mixtures of isozyme 1 and 2, although erythrocytes, the source of enzyme in those 898 
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early studies, contain predominantly isozyme 1 (114), and similar to the rat liver 899 
enzyme, human PRPP synthase was isolated as large oligomeric structures (115, 116). 900 
Human isozyme 1 and 2 differ in 15 amino acid residues, human and rat isozyme 1 901 
are identical, whereas human and rat isozyme 2 differ in only three amino acid 902 
residues. 903 
 Although native PRPP synthase isolated from tissues may better represent the 904 
physiological state of the enzyme, efforts have been spent also to characterize the 905 
individual isozymes. Isozymes 1 and 2 of both humans and rat have been purified and 906 
characterized after expression of their recombinant genes in E. coli (71, 73). As 907 
expected from the close identity of the four enzymes they shared many similarities in 908 
physico-chemical properties. They all oligomerize to very large structures with 909 
molecular masses around 1000 kDa (human isozyme 1 and 2, rat isozyme 1) or 910 
approximately 550 kDa (rat isozyme 2) as determined by exclusion chromatography. 911 
Even though they are quite similar in primary structure, there are also differences 912 
between human isozyme 1 and 2. Different purification procedures were employed for 913 
the two isozymes; isozyme 2 was much more labile to heat inactivation than isozyme 914 
1; isozyme 1 was saturated by lower concentrations of ATP, ribose 5-phosphate and 915 
Mg2+ than isozyme 2; and isozyme 1 was more prone to inhibition by ribonucleoside 916 
diphosphates than isozyme 2. Comparison of human and rat enzymes revealed very 917 
few differences (71, 73). Some kinetic properties of PRPP synthases of humans and 918 
rat are listed in Table 2. 919 
 (b) Three-dimensional structure. Human PRPP synthase isozyme 1 three-920 
dimensional structure has been determined from a number of crystal forms (Table 1). 921 
(a) hPRS1wild-type-PRPP synthase with three SO42- bound, one at the phosphate 922 
position of ribose 5-phosphate, one at the position of the α-phosphate of ADP at the 923 
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allosteric site, and one at a new, third position at the parallel dimer interface, 924 
determined at 2.0 Å resolution (PDB code 2h06); (b) ATP/SO42-/Cd2+-PRPP synthase 925 
(also wild-type) with three SO42- bound as in the hPRS1wild-type-PRPP synthase 926 
crystal form, ATP (modelled to only AMP) at the active site and one Cd2+ per 927 
monomer, determined at 2.2 Å resolution (PDB code 2hcr) (51); (c) PRS1 (wild-type 928 
PRPP synthase) with SO42- bound, determined at 2.0 Å resolution (PDB code 3s5j) 929 
(117, 118). In addition, three-dimensional structures of some mutant variants have 930 
been determine as well and are described below. From the 46 % identity among B. 931 
subtilis and human PRPP synthase isozyme 1 amino acid sequences, it comes as no 932 
surprise that the three-dimensional structure of the two enzymes are essentially 933 
identical. Superimposition of hPRS1wild-type-PRPP synthase and various B. subtilis 934 
PRPP synthase structures revealed root mean-square deviation values of 1.0 to 1,2 Å. 935 
As expected, also the human PRPP synthase isozyme 1 has the hexameric propeller 936 
structure of B. subtilis PRPP synthase (Fig. 3C) (51). In addition, the structure of 937 
human PRPP synthase isozyme 1 has been visualized by negative stain electron 938 
microscopy. The apo and the ADP-bound forms have a three-leaf clover structure, 939 
into which the crystal structure of isozyme 1 could be docked (118). 940 
 (c) Mutant PRPP synthases. A number of variants of human PRPP synthase 941 
isozyme 1 have been discovered because of their severe clinical effects on the affected 942 
individuals. As reviewed previously (119), these pathological effects are caused either 943 
by increased activity of PRPP synthase isozyme 1, i.e. “superactivity” of the enzyme 944 
or overexpression of the PRPS1 gene, which results in an array of physiological 945 
effects including hyperuricemia, gouty arthritis or neurosensory defects, or by reduced 946 
activity of PRPP synthase isozyme 1, resulting in neuropathy, deafness or intellectual 947 
disabilities. Historically, these altered PRPP synthases were described by the 948 
 40
somewhat imprecise designations “gain of function” or “loss of function”. Sixteen 949 
mutant variants affecting 15 amino acid positions have been discovered and are 950 
summarized in Table 4. (No mutant forms of PRPP synthase isozyme 2 or PAP have 951 
been described). The loss of function of PRPS1 variants (reduced activity in Table 4) 952 
are the variants Asp64Asn, Ala86Thr, Met114Thr, Gln132Pro, Val141Leu, 953 
Leu151Pro, Ile289Thr and Gly305Arg variants, which had 40 to 70 % of the specific 954 
activity of normal PRPP synthase (120-122). In Fig. 2 each of these amino acid 955 
positions is indicated by blue arrow heads, which point to the homologous position in 956 
B. subtilis PRPP synthase. It is evident that none of these amino acid alterations are 957 
within positions that are directly involved in catalysis, which presumably would have 958 
produced inactive enzyme forms. Asp64 and Met114, equivalent to B. subtilis PRPP 959 
synthase Glu70 and Leu120, respectively, are located at stretches of amino acids 960 
involved in the formation of the bent dimer, Val141 equivalent to B. subtilis PRPP 961 
synthase Ile147, is located close to sequences that are involved the formation of the 962 
parallel dimer, and Gln132, Ile289 and Gly305, equivalent to B. subtilis PRPP 963 
synthase Gln138, Ser293 and Gln308 are within or close to positions involved in 964 
allosteric regulation of PRPP synthase activity. Finally, Ala86, equivalent to B. 965 
subtilis PRPP synthase Ile92 is located close to the regulatory flexible loop. 966 
Altogether, the amino acid positions causing reduced activity of PRPP synthase 967 
isozyme 1 are located at positions secondary to catalysis, and, rather, their effect may 968 
be to alter the secondary structure, resulting in poorer enzymatic function. 969 
 The gain of function variants (increased activity in Table 4) are the variants 970 
Asp51His, Asn113Ser, Leu128Ile, Asp182His, Ala189Val and His192Leu. The 971 
variant forms of PRPP synthase have increased activity primarily because of their 972 
reciprocol effects on allosteric regulation by ADP and Pi, namely, reduced inhibition 973 
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by the former and increased stimulation by the latter (72, 123). Studies of these PRPP 974 
synthase mutant variants have proven valuable in the elucidation of the allosteric 975 
regulation of the enzyme, and we shall return to a further description of them in the 976 
section “Regulation of PRPP synthase activity”. 977 
 The structure of three mutant variants has been determined. One is the Asp51His 978 
variant, which has SO42- bound at the position of the α-phosphate of ADP at the 979 
allosteric site as well as Mg2+ (PDB code 4f8e) (124). Patients containing the 980 
Asp51His variant suffer from hyperuricemia and severe gout. The other structures are 981 
those of the Ser131Ala (PDB code 2h07) and Tyr145Met (PDB code 2h08) variants, 982 
each with three SO42- bound as described for the hPRS1wild-type-PRPP synthase 983 
structure. The authors used the observation of these SO42- as indicative of a second 984 
allosteric Pi-binding site (51). 985 
 (d) PRPP synthase isozyme 2 and Myc-driven cancers. As mentioned above, no 986 
mutants of human PRPP synthase isozyme 2, specified by the PRPS2 gene, have been 987 
described. Remarkably, however, the activity of isozyme 2 has been shown to be 988 
critical in developing and maintaining cancers caused by Myc-transcription factor. 989 
The eukaryotic translation initiation factor 4E, is also involved in the development of 990 
this type of cancer. The PRPS2 gene, but not the PRPS1 gene, contains a pyrimidine-991 
rich translational element in the 5’-untranslated region. Myc-driven hyperactivation 992 
results in an interaction of the eukaryotic translation initiation factor 4E and possibly 993 
other factors with the pyrimidine-rich translational element and results in an increase 994 
of translation of PRPS2-specific mRNA, which results in increased PRPP synthase 995 
isozyme 2-synthesis and, thus, increased nucleotide production. The increase in 996 
nucleotide synthesis inhibits PRPP synthase isozyme 1, whereas isozyme 2 is less 997 
sensitive to feedback inhibition by ribonucleotides. Also, the lack of the pyrimidine-998 
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rich translational element within the PRPS1 mRNA prevents the stimulation of 999 
synthesis of isozyme 1. Altogether, compelling evidence shows that PRPP synthase 1000 
isozyme 2 plays an important role in the metabolism of cells with Myc-driven cancers 1001 
(125). 1002 
 (ii) PAP. Mammalian PAP-39 and PAP-41 may be variants of the S. cerevisiae 1003 
and S. pombe PRS1-specified gene products described previously, i.e. PRPP synthase-1004 
like proteins containing an NHR. The amino acid sequence of human PRPP synthase 1005 
isozyme 1 is 41% identical to both PAP-39 and PAP-41; the amino acid sequence of 1006 
PAP-39 is 76% identical to that of PAP-41. The NHRs are both located within the 1007 
catalytic flexible loop and are 29 and 30 amino acid residues in length, respectively. 1008 
Thus, the additions are located at a position similar to NHR1 of S. cerevisiae Prs1, 1009 
NHR5-2 of S. cerevisiae Prs5 and the NHR of S. pombe Prs1, but differ in length (Fig. 1010 
5). The identity of B. subtilis PRPP synthase and PAP-39 and PAP-41 is 31 and 34 %, 1011 
respectively. After removal of the additions, these values increase to only 34 and 37 1012 
%, respectively. Inspection of important amino acid residues reveal that the ribose 5-1013 
phosphate binding site is well-preseved in PAP-39 and PAP-41. In contrast, residues 1014 
involved in the binding of ATP and residues important for catalysis are poorly 1015 
conserved. Specifically, the two important residues of the catalytic flexible loop 1016 
(Lys197 and Arg199 in B. subtilis) are absent in the two PAPs. Data for PAP-39 is 1017 
included in Table S3. Originally, the PAPs were identified as subunits co-purifying 1018 
with rat PRPP synthase. Interaction of PRPP synthase and PAP has been 1019 
demonstrated by several methodologies, such as crosslinking and co-1020 
immunoprecipitation. The PAP could be removed from PRPP synthase isloated from 1021 
rat liver by exclusion chromatography in the presence of one molar magnesium 1022 
chloride. Both of these latter processes yielded PRPP synthase with increased activity, 1023 
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which suggested that the PAPs play a negative regulatory role on PRPP synthase 1024 
activity (113). Furthermore, a protein devoid of PRPP synthase acitivty was obtained 1025 
after expression of the PAP-39 specifying gene in E. coli. Partial reconstitution of rat 1026 
PRPP synthase activity could be achieved by co-expression of recombinant genes 1027 
specifying PRPP synthase isozymes 1 and 2 and PAP-39 in E. coli, which resulted in 1028 
an active oligomeric enzyme eluting near the void volume, i.e. an enzyme consisting 1029 
of a large number of subunits (126). 1030 
 Mammalian and yeast PRPP synthase structures resemble one another in 1031 
interesting ways. Both mammalian and yeast PRPP synthases have constituent 1032 
subunits of “ordinary” PRPP synthase polypeptides, cf. i.e. isozymes 1 and 2 of 1033 
humans or rat and Prs2, Prs3 and Prs5 of S. cerevisiae, as well as the NHR containing 1034 
polypeptides PAP-39 and PAP-41 of humans or rat and Prs1 and Prs5 of S. cerevisiae 1035 
as described above. Indeed, the presence of multiple, heterogenous subunits including 1036 
subunits with NHR sequences may be widespread among eukaryotic organisms. The 1037 
studies with yeast suggest that such heterologous structures may play roles in celluar 1038 
regulation that are not yet well-defined. 1039 
 The crystal structures of human PAP-39 and PAP-41 have been determined at 2.7 1040 
and 2.6 Å resolution (PDB codes 2c4k and 2ji4, respectively). We found that 1041 
superimposition of these two structures with that of B subtilis PRPP synthase (PDB 1042 
code 1dku) revealed root mean-square deviation values of 1.1 and 0.97 Å for PAP-39 1043 
and PAP-41, respectively, which indicate that the three-dimensional structures of the 1044 
PAPs and human and B. subtilis PRPP synthases are essentially identical. 1045 
 Other class I PRPP synthases. Some interest has been devoted to PRPP synthase 1046 
of the mosquito Culex pipiens pallens. This mosquito is the major vector for various 1047 
roundworms causing lymphatic filariasis (elephantiasis) and for the Japanese 1048 
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encephalitis virus. An important insecticide used in controlling C. pipiens pallens and 1049 
other insects as well is the pyrethroid ester deltamethrin. Many insect species develop 1050 
deltamethrin-resistance by knock-out mutations, and increased expression of specific 1051 
genes may assist in providing resistance. Expression of the PRPS1 gene is one 1052 
example of this phenomenon. The PRPS1 encoded enzyme is a typical cleass I PRPP 1053 
synthase. The exact mechanism of the contribution of overexpression of PRPS1 to 1054 
deltamethrin-resistance remains to be established (127). 1055 
 Planarians, with Dugesia japonica as an example, are studied because of their 1056 
remarkable ability to regenerate from injuries such as lost body parts. A PRPP 1057 
synthase-specifying ortholog (DjPRPS) of D. japonica has been cloned. The deduced 1058 
amino acid sequence reveals a typical class I PRPP synthase, with 37 % identity to the 1059 
amino acid sequence of B. subtilis PRPP synthase (128). 1060 
 1061 
Class II PRPP Synthases 1062 
S. oleracea isozymes 3 and 4 were proposed to constitute a second class of PRPP 1063 
synthases, class II, based on a comparison of the biochemical properties of the 1064 
enzymes (14, 15). Both isozyme 3 and 4 are active in the absence of Pi, and both 1065 
enzymes are inhibited by the ribonucleoside diphosphates ADP and GDP in a 1066 
competitive manner, i.e. they compete with ATP for binding at the active site. Thus, 1067 
no allosteric inhibition by either of these ribonucleoside diphosphates was detected. 1068 
Kinetic parameters are given in Table 2. Both of the S. oleracea isozymes are able to 1069 
use ATP, dATP, GTP, CTP and UTP as diphosphoryl donors. The apparent Michaelis 1070 
constants for the other diphosphoryl donors for isozyme 3 and isozyme 4 varied 1071 
between 85 and 680 μM. Exclusion chromatography of isozyme 4 revealed a 1072 
molecular mass of 110 kDa. Identical results were obtained in Tris- or phosphate ion-1073 
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based buffer and in the presence or absence of MgATP. Recombinant S. oleracea 1074 
isozyme 3 eluted identically to isozyme 4 in exclusion chromatography. With a 1075 
calculated molecular mass of the subunit as 35.4 kDa, this value of 110 kDa is 1076 
consistent with a homotrimeric quaternary structure (46, 47). Some controversy exists 1077 
on this point, as characterization of sugarcane class II PRPP synthase revealed a 1078 
molecular mass of 214 kDa, i.e. a value consistent with a hexameric quaternary 1079 
structure. Like S. oleracea PRPP synthase isozyme 3 and 4, the activity of sugarcane 1080 
PRPP synthase is independent of Pi (129). 1081 
 Amino acid sequence alignments of PRPP synthase isozyme 3 or 4 with the 1082 
amino acid sequence of B. subtilis PRPP synthase revealed a conservation of amino 1083 
acids along the polypeptide. Thus, a small part of the regulatory flexible loop (Phe97-1084 
Thr114 of isozyme 4), the PRPP binding site consisting of the PP loop (Asp183-1085 
Ala186 of isozyme 4) and the ribose 5-phosphate binding loop (Gly222-Thr237 of 1086 
isozyme 4) are extensively conserved. The catalytic flexible loop (Lys204-Leu215) is 1087 
less conserved, but the apparently indispensable residues, Lys204 and Arg206, are 1088 
retained. The amino acid residues important for binding of the adenine moiety of 1089 
ATP, Phe41, Asp43 and Gln47, and the catalytically important residues His141 are 1090 
also conserved (Fig. 2 and Tables S1 and S2). Altogether, it is therefore likely that the 1091 
mechanism of catalysis of class II PRPP synthases is identical or similar to that of 1092 
class I PRPP synthases. 1093 
 The amino acid residues involved in the formation of the two types of subunit-1094 
subunit interactions identified in B. subtilis PRPP synthase, i.e. the bent dimer and the 1095 
parallel dimer are poorly conserved in the class II PRPP synthases (Table 3). In class 1096 
II PRPP synthases represented by the S. oleracea PRPP synthase isozyme 4, only 1097 
three of the eight residues involved in the formation of the B. subtilis PRPP synthase 1098 
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bent dimer are conserved, and only four of the 12 residues involved in the formation 1099 
of the B. subtilis PRPP synthase parallel dimer are conserved. It is likely, therefore, 1100 
that the quaternary structure of class II PRPP synthases differs from that of class I 1101 
enzymes. Also, the amino acid residues identified as involved in allosteric regulation 1102 
of B. subtilis PRPP synthase are poorly conserved in S. oleracea PRPP synthase 1103 
isozyme 4; among the 20 residues listed in Table S2 only six are conserved, which is 1104 
consistent with the lack of allosteric regulation of class II PRPP synthases. 1105 
 The amino acid sequences of S. oleracea PRPP synthase isozyme 2 (class I) and 1106 
isozyme 3 (class II) contain extensions of 76 and 87 amino acids, respectively, at the 1107 
N-terminus as compared to isozyme 4. For isozyme 2 this extension contains an 1108 
amino acid sequence that indicates its localization in chloroplasts, whereas for 1109 
isozyme 3 the extension contains an amino acid sequence that indicates its 1110 
localization in mitochondria. Indeed, in vitro expression of PRS2 and synthesis of 1111 
isozyme 2 in the presence of chloroplasts showed that this isozyme was transported to 1112 
chloroplasts (15). Unlike S. oleracea PRPP synthase isozyme 2 and 3, the amino acid 1113 
length of isozyme 4 is similar to that of other PRPP synthases (318 compared to 316 1114 
of B. subtilis PRPP synthase), and, thus, isozyme 4 is believed to be located in the 1115 
cytoplasm (15).  1116 
 Interestingly, previous analyses of plant PRPP synthases may provide some 1117 
additional information on the class II enzymes. PRPP synthase from spinach leaves 1118 
was partially purified. The activity was independent of Pi. In fact, Pi inhibited the 1119 
activity with half-maximal inhibition at 28 μM. The apparent KM values for ATP, 1120 
ribose 5-phosphate and Mg2+ were 36 μM, 10 μM and 1 mM, respectively. ATP was 1121 
by far the best diphosphoryl donor, but GTP, UTP and CTP also were diphosphoryl 1122 
donors. The PRPP synthase activity was found predominantly in the cytosol (>95% of 1123 
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the total activity), with minor contributions by the nuclear, chloroplast and 1124 
mitochondrial fraction (1 to 2%) (130). These data have to be reevaluated in light of 1125 
the present knowledge of multiple isozymes in spinach. Also, rubber tree (Hevea 1126 
brasiliensis) latex PRPP synthase has been partially purified and characterized. 1127 
Exclusion chromatography revealed a molecular mass of 200 kDa. The authors 1128 
estimated the subunit molecular mass as 56 kDa following gel electrophoresis under 1129 
denaturing conditions. Actually, a band corresponding to a polypeptide of molecular 1130 
mass 35 kDa is also visible in the photograph of the gel. This size, 35 kDa, is the 1131 
“standard” size of PRPP synthases. Activity was obtained in the absence of Pi. ATP 1132 
functioned as diphosphoryl donor, whereas neither GTP, CTP nor UTP functioned as 1133 
diphosphoryl donor. Apparent KM values for ATP and ribose 5-phosphate were 1134 
determined as 0.2 M and 40 μM, respectively (131). As before, the data should be 1135 
reevaluated with the current knowledge of multiple forms of PRPP synthase. It 1136 
remains unknown if the latex fraction contains a specific PRPP synthase. 1137 
 BLAST analysis with the amino acid sequences of S. oleracea or A. thaliana 1138 
PRPP synthase isozyme 3 or 4 as the queries revealed the presence of these enzymes 1139 
also in green algae species such as Chlamydomonas reinhardtii (accession 1140 
XP_001694483 [an isozyme 3-like sequence]) (132), Chlorella variabilis 1141 
(XP_005848636 [isozyme 3-like]) (133), Coccomyxa subellipsoidea 1142 
(XP_005643144.1 [353 amino acid sequence, isozyme 4-like]) (134), Ostreococcus 1143 
lucimarinus (XP_001421441.1 [305 amino acid sequence, isozyme 4-like] and 1144 
XP_001421590 [304 amino acid sequence, isozyme 4-like]) (135), Ostreococcus tauri 1145 
(XP_003083594.1 [396 amino acid sequence, isozyme 3-like] and XP_003083246.1 1146 
[552 amino acid sequence]) (136), and Volvox carteri (XP_002955183 [398 amino 1147 
acid sequence, isozyme 3-like) (137). BLAST analysis with S. oleracea PRPP 1148 
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synthase isoenzyme 1 as the query revealed the presence of class I PRPP synthase 1149 
also in O. lucimarinus, C. variabilis, C. subellipsoidea, and V. carteri. Thus, in 1150 
general the class II PRPP synthases seem to be an addition to the classical, class I, 1151 
PRPP synthases. It should be added that the completion of the A. thaliana genome 1152 
sequencing revealed the presence of a gene encoding a class I PRPP synthase isozyme 1153 
5 (16). 1154 
Archaeal PRPP Synthases 1155 
The biochemical characterization of PRPP synthase of M. jannaschii persuaded the 1156 
authors to propose the existence of a third class of PRPP synthases. The activity of 1157 
this enzyme is activated by Pi and it has restricted diphosphoryl donor capacity (ATP 1158 
and dATP only), which are properties of class I PRPP synthases. However, ADP 1159 
binds to only the active site, and the enzyme appears to be unregulated by an allosteric 1160 
mechanism involving purine ribonucleoside diphosphates, which is a property of class 1161 
II PRPP synthases. Additionally, the quarternary structure of M. jannaschii PRPP 1162 
synthase is tetrameric (48). In light of three-dimensional structures of PRPP synthase 1163 
of T. volcanium, and S. solfataricus, which are dimers, it seems more reasonable to 1164 
define this class of PRPP synthases as “archaeal PRPP synthases” rather than class III. 1165 
Amino acid sequence alignments of PRPP synthase of the three archaeal species, M. 1166 
jannaschii, T. volcanium, and S. solfataricus, with the amino acid sequence of B. 1167 
subtilis PRPP synthase revealed conservation of amino acids along the polypeptide. 1168 
The regulatory flexible loop, the PP loop and the ribose 5-phosphate binding loop are 1169 
extensively conserved; the catalytic flexible loop is less conserved, but the apparent 1170 
indispensable lysine and arginine residues are retained. The amino acid residues 1171 
important for binding of the adenine moiety and the catalytically important histidine 1172 
residues are also conserved (Table S1). As with the class II PRPP synthases, it is 1173 
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likely that the archaeal PRPP synthases and class I PRPP synthases share identical 1174 
catalytic mechanisms. 1175 
 M. jannaschii. The amino acid sequences involved in various functions are 1176 
conserved in M. jannaschii PRPP synthase, i.e. the regulatory flexible loop, Leu88-1177 
Ser104, the the PP loop, Asp163-Ala166, the catalytic flexible loop, Lys186-Ala197, 1178 
the ribose 5-phosphate binding loop, Asp205-Thr220 (Table S1). Also, the two-1179 
domain structure of the M. jannaschii PRPP synthase subunit resembles that of the B. 1180 
subtilis enzyme. 1181 
 Biochemical characterization of PRPP synthase from M. jannaschii revealed 1182 
properties unlike those described above for class I and class II PRPP synthases (Table 1183 
2). Apparently, the poor affinity for both substrates may be compensated by a very 1184 
large Vmax value. Additionally, the activity of M. jannaschii PRPP synthase is 1185 
stimulated by Pi, diphosphoryl donors are ATP and dATP, ADP is a competitive 1186 
inhibitor, and ADP binds to a single site per subunit, hence the active site. These 1187 
properties partly point to a class I enzyme, i.e. restricted diphosphoryl donor capacity 1188 
and activation by Pi, and partly to a class II enzyme, i.e. lack of allosteric regulation. 1189 
The quaternary structure of M. jannaschii PRPP synthase was furthermore found to be 1190 
tetrameric (48). 1191 
 The structure of M. jannaschii PRPP synthase, as deduced from x-ray 1192 
crystallographic analysis, is considerably more compact than that of B. subtilis PRPP 1193 
synthase, primarily because of truncations at the N- and C-terminal ends as well as 1194 
one shorter loop in the interior of the sequence. As with B. subtilis PRPP synthase, the 1195 
structure of M. jannsachii PRPP synthase revealed two different types of subunit-1196 
subunit interactions; these were revealed by the structure of Apo-PRPP synthase 1197 
structure (PDB code 1u9y), and the structure of the AMP/R5P-PRPP synthase 1198 
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complex (with AMP and ribose 5-phosphate bound, PDB code 1u9z). The tetrameric 1199 
M. jannaschii PRPP synthase could be superimposed easily with two of the subunits 1200 
of B. subtilis PRPP synthase to form almost identical bent dimers. Consistent with the 1201 
bent dimer-organization of M. jannaschii PRPP synthase, six of the eight amino acid 1202 
residues selected in Table 3 were identical or conserved among B. subtilis and M. 1203 
jannaschii PRPP synthases. Interestingly, the interface of the bent dimer contains 1204 
residues involved in the binding of the adenine moiety of ATP, namely Phe32B 1205 
(Phe40D of B. subtilis PRPP synthase), Asp34B (Asp42D), Glu36B (Glu44D) and 1206 
Arg92A (Arg101A). The rest of the active site, i.e. the binding of the remaining part 1207 
of ATP and ribose 5-phosphate, is provided entirely by one subunit of a bent dimer, 1208 
indicating that substrate recognition and catalytic machinery of B. subtilis and M. 1209 
jannaschii PRPP synthases are identical. The conservation of amino acid residues 1210 
involved in substrate binding and catalysis is apparent from the amino acid 1211 
comparison of Table S1. In contrast, the other subunit-subunit interaction of M. 1212 
jannaschii did not superimpose with the linear dimers of the B. subtilis enzyme. Only 1213 
four of 12 amino acid residues involved in the parallel-dimer formation of B. subtilis 1214 
PRPP synthase were identical or conserved (Table 3). The allosteric effectors of B. 1215 
subtilis PRPP synthase, ADP and Pi, bind to residues at the interface of the parallel 1216 
dimer, which is not conserved among the two enzymes, and very few if any amino 1217 
acid residues involved in allosteric regulation of B. subtilis PRPP synthase are 1218 
conserved in M. jannaschii PRPP synthase (Table S2). This is consistent with the lack 1219 
of allosteric regulation in vitro of M. jannaschii PRPP synthase, which binds only a 1220 
single molecule of ADP per subunit (48). 1221 
 T. volcanium. As was described above for M. jannsachii PRPP synthase, amino 1222 
acids involved in the formation of the bent dimer are relatively well-conserved 1223 
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relative to the homologous amino acid residues of B. subtilis PRPP synthase, whereas 1224 
the amino acid residues involved in the formation of the parallel dimer are much less 1225 
conserved. Amino acid residues involved in substrate binding and catalysis are well-1226 
conserved (Table S1), whereas only few amino acid residues involved in allosteric 1227 
regulation of B. subtilis PRPP synthase are conserved in T. volcanium PRPP synthase 1228 
(Tables S2). 1229 
 Structures of several crystal forms of T. volcanium PRPP synthase have been 1230 
described. (a) ADP/SO42--PRPP synthase with ADP and SO42- present at the active 1231 
site representing ATP and the phosphoryl moiety of ribose 5-phosphate, determined at 1232 
1.5 Å resolution (PDB code 3lrt). The active site is located in the cleft between the 1233 
two domains as in the B. subtilis enzyme. The binding of ADP is well defined; the 1234 
adenine moiety is stacked between Arg91 and Phe32 and N6 is bound to Asp34 and 1235 
Glu36, the ribose hydroxyls are bound to Glu92, His93 and Tyr96. In addition, ADP 1236 
interacts with the side chains of amino acids residues Asp34, Glu36, Arg91 and 1237 
Ser214 through water molecules. The crystal form has an open conformation, i.e. the 1238 
catalytic flexible loop is open, resulting in full accessibility of the active site for 1239 
substrates. The side chain nitrogens of the catalytic flexible loop-Lys184 are located 1240 
14 to 16 Å away from the β-phosphate oxygen of ADP (138); (b) mATP/SO42--PRPP 1241 
synthase determined at 1.8 Å resolution (PDB code 3lpn). In this crystal form the 1242 
ATP analog α,β-methylene ATP replaces ADP of the ADP/SO42--PRPP synthase 1243 
described above. The binding of α,β-methylene ATP, including the triphosphate chain 1244 
is well defined and shows His93 interacting with the oxygens of the β- and γ-1245 
phosphates, and Tyr96, His124 and Asp125 interacting with the γ-phosphate. The 1246 
catalytic flexible loop remained open (138). (c) ADP-Mg2+/R5P-PRPP synthase 1247 
determined 1.8 Å resolution (PDB code 3mbi). Here MgADP and ribose 5-phosphate 1248 
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are located at the active site. Mg2+ coordinates the polypeptide through His124, the α- 1249 
and β-phosphates as well as three water molecules. Thus, the binding of this Mg2+ ion 1250 
resembles that of the MG2 site of B. subtilis PRPP synthase, except for the 1251 
coordination of Mg2+ to the γ-phosphate rather than water in the B. subtilis enzyme. 1252 
Furthermore, the catalytic flexible loop is closed, i.e. it is bent approximately 45° 1253 
towards the bound ligands, MgADP and ribose 5-phoshate, compared to the open 1254 
form; this results in the placement of Lys184 and Arg186 close to the β-phosphate of 1255 
ADP (and presumably of ATP), and in shielding of the active site and the transition 1256 
state from the solvent (138). The importance of this closure of the catalytic flexible 1257 
loop for catalysis is discussed further below in the section “Mechanism of Catalysis”. 1258 
 The crystal structure as well as molecular sieving revealed that T. volcanium 1259 
PRPP synthase is a dimer, which does not form higher symmetry oligomers 1260 
(hexamers or tetramers) like those described for the class I PRPP synthases (138). 1261 
Also the crystal structure with α,β-methylene ATP/ADP and ribose 5-phosphate 1262 
present revealed a dimeric quaternary structure. However, molecular sieving in the 1263 
presence of ATP (or α,β-methylene ATP) and ribose 5-phosphate has not been 1264 
performed, so formation of a tetramer resembling that of M. jannaschii PRPP 1265 
synthase under some conditions cannot be ruled out. 1266 
 S. solfataricus. S. solfataricus PRPP synthase resembles PRPP synthases from M. 1267 
jannaschii and T. volcanium with respect to conservation or lack of conservation of 1268 
amino acid residues involved in dimer formation (Table 3), substrate binding and 1269 
catalysis (table S1), and allosteric regulation (Table S2). Structural information for S. 1270 
solfataricus PRPP synthase is available from analysis of a crystal form with AMP and 1271 
sulfate representing the phosphoryl group of ribose 5-phosphate at 2.8 Å resolution 1272 
(PDB code 4twb). The enzyme appears to be active as a dimer like that described for 1273 
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T. volcanium PRPP synthase. Amino acid sequence identity of S. solfataricus and T. 1274 
volcanium PRPP synthases is 29 %. The fold of the subunit resembles that of other 1275 
PRPP synthases, and the binding of the nucleotide substrate ATP (modeled to only the 1276 
AMP portion) is highly conserved in comparison to the PRPP synthases of T. 1277 
volcanium, M. jannaschii and B. subtilis (139). 1278 
 Other archaeal PRPP synthases. The gene encoding PRPP synthase of the 1279 
hyperthermophilic archaeon Thermococcus kodakaraensis has been expressed in E. 1280 
coli and PRPP synthase purified to near homogeneity. Recombinant T. kodakaraensis 1281 
PRPP synthase accepts ATP, CTP and GTP as diphosphoryl donors, with ATP as the 1282 
preferred diphosphoryl donor. The enzyme eluted as a monomer in exclusion 1283 
chromatography (140). Chromatography was performed without the presence of 1284 
substrates. It is therefore possible that the active enzyme consists of more than one 1285 
subunit. Indeed, comparison of amino acid residues involved in the formation of the 1286 
bent dimer of M. jannaschii with those of T. kodakaraensis revealed an almost exact 1287 
match, suggesting that active T. kodakaraensis PRPP synthase may constitute a 1288 
tetramer similar to that of M. jannaschii PRPP synthase. The similarity of the amino 1289 
acid sequence of T. kodakaraensis PRPP synthase with those of, M. jannaschii, S. 1290 
sulfolobus and T. volcanium is 52 to 58% (identity 32 to 40%), where with B. subtilis 1291 
PRPP synthase the values are 47% (similarity) and 28% (identity). 1292 
 The genomes of the following archaeal species appear to contain two prs genes: 1293 
Archaeoglobus fulgidus, Archaeoglobus veneficus, Ferroglobus placidus, 1294 
Halorhabdus utahensis, Methanocella conradii, Thermofilum pendens, 1295 
Thermogladius cellulolyticus. No biochemical information is available on the 1296 
properties of the corresponding proteins. Amino acid sequence comparison of two 1297 
putative A. fulgidus PRPP synthases and B. subtilis PRPP synthase reveals a high 1298 
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degree of conservation of amino acid residues involved in substrate binding and 1299 
catalysis. Specifically, the two important lysine and arginine residues are present in 1300 
both sequences, Lys172 and Arg175 in sequence 1, Lys186 and Arg 188 in sequence 1301 
2 (Table S3). Indeed, amino acid sequence comparison reveals that A. veneficus, F. 1302 
placidus, M. conradii, T. pendens, T. cellulolyticus may encode two bonafide PRPP 1303 
synthases as evaluated by the presence of conserved or identical amino acids at 1304 
positions homologous to B. subtilis PRPP synthase residues Phe40, His135, Asp174 1305 
of the ribose 5-phosphate binding loop and Lys197 and Arg199 of the catalytic 1306 
flexible loop. In contrast, one of the putative PRPP synthases of H. utahensis has 1307 
aspartate and threonine rather than lysine and arginine in the catalytic flexible loop, 1308 
and, thus, very likely does not represent an active PRPP synthase. 1309 
 In spite of large variations in protein structure among class I, class II and archaeal 1310 
PRPP synthases as a result of the different oligomerization properties described 1311 
above, it obvious that the catalytic mechanism essentially is the same among the three 1312 
PRPP synthase classes as evaluted by the conservation of the catalytically important 1313 
amino acid residues in the three classes. 1314 
 1315 
MECHANISM OF CATALYSIS 1316 
The three-dimensional structure of the important catalytic flexible loop, Lys197 to 1317 
Met208 of B. subtilis PRPP synthase, Lys186 to Ala197 of the M. jannaschii enzyme, 1318 
Lys188 to Ile199 of the S. solfataricus enzyme, and Lys194 to Met205 of human 1319 
PRPP synthase isozyme 1, remained unresolved in studies of the structures of these 1320 
enzymes (48-51, 139). However, the solution of the T. volcanium PRPP synthase 1321 
structure revealed that the binding of the substrate ribose 5-phosphate and the 1322 
substrate analog MgADP resulted in a closed conformation of the catalytic flexible 1323 
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loop, in which strands β10 and β11 move 17 Å toward the substrates and bring the 1324 
important catalytic residues, Lys184 and Arg186, into proximity with ribose 5-1325 
phosphate and the triphosphate chain of the nucleotide (Fig. 6A). According to this 1326 
structure, Lys184 and Arg186 bind to oxygen(s) of the β-phosphate of ATP. 1327 
Additionally, Mg2+ coordinates to a nitrogen of His124 as well as to oxygens of the α- 1328 
and β-phosphates of ADP, and, presumably of ATP. In the open conformation, the 1329 
C5’, the α-phosphorus and the β-phosphorus of ADP or ATP are essentially linearly 1330 
arranged, whereas in the closed conformation the β-phosphate is bent approximately 1331 
90 ° relative to the C5’, and the α-phosphorus, and, thus locates the β-phosphorus in 1332 
ideal position for nucleophilic attack by the O1 of ribose 5-phosphate (Fig. 6B) (138). 1333 
Only a single Mg2+ was identified at the active site of T. volcanium PRPP synthase, 1334 
and biochemical information as to the number of Mg2+ necessary for catalysis has not 1335 
been published. This is important because dual roles for Mg2 have been identified in 1336 
the reaction mechanism of other PRPP synthases. 1337 
 Additional information was obtained from studies of two structures of activated 1338 
B. subtilis PRPP synthase. In the first of theses structures, a transition-state analog of 1339 
phosphoryltransfer reactions, AlF3, was employed in the presence of the product AMP 1340 
and the substrate ribose 5-phosphate, which generated a transition-state bound 1341 
complex (AlF3-PRPP synthase structure) (Fig. 6C). Here Al3+ represents the β-1342 
phosphorus, whereas the three F- represent the three oxygens of the β-phosphate, and 1343 
the α- and γ-phosphates were provided by two AMP molecules as described before. In 1344 
the second of these structures, the substrate analog α,β-methylene ATP and the 1345 
substrate ribose 5-phosphate were employed to generate an active-state quaternary 1346 
complex (mATP/R5P-PRPP synthase structure). In the former structure containing 1347 
AlF3, the catalytic flexible loop was closed and revealed contacts between Lys197 and 1348 
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Arg199 with the β-phosphoryl group of ATP, whereas in the second, mATP/R5P 1349 
structure, the catalytic flexible loop was open. Thus, the contacts between Lys197 and 1350 
Arg199 observed in the AlF3-structure appear to be lost in the active state quarternary 1351 
complex (mATP/R5P), where the flexible catalytic loop remains unresolved. Thus, 1352 
loop closure appears to be transient and specific for only the transition state. Al3+ of 1353 
the AlF3 structure has an octahedral coordination with the C1-oxygen of ribose 5-1354 
phoshate, the three F- as well as one oxygen from each of the α- and γ-phosphoryl 1355 
groups. The distances from the Al3+, which corresponds to the β-phosphorus of ATP, 1356 
to the C1 oxygen of ribose 5-phosphate and the oxygen of the α-phosphoryl group are 1357 
2.0 and 1.9 Å, respectively, and, thus these cooordinations have partial bond 1358 
character. In the AlF3 structure Mg2+ is located on both sides of the triphosphate 1359 
chain. As observed with T. volcanium PRPP synthase, the binding of Mg2+ at the 1360 
MG2 site of B. subtilis PRPP synthase results in bending of the triphosphate chain of 1361 
ATP. This bent conformation is caused by the tridentate conformation, α,β,γ-MgATP. 1362 
Furthermore, the Mg2+ of the MG1 site coordinates to the γ-phosphate (as well as to 1363 
ribose 5-phosphate and Asp174) and, thus, the two Mg2+ are responsible for a tight 1364 
conformation of the triphosphate chain of ATP, and a perfect inline geometry of the 1365 
C1 oxygen of ribose 5-phosphate, the β-phosphate and the α-phosphate is created. 1366 
Furthermore, the bent conformation of the triphosphate chain results in electrostatic 1367 
repulsion among the phosphoryl groups, whereas the coordination of Mg2+ to a 1368 
nitrogen of His135 may withdraw charge from the phosphoryls coordinated to the 1369 
Mg2+ at the MG2 site (54). 1370 
 Although the Al3+-generated transition-state adopts a hexacoordinated octahedral 1371 
bipyrimidal structure rather than the pentacoordinated trigonal-bipyrimidal transition- 1372 
state expected for a phosphotransfer mechanism, the data are in agreement with an 1373 
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associative nucleophilic substitution, SN2, mechanism. This mechanism is supported 1374 
by the perfect inline orientation of the nucleophile (the C1 oxygen of ribose 5-1375 
phosphate), the partial bond character between the attacking nucleophile and the 1376 
transferred group (represented by Al3+), a transient charge of -2 (provided by the two 1377 
“free” γ-phosphoryl oxygens and reprensented by fluorides). An effect of the two 1378 
basic amino acid residues of the catalytic flexible loop, Lys197 and Arg199, may be 1379 
stabilization of the transient negative charge. The SN2 mechanism is supported by 1380 
previous studies of S. enterica PRPP synthase, which showed that the product of 1381 
reaction of ATP with [1-18O]ribose 5-phosphate was [18O]PRPP rather than 1382 
[18O]AMP (66, 141). 1383 
 1384 
REGULATION OF PRPP SYNTHASE ACTIVITY 1385 
All PRPP synthases analyzed, class I from microbes (S. enterica (69), B. subtilis (70), 1386 
E. coli (45, 75), humans (72, 142), rat (143, 144)), class II (spinach isozymes 3 and 4 1387 
(46, 47)) as well as the archaeon M. jannaschii (48), are inhibited in a competitive 1388 
manner by ADP, which binds in competition with ATP at the active site. 1389 
Superimposed on the competition of ADP and ATP at the active site is allosteric 1390 
inhibition by ADP. This allosteric inhibition is well documented. However, let us first 1391 
mention some results of a steady state kinetic analysis of the binding of allosteric 1392 
effectors to E. coli PRPP synthase, which showed that Pi and ADP compete for 1393 
binding to the same site (75). Additionally, Pi is required for the activity of the class I 1394 
PRPP synthases of S. enterica (35, 56), E. coli (45), B. subtilis (70), B. caldolyticus 1395 
(55), humans (73), and rat (71), as well as for the stability in the absence of MgATP 1396 
of S. enterica and E. coli PRPP synthases (35, 45). Finally, Pi can be replaced as an 1397 
activator by high concentration of SO42- (49, 71, 73). Altogether, it is therefore more 1398 
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correct to say that that PRPP synthase is allosterically regulated with Pi as an 1399 
allosteric activator and ADP as an allosteric inhibitor (75). 1400 
 Allosteric inhibition of PRPP synthase by ADP was demonstrated by detailed 1401 
steady state kinetic analysis. A distinctive feature of allosteric binding by ADP is that 1402 
it requires the active site to be fully occupied by both ATP or ADP and ribose 5-1403 
phosphate. This was concluded from the observation that ADP inhibition becomes 1404 
stronger as the enzyme approaches saturation with ribose 5-phosphate; this is 1405 
explained by the ordered binding of substrates in which ribose 5-phosphate binds last, 1406 
i.e., ADP binding at the active (ATP) site induces apparent substrate inhibition by 1407 
ribose 5-phosphate (69). The presence of a separate ADP binding site was 1408 
demonstrated directly by equilibrium binding dialysis. Thus, ATP (actually the 1409 
unreactive analog α,β-methylene ATP) binds to a single site per molecule, the active 1410 
site, in the presence of ribose 5-phosphate. In the absence of ribose 5-phosphate ADP 1411 
binds to the same site as ATP, whereas in the presence of ribose 5-phosphate ADP 1412 
binds to the additional allosteric site to yield two bound ADP per monomer (68). 1413 
 The synthesis of PRPP was furthermore studied in vivo. Purine starvation of S. 1414 
enterica resulted in accumulation of PRPP, whereas purine nucleotides were depleted 1415 
suggesting that these conditions caused reduction of an inhibitor of PRPP synthesis. 1416 
This inhibitor could very well be ADP (145). Also, the addition of adenine to cultures 1417 
of S. enterica caused a dramatic reduction in the PRPP pool, which only slowly 1418 
returned to the previous level. Adenine and PRPP react in vivo to form AMP followed 1419 
by the formation ADP, which causes inhibition of PRPP synthase. Therefore, the 1420 
PRPP pool only slowly returns to the level before adenine-addition (146). 1421 
 PRPP synthase from some organisms such as B. subtilis, B. caldolyticus and 1422 
mammals are also allosterically inhibited by GDP (55, 70, 71, 73). 1423 
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 Characterization of several mutations in human PRPP synthase isozyme 1 1424 
demonstrated the existence and physiological importance of the allosteric site in human 1425 
PRPP synthase. The mutant forms were identified in the human PRS1 genes of 1426 
individuals with inherited defects in purine metabolism (72). The positions of the amino 1427 
acid replacements identified, Asp51His, Asn113Ser, Leu128Ile, Asp182His, Ala189Val, 1428 
and His192Gln, are indicated by arrows above the deduced B. subtilis PRPP synthase 1429 
amino acid sequence of Fig. 2. The affected individuals exhibit hyperuricemia, gouty 1430 
arthritis, and in some cases neurosensory defects, with an X-linked pattern of 1431 
inheritance. Six different mutations in human PRPP synthase isozyme 1 have been 1432 
characterized at the molecular level. The kinetics of inhibition of the purified 1433 
recombinant mutant enzymes by ADP and GDP confirmed that they were much less 1434 
sensitive to inhibition than the wild-type isozyme and that the pattern of inhibition by 1435 
ADP with respect to ATP was altered from a complex pattern of inhibition of the wild-1436 
type enzyme to simple competitive. Thus, the existence of a distinct allosteric mode of 1437 
inhibition by ADP and GDP was demonstrated. The fact that desensitization to allosteric 1438 
inhibition results in metabolic defects that are readily explained by overproduction of 1439 
PRPP in human cells is strong evidence that this inhibition is critical for normal 1440 
regulation of PRPP synthesis. The mutations that destroy allosteric inhibition in human 1441 
PRPP synthase are scattered throughout the primary sequence, but localised in the three-1442 
dimensional structure almost exclusively in the interface between dimers in the hexamer. 1443 
 In molecular terms the mechanism of allosteric inhibition may be described by 1444 
comparing the three-dimensional structures of various PRPP synthase complexes. Thus, 1445 
the B. subtilis SO42--, ADP-, GDP- and mGDP-PRPP synthase complexes are 1446 
characterized by tight packing of both the N- and C-terminal domains and represent an 1447 
inactive form (the T-state) of the enzyme, whereas the B. subtilis AlF3- and mATP/R5P-1448 
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PRPP synthase complexes are less tightly packed and represent an active form (the R-1449 
state) of the enzyme. Of particular importance is a comparison of the crystal structures of 1450 
the transition-state complex, AlF3-PRPP synthase, and the inhibited-state quaternary 1451 
complex, mGDP-PRPP synthase. The latter complex contained Mg2+, α,β-methylene 1452 
ATP and ribose 5-phosphate in the active site as well as methylene GDP in the allosteric 1453 
site. The binding of ribose 5-phosphate, the adenine base of ATP, the γ-phosphate as 1454 
well as Mg2+ of the MG1 site is virtually identical in the two complexes. In contrast, 1455 
Mg2+ at the MG2 site was displaced, and the torsional angle of the glycosidic bond of 1456 
ATP differed by a 55° rotation among the two structures, 72° (in mGDP-PRPP synthase) 1457 
versus 127° (in AlF3-PRPP synthase). This rotation displaces the α- and β-phosphates of 1458 
the nucleotide bound to the active site and appears to prevent the inline arrangement of 1459 
the C1 oxygen of ribose 5-phosphate and the β- and α-phosphates of ATP necessary for 1460 
nucleophilic attack The important amino acid residues involved in these alterations are 1461 
located within the regulatory flexible loop (Tyr97-Thr113, Fig. 2). Thus, for the binding 1462 
of the ribose moiety of ATP a shift in hydrogen bonding of the C2’ oxygen and Gln102 1463 
to hydrogen bonding of the C3’ oxygen and Glu110 occurred. Additionally, the MG2-1464 
coordinated water molecules changed from coordinating to Arg101, Asp103 and Arg104 1465 
to coordinate only Asp103, whereas Arg104 changed to form hydrogen bonding to 1466 
oxygens of the α-phosphoryl. Arg101 no longer formed hydrogen bonding in the T-state 1467 
(54). 1468 
 As expected from the analysis of the mutant variants of human PRPP synthase 1469 
isozyme 1 described above, these altered substrate-binding capabilities are 1470 
accompanied by transitions in the hexameric structure. Reciprocal interactions 1471 
between two C-terminal domain amino acid residues Val178-Asp195, Arg198 and 1472 
Asn209-Val211 result in a tightly packed interface. This stretch of amino acid 1473 
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residues straddles the catalytic flexible loop (Lys197-Met208). Particularly important 1474 
is a hydrophobic pocket consisting of Ile192, Ile194 and Val211. Altogether, the 1475 
interactions prevent loop closure. The binding of substrates at the active site as well as 1476 
SO42- (and hence presumably Pi) at the allosteric site decouples these C-terminal 1477 
amino acid interactions and permits loop closure. On the other hand, when ADP or 1478 
GDP is bound at the allosteric site, interactions of the C2’ hydroxyl of the bound ADP 1479 
or GDP with Gln140, which interacts with the imidazole moiety of His149 through a 1480 
water molecule and hence interaction with Leu134 results in maintaining the 1481 
hydrophobic pocket and the tight C-terminal domain interaction. All these interactions 1482 
are lost in the transition-state like complex, AlF3. (54). 1483 
 Site-directed mutagenesis of the B. subtilis prs gene was performed to generate 1484 
mutant variants with similar amino acid alterations equivalent to the naturally 1485 
occurring mutations in human PRPP synthase isozyme 1 describe above (54). As 1486 
observed for the human counterparts, the kinetic properties of Pi activation among the 1487 
mutant variants were generally shifted toward an increased affinity for Pi. The mutant 1488 
B. subtilis enzymes displayed about 10-fold decrease or more in the half-saturation 1489 
concentrations for Pi when compared to the wild-type form. Except for the Asp57His 1490 
variant (homologous to human Asp51His variant), whose Pi dependence on activity 1491 
was similar to that of the wild-type, and Asp196Gln (homologous to human 1492 
His192Gln), whose activity appeared independent of Pi within the range of Pi 1493 
concentrations applied. 1494 
 The B. subtilis PRPP synthase variants described above were also analyzed with 1495 
respect to inhibition by the nucleoside diphosphate GDP, which is less complex than 1496 
ADP inhibition as GDP only binds to the regulatory site and not the active site. When 1497 
inhibition by GDP of each of the mutant PRPP synthases was analyzed at a Pi 1498 
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concentration corresponding to the individual half-saturation concentration value for 1499 
Pi, similar KiGDP values were obtained for the wild-type and the following variants 1500 
Asn119Ser (homologous to human Asn113Ser), Leu134Ile (homologous to human 1501 
Leu128Ile), Asp186His (homologous to human Asp182His) and Ala193Val 1502 
(homologous to human Ala189Val). This observation indicates that PRPP synthase 1503 
may represent the V-system of the Monod, Wyman and Changeux model for allosteric 1504 
systems (147), where the activator (Pi) and the inhibitor (GDP) compete for binding to 1505 
the same site to alter the equilibrium between the R and T conformer of the enzyme. 1506 
The mutant enzymes described above that have increased affinity for Pi all have 1507 
changed equilibrium between conformers that further the R-conformer compared to 1508 
wild type enzyme. 1509 
 Mapping of each of the amino acid substitutions in the structure (cf. Fig. 2) that 1510 
influence this equilibrium between active and inactive conformer shows that three 1511 
amino acid residues, Asp186, Ala193 and Asp186 are located within the region of the 1512 
C-terminal domain interaction, which is important for transition of the allosteric 1513 
signal, i.e. the binding of ribonucleoside diphosphate at the allosteric site. 1514 
Additionally, Asn199 is located at the N-terminal interface of the bent dimer, and 1515 
likewise may perturb the binding of ribonucleoside diphosphate at the allosteric signal 1516 
as described above. Finally, Leu134 is involved in the transmission of the allosteric 1517 
signal. Almost all of the amino acid substitutions are located on the interface within a 1518 
dimer or between dimers in the hexamer. These positions are in accordance with the 1519 
existence of an equilibrium between the active and the inactive form of class I PRPP 1520 
synthase that can be altered by side chain substitutions that stabilize any of the two 1521 
conformers, the active R or the inactive T conformer. 1522 
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 A large number of mutations have furthermore been identified in the gene 1523 
specifying human PRPP synthase isozyme 1 of patients suffering from relapse of 1524 
acute lymphoblastic leukemia. Negative feedback-defective PRPP synthase resulted 1525 
from the mutations that arose after treatment with 6-mercaptopurine and 6-1526 
thioguanine as chemotherapeutics. Twenty-nine lesions affecting 14 amino acid 1527 
positions have been identified. Some of these positions were already known from the 1528 
previous analysis of PRPP synthase from patients with gout or uric acid 1529 
overproduction, Asn113, Asp182 and Ala189. At the latter position two variants were 1530 
identified (Ala189Thr, 10 patients, and Ala189Val, one patient). Mapping of the 1531 
amino acid alterations on the three-dimensional structure of human PRPP synthase 1532 
isozyme 1 revealed the location of the variations at the allosteric site (Ser102, 1533 
Asn143, Thr302) or at the dimer interface (Asn113, Gly173, Lys175, Asp182, 1534 
Ala189, Leu190). The conclusion from this analysis is that the cytotoxic effect of 1535 
administering compounds such as 6-mercaptopurine and 6-thioguanine may be 1536 
counteracted by mutations that accelerate the production of PRPP and hence 1537 
accelerating the de novo synthesis of purine nucleotides, which competes with the 1538 
cytotoxic compounds (148). 1539 
 Fortuitously, the presence of Ca2+ during crystallization of B. subtilis PRPP 1540 
synthase allowed important conclusions about the mechanism of inhibition by this ion 1541 
to be drawn (54). Ca2+ was identified as a hepta-coordinating metal ion at the MG1 1542 
site of the GDP-PRPP synthase complex, whereas Mg2+ occupied the MG2 site (Fig. 1543 
6D). In contrast to this Mg2+/Ca2+ arrangement, two Mg2+ were found at the other 1544 
active site of the asymmetric unit of the GDP-PRPP synthase complex. The ligands 1545 
coordinated to Ca2+ resembled those coordinated to Mg2+: Asp174, oxygens of C1, C2 1546 
and C3 of ribose 5-phosphate, oxygen of the γ-phosphate, a water molecule, with an 1547 
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additional seventh coordination to oxygen of the β-phosphate of ATP. In particular, 1548 
this latter coordination of Ca2+ causes perturbation of the inline arrangement of the C1 1549 
oxygen of ribose 5-phosphate and the β- and α-phosphates of ATP described above 1550 
(54). Previous kinetic analysis revealed that Ca2+, which does not support PRPP 1551 
synthase activity alone, is an inhibitor of PRPP synthase activity even in the presence 1552 
of a very large excess of Mg2+ ions (56, 57). 1553 
 The detailed molecular description of the regulation of PRPP formation has 1554 
prompted the application of this knowledge for the improvement of commercially 1555 
important products of biochemical pathways for which PRPP is an intermediate. The 1556 
previously discussed improvement of riboflavin synthesis by E. gossypii harboring 1557 
feedback-resistant variants of PRPP synthase is one example (112). Another example 1558 
is the production of purine nucleosides by Bacillus amyloliquefaciens. The following 1559 
PRPP synthase variants were constructed with the equivalent variant of human PRPP 1560 
synthase isozyme variant shown in parenthesis: Asp58His (Asp51His), Asn119Ser 1561 
(Asn113Ser) and Leu134Ile (Leu128Ile). As expected, the B. amyloliquefaciens PRPP 1562 
synthase variants Asn119Ser and Leu134Ile were activated at lower Pi concentrations 1563 
and were relatively more resistant to inhibition by ADP and GDP compared to the 1564 
wild type, and, indeed, both B. amyloliquefaciens and B. subtilis strain carrying the 1565 
mutations specifying Asn119Ser or Leu134Ile had improved production of purine 1566 
nucleosides presumably due to increased purine de novo synthesis. Kinetic constants 1567 
of B. amyloliquefaciens PRPP synthase are given in Table 2 (149). 1568 
 1569 
PHOSPHORIBOSYL BISPHOSPHATE PHOSPHOKINASE 1570 
Mutants that are defective in the prs gene have been isolated in E. coli and S. enterica 1571 
as described further below. Strains with knockout mutations (Δprs) have a 1572 
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simultaneous requirement for five metabolites: purine and pyrimidine nucleosides, 1573 
histidine, tryptophan and NAD (2, 3). Mutants that suppress the requirement for NAD 1574 
can be easily isolated. These mutants retain the other four requirements; their genetic 1575 
defect maps to the pstSCAB-phoU operon (150, 151). Lesions in this operon result in 1576 
constitutive expression of the Pho regulon operons, which are involved in the 1577 
assimilation of Pi and the acquisition of Pi from other sources (152). Genetic analysis 1578 
revealed that suppression of the NAD requirement suppression phenotype originated 1579 
from increased expression of the phnN cistron of the tetrakaidecacistronic phnC-P 1580 
operon (150). The gene products of this operon are involved in the catabolism of 1581 
phosphonates (152). It was furthermore shown that the phnN cistron specifies a 1582 
phosphokinase with the ability to use ribosyl 1,5-bisphosphate as a substrate: ribosyl 1583 
1,5-bisphosphate + ATP → PRPP + ADP, i.e. a ribosyl bisphosphate phosphokinase 1584 
(EC 2.7.4.23) (Fig. 7A). It was shown that the enzyme was able to convert ribosyl 1,5-1585 
bisphosphate to a product that functioned as a substrate for purified xanthine 1586 
phosphoribosyltransferase and that the product was xanthosine 5’-monophosphate 1587 
according to the chemical equation xanthine + PRPP → xanthosine 5’-1588 
monophosphate + PPi (151). Subsequently, it was shown that ribosyl 1,5-bisphosphate 1589 
is an intermediate in phosphonate catabolism (153). However, ribosyl 1,5-1590 
bisphosphate is also a metabolite in cells that are not thriving on phosphonate, 1591 
although the origin and metabolic role of the compound under these conditions remain 1592 
unclear. Even though the reaction product of ribosyl bisphosphate phosphokinase is 1593 
PRPP, the amount synthesized is insufficient to replace the activity of PRPP synthase 1594 
even in cells growing with phosphonate as their Pi source (B.H.-J., unpublished result) 1595 
or in cells that express phnN in a multi-copy plasmid (151). The amino acid sequences 1596 
of ribosyl bisphosphate phosphokinase and PRPP synthase only show low similarity, 1597 
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approximately 25%. Among the amino acid residues of B. subtilis PRPP synthase 1598 
with annotated functions from the crystal structure, very few if any at all, can be 1599 
recognized in the amino acid sequence of ribosyl bisphosphate phosphokinase. 1600 
Likewise, the similarity of ribosyl bisphosphate phosphokinase to type I 1601 
phosphoribosyltransferase and type II phosphoribosyltransferase is very low, 16% 1602 
with adenine phosphoribosyltransferase (type I) and with quinolinate 1603 
phosphoribosyltransferase (type II). Thus, the evolutionary origin and mechanism of 1604 
phosphoribosyl bisphosphate phosphokinase remain enigmatic; a deeper 1605 
understanding awaits the determination of the three-dimensional structure of the 1606 
enzyme. The physiologic importance of phosphoribosyl bisphosphate phosphokinase 1607 
in the context of phosphonate catabolism has been discussed and previously reviewed 1608 
(154, 155). 1609 
 1610 
DIPHOSPHORYL-, NUCLEOTIDYL- AND PHOSPHORYLTRANSFER 1611 
In spite of a large number of di- or triphosphate-containing compounds, very few 1612 
enzymes catalyze the transfer an intact diphosphoryl group, i.e. attack the β-1613 
phosphorus of ribonucleoside triphosphates, in contrast to enzymes that catalyze the 1614 
transfer of a phosphoryl group, i.e. attack the γ-phosphorus, and enzymes that catalyze 1615 
the transfer of a nucleotidyl group, i.e. attack the α-phosphorus. These latter two 1616 
groups of enzymes are much more abundant than the diphosphoryltransferases. Below 1617 
we shall give examples of the mechanism of catalysis of each of these three enzyme 1618 
classes as a means of comparing catalytic strategies for nucleophilic substitutions on 1619 
the α-, β- and γ-phosphorus atoms of nucleoside triphosphate substrates. 1620 
 1621 
Substitution Reactions at α-, β- or γ-Phosphates 1622 
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Diphosphoryltransfer 1623 
 The diphosphoryltransferases other than PRPP synthase are 2-amino-4-hydroxy-6- 1624 
hydroxymethyldihydropterin diphosphokinase (ATP:2-amino-4-hydroxy-6-1625 
hydroxymethyl-7,8-dihydropterin 6'-diphosphotransferase, EC 2.7.6.3) encoded by 1626 
folK in E. coli (156), the stringent factor or GTP/GDP 3’-diphosphokinase 1627 
(ATP:nucleoside-5'-phosphate pyrophosphotransferase, EC 2.7.6.5) encoded by relA 1628 
in E. coli (157, 158), and in some organisms thiamine diphosphokinase 1629 
(ATP:thiamine diphosphotransferase, EC 2.7.6.2) (159), and nucleotide 1630 
diphosphokinase (ATP:nucleoside-5'-phosphate diphosphotransferase, EC 2.7.6.4) 1631 
(160) (Fig. 7B-F). In addition, a number of other enzymes, primarily 1632 
diphosphohydrolases, catalyze reactions with nucleophilic attack on the β-phosphorus 1633 
of (deoxy)ribonucleoside triphosphates with the release of PPi and the corresponding 1634 
(deoxy)ribonucleoside 5’-monophosphate, and are members of the so-called Nudix 1635 
enzyme superfamily as reviewed previously (161-163). 1636 
 (i) Hydroxymethyldihydropterin diphosphokinase. In addition to PRPP 1637 
synthase, the crystal structure of a number of enzymes catalyzing 1638 
diphosphoryltransfer reactions has been determined. These allow the comparison of 1639 
the active sites and catalytic mechanism of these enzymes. 1640 
Hydroxymethyldihydropterin diphosphokinase of E. coli contains 159 amino acid 1641 
residues, is monomeric with a molecular mass of 18 kDa, and catalyzes the 1642 
diphosphorylation of 6-hydroxymethyl 7,8-dihydropterin, the commited step in folate 1643 
biosynthesis (Fig. 7C). The structure of E. coli hydroxymethyldihydropterin 1644 
diphosphokinase with a variety of ligands has been determined: these include the 1645 
ternary complex with a substrate analog and a substrate, enzyme-Mg2+α,β-methylene 1646 
ATP-hydroxydihydropterin complex (PDB code 1q0n) (164). Additional reports on 1647 
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crystal or solution structures of hydroxymethyldihydropterin diphosphokinase of E. 1648 
coli and Haemophilus influenzae have been published (165-167). Structural and 1649 
mechanistic properties of this enzyme have been previously reviewed (168). Only 23 1650 
amino acid residues are identical between E. coli hydroxymethyldihydropterin 1651 
diphosphokinase and PRPP synthase, and the folds of the two polypeptides are very 1652 
different. The former enzyme adopts a fold comprised of four α-helices and six β-1653 
strands, β1α1β2β3α2β4β5β6α3α4. Substrate recognition is mediated by three loop regions 1654 
located between β1 and α1 (loop L1), between β2 and β3 (loop L2) and between α2 and 1655 
β4 (loop L3). ATP binds first to hydroxymethyldihydropterin diphosphokinase, which 1656 
results in large structural changes in the three loops, in particular L2 and L3, and 1657 
allows the binding of the second substrate, hydroxymethyldihydropterin (164, 169, 1658 
170). Furthermore, two Mg2+ are bound within active site (Fig. 8A). One Mg2+, MgA, 1659 
coordinates to oxygens of the α- and β-phosphates of ATP, to Asp95 and Asp97 as 1660 
well as to two water molecules. A second Mg2+, MgB, coordinates to oxygens of the 1661 
β- and γ-phosphates of ATP, to the hydroxyl of the substrate 1662 
hydroxymethyldihydropterin, to Asp95 and Asp97, as does the first Mg2+, and finally 1663 
to a water molecule. MgB thus coordinates both substrates. This arrangement of Mg2+, 1664 
substrate and amino acid residues places the hydroxymethyldihydropterin hydroxyl at 1665 
a distance of 3.2 Å to β-phosphorus of ATP (164). The triphosphate chain of ATP and 1666 
the hydroxyl of hydroxymethyldihydropterin are organized in a head to head 1667 
arrangement much like that of ribose 5-phosphate and ATP of PRPP synthase with the 1668 
γ-phosphate ”bent” away, rather than in a linear arrangement, which allows attack of 1669 
the hydroxymethyldihydropterin hydroxyl on the β-phosphate of ATP (Fig. 8A). 1670 
 (ii) Thiamine diphosphokinase. Thiamine diphosphate is the active cofactor in a 1671 
number of C-C bond formation and scission processes (171). Some organisms 1672 
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synthesize thiamine diphosphate by diphosphoryltransfer of the β,γ-diphosphoryl 1673 
group of ATP to thiamine (Fig. 7F), whereas others phosphorylate thiamine phosphate 1674 
in a single phosphoryl transfer reaction. The crystal structure of mouse thiamine 1675 
diphosphokinase, which utilizes the former mechanism, has been solved; the enzyme 1676 
structure contained AMP and pyrithiamine diphosphate, i.e. the products of the 1677 
reaction of ATP with pyrithiamine, a thiamine analog which contains a sustituted 1678 
pyrimidine moiety rather than a substitued thiazole moiety. The structure also 1679 
contained one Mg2+, which coordinated to oxygens of the AMP-phosphate, to the α-1680 
phosphate of pyrithiamine diphosphate and to the carboxyls of Asp46, Asp71, Asp73 1681 
and Asp100 (PDB code 2f17). The coordination of Mg2+ to the α-phosphate of 1682 
pyrithiamine diphosphate is consistent with (but does not demonstrate) a bent 1683 
structure of the triphosphate chain of the substrate ATP, as was observed in PRPP 1684 
synthase and hydroxymethyldihydropterin diphosphokinase. However, the authors 1685 
also suggested that the data permitted a linear arrangement of the triphosphate chain 1686 
and a more or less perpendicular orientation of the pyrithiamine with the hydroxyl 1687 
group oriented for nucleophilic attack on a β-phosphate oxygen (172). The structure 1688 
of thiamine diphosphokinase from a few other organisms have been solved. These 1689 
include the structure of the Streptococcus mutans enzyme with thiamine diphosphate 1690 
and two Mg2+ present, but without an adenylyl moiety present (PDB code 3ihk), 1691 
Candida albicans with thiaminyl imidodiphosphate present (173), and S. cerevisiae 1692 
with thiamine present (PDB code 1ig0) (174). The exact architecture of the active site 1693 
with substrates and Mg2+ cannot presently be clearly established. 1694 
 (iii) GTP/GDP 3’-diphosphokinase. The structure of the third 1695 
diphosphoryltransferase, GTP/GDP 3’-diphosphokinase (Fig. 7D), is poorly 1696 
characterized, presumably because the C-terminus associates with the ribosome. This 1697 
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association may hamper crystallization because that region may be disordered when 1698 
not bound. However, important conclusions have been obtained from the studies of 1699 
the bifunctional RelA/SpoT homolog (RelSeq) of Streptococcus dysgalactiae subsp. 1700 
equisimilis in which the diphosphoryltransferase (RelA) and diphosphohydrolytic 1701 
(SpoT) activities are located in the same polypeptide but in different domains (175). 1702 
The diphosphoryltransferase domain of RelSeq bears some structural resemblance to 1703 
the so-called palm domain of human DNA polymerase β, in which two Mg2+ 1704 
intricately position the substrates, primer and deoxyribonucleoside triphosphate, 1705 
through coordination to the 3’-hydroxyl of the nucleophilic primer and to oxygens of 1706 
each of the α-, β- and γ-phosphates of the incipient deoxyribonucleoside triphosphate, 1707 
and by means of coordination to three invariably conserved aspartate residues 1708 
(Asp190, Asp192, Asp256) (176). Unlike DNA polymerase β and PRPP synthase, 1709 
RelSeq appears to carry out catalysis by the assistance of only a single Mg2+. Thus, the 1710 
dependence of the diphosphoryltransfer reaction on the Mg2+ concentration parallels 1711 
the ribonucleoside triphosphate concentration; that is, there is no stimulation of 1712 
diphosphoryltransfer activity by excess Mg2+ (177). RelSeq contains only two of the 1713 
three acidic residues: Asp264, which is homologous to Asp190 of DNA polymerase, 1714 
and Glu323, which is homologous to Asp256. The lack of a homologue of the third 1715 
aspartate residue may imply inability to bind a second Mg2+ (175). However, this 1716 
view that GTP/GDP 3’-diphosphokinase requires only as single Mg2+ has been 1717 
challenged. The activity of monofunctional E. coli GTP/GDP 3’-diphosphokinase is 1718 
stimulated by Mg2+ in excess of the ribonucleoside triphosphate (ATP and GTP) 1719 
concentration; this is unlike the activity of RelA/SpoT bifunctional M. tuberculosis 1720 
GTP/GDP 3’-diphosphokinase, which was inhibited at increased Mg2+ concentrations. 1721 
Analysis of mutant variants of these two GTP/GDP 3’-diphosphokinases revealed the 1722 
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importance of the amino acid sequence 306-Glu-Any-Asp-Asp-309 in E. coli 1723 
GTP/GDP 3’-diphosphokinase (homologous to 348-Arg-Any-Lys-Asp-351 in M. 1724 
tuberculosis GTP/GDP 3’-diphosphokinase). After swapping these motifs, the activity 1725 
of E. coli GTP/GDP 3’-diphosphokinase is inhibited by excess Mg2+, whereas the 1726 
activity of M. tuberculosis GTP/GDP 3’-diphosphokinase chimera is stimulated by 1727 
Mg2+ (178). It is possible that the mechanism of diphosphoryltransfer of bifunctional 1728 
GTP/GDP 3’-diphosphokinases, such as those of S. dysgalactiae or M. tuberculosis, 1729 
may deviate from that of PRPP synthase and hydroxymethyldihydropterin 1730 
diphosphokinase by the apparent requirement of only a single Mg2+, whereas the 1731 
mechanism of diphosphoryltransfer of monofunctional GTP/GDP 3’-1732 
diphosphokinases, such as that of E. coli, may resemble other 1733 
diphosphoryltransferases in requiring two Mg2+ for activity. 1734 
 (iv) MutT. For the sake of completeness, we include a brief description of one 1735 
member of the Nudix hydrolases, MutT, encoded by the mutT gene in E. coli. Like the 1736 
diphosphoryltransfreases, MutT catalyzes a nucleophilic substitution reaction on the 1737 
β-phosphorus but using water as the nucleophile. MutT contains 129 amino acid 1738 
residues, has a molecular mass of 15 kDa and is active as a monomer. The solution 1739 
structure has been determined (179). The enzyme is also designated 8-oxo-dGTP 1740 
diphosphohydrolase because 8-oxo-dGTP appears to be the best substrate in vitro, and 1741 
is probably also the most important substrate in vivo. Other (deoxy)ribonucleoside 1742 
triphosphates are also hydrolyzed, albeit at much higher KM values (180). 8-Oxo-1743 
dGTP results from oxidation of dGTP, and may be misincorpoated into DNA opposite 1744 
of deoxyadenylate residues, which would result in AT → GC transversions (181). The 1745 
frequency of such transversions increases by 100 to 1000 fold in a mutT strain (182). 1746 
Like PRPP synthase and other diphosphoryltransferases, MutT requires two divalent 1747 
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metal ions (Mg2+ or Mn2+ with a preference for Mg2+), for activity. One ion is 1748 
enzyme-bound, and the other is bound to the (deoxy)ribonucleoside triphosphate. The 1749 
enzyme-bound Mg2+/Mn2+ coordinates to the nucleophilic water, to Gly38, Glu56, 1750 
Glu57 and Glu98 and to a second water molecule, whereas the nucleotide-bound 1751 
Mg2+/Mn2+ coordinates to oxygens of the β- and γ-phosphates (162, 183). Catalysis 1752 
involves the abstraction of a proton of the nucleophilic water by Glu53, followed by 1753 
attack on the β-phosphorus and displacement of 8-oxo-dGMP and MgPPi (162). The 1754 
biochemistry, physiology and genetics of MutT as well as other members of the 1755 
Nudix enzyme family have been previously reviewed (161, 162). 1756 
 Nucleotidyltransfer. Nucleotidyltransferases catalyze reactions of the type 1757 
acceptor + (deoxy)ribonucleoside-P-P-P → acceptor-P-(deoxy)ribonucleoside + PPi. 1758 
Examples include reactions catalyzed by nucleic acid polymerases (DNAn + dNTP → 1759 
DNAn+1 + PPi, or RNAn + NTP → RNAn+1 + PPi,) or glucose 1-phosphate 1760 
uridylyltransferase (glucose 1-phosphate + UTP → UDP-glucose + PPi). Indeed, 1761 
nucleic acid polymerases and sugar phosphate nucleotidyltransferases (sometimes 1762 
called sugar nucleoside diphosphate diphosphorylases) are the most prominent 1763 
members of this class of enzymes. These reactions have substitutions with 1764 
nucleophilic attack on the α-phosphorus of ribonucleoside triphosphate or 1765 
deoxyribonucleoside triphosphate in common. The structure of the active sites of 1766 
RNA and DNA polymerases are quite similar. Here we shall return to the human 1767 
DNA polymerase β, briefly described above, to further describe the active site and the 1768 
mechanism of catalysis, which involves the intricate positioning of two Mg2+ ions by 1769 
means of coordination to three conserved aspartate residues, as was originally 1770 
suggested by Steitz and Steitz for DNA polymerase I and other nucleic acid 1771 
polymerases (184). Fig. 8B shows the binding of the two Mg2+ to the active site of 1772 
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DNA polymerase β. MgA coordinates to oxygens of the α-, β- and γ-phosphates, to 1773 
Asp190 and Asp192 and to a water molecule, whereas MgB coordinates to an oxygen 1774 
of the α-phosphate, to the two carboxylate oxygens of Asp190, and to Asp192 and 1775 
Asp256. The sixth coordination of MgB is not detected. Presumably this coordination 1776 
normally involves the 3’-hydroxyl of the deoxyribosyl that receives the nucleotidyl 1777 
moiety. This 3’-hydroxyl is missing in 2’,3’-dideoxyribonucleotides, and, possibly, 1778 
the crystal packaging does not allow space for a water molecule (176). Similar 1779 
geometric arrangements are found in other DNA polymerases, such as DNA 1780 
polymerase II (185). Extensive reviews of the structure and function of DNA 1781 
polymerase β and other DNA polymerases have been previously published (186, 187). 1782 
The binding of two Mg2+ by a triad of aspartate residues is found also in RNA 1783 
polymerases. Reviews of the importance of Mg2+ in DNA and RNA synthesis have 1784 
been previously published (188, 189). 1785 
 An example of a sugar phosphate nucleotidyltransferases is the glmU gene 1786 
product, a bifunctional enzyme that catalyzes the acetylation of 2-amino-glucose 1-1787 
phosphate and the uridylylation of N-acetyl-2-amino 1-phosphate to yield UDP-N-1788 
acetylglucosamine. The two activities are located in different domains, with the 1789 
uridylyltransferase allocated to the N-terminal domain (190). UDP-N-1790 
acetylglucosamine is a precursor of cell wall synthesis in many bacterial and fungal 1791 
species as well as a substrate in glycosylation reactions in eukaryotic species (191). 1792 
The crystal structure of GlmU of M. tuberculosis contains two Mg2+. One (MgA2+) 1793 
coordinates to Asn239 and Asp114, to an oxygen of the phosphate of N-1794 
acetylglucosamine 1-phosphate, and to an oxygen of the α-phosphate of UTP, and 1795 
thus, MgA2+ bridges the two substrates. The other (MgB2+) coordinates to oxygens of 1796 
the α-, β- and γ-phosphates of UTP and to three water molecules. Thus, MgB2+ 1797 
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apparently does not coordinate to any amino acid residue (and formally there is no 1798 
MgB2+ binding-site). Rather, the uridylylation domain of GlmU appears to harbor a 1799 
single enzyme-bound Mg2+ (MgA2+), whereas the other Mg2+ enters as MgUTP during 1800 
the catalytic cycle. This two-Mg2+-mediated mechanism is believed to be general in 1801 
sugar nucleotide synthesis (192), as similar active site arrangements are observed for 1802 
2-keto-3-deoxymanno-octulonate cytidylyltransferase of E. coli (PDB code 3k8d) 1803 
(193), glucose 1-phosphate uridylyltransferase of Corynebacterium glutamicum (PDB 1804 
code 2pa4) (194), 2-C-methylerythritol 4-phosphate cytidylyltransferase of 1805 
Mycobacterium smegmatis (PDB code 2xwl) and M. turberculosis (PDB code 2xwn) 1806 
(195). 1807 
 A exception to this two-Mg2+ mediated mechanism is N-acetylglucosamine 1808 
uridylyltransferase of C. albicans, which contains only a single Mg2+ presumably 1809 
coordinated to oxygens of the α-, β- and γ-phosphates of UTP, i.e. MgB2+ in analogy 1810 
with M. tuberculosis GlmU. Furthermore, the function of MgA2+ may be performed by 1811 
Lys421, because the ε-N of this residue coordinates oxygens of the α- and β-1812 
phosphates of UDP-N-acetylglucosamine after product formation, and, thus, it also 1813 
presumably coordinates with oxygens of the phosphate of N-acetylglucosamine and of 1814 
the α-phosphate of UTP during catalysis. Arg116 may also participate in the function 1815 
performed MgA2+ in other sugar phosphate nucleotidyltransferases (196). 1816 
 Phosphoryltransfer. In general, enzymes catalyzing phosphoryl transfer 1817 
reactions also require two Mg2+, as demonstrated from studies of Pyrococcus furiosus 1818 
UMP kinase (PDB code 2bmu) (197), Staphylococcus aureus tagatose 6-phosphate 1819 
kinase (PDB code 2jg1) (198), Bifidobacterium longum N-acetylhexosamine kinase 1820 
(PDB code 4wh3) (199), mammalian cyclin-dependent kinase 2 (PDB code 3qhw) 1821 
(200), or cAMP-dependent protein kinase A (PDB codes 1l3r and 4hpu) (201, 202). 1822 
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We shall use protein kinase A for a more detailed description. Crystals of the enzyme 1823 
were obtained as a complex with reaction-inert β,γ-imido ATP, Mg2+ and a serine-1824 
containing peptide substrate. Of the two Mg2+, MgA2+ coordinates to oxygens of the α- 1825 
and γ-phosphates, to the bridging N of the β- and γ-phosphates of β,γ-imido ATP, to 1826 
Asn171 and Asp184, as well as to a water molecule, whereas the other, MgB2+, 1827 
coordinates to oxygens of the β- and γ-phosphates, to both of the oxygens of Asp184, 1828 
as well as to two water molecules (Fig. 8C). Unlike the examples of diphosphoryl and 1829 
nucleotidyltransfer reactions described above, there is apparently no coordination 1830 
between Mg2+ and the nucleophilic hydroxyl of the serine residue of the peptide 1831 
substrate. However, this oxygen appears to be held firmly in place by hydrogen 1832 
bonding to Lys168 and Asp166 (202). 1833 
 The number of Mg2+ in kinase-catalyzed reactions may vary from enzyme to 1834 
enzyme. Typically, nucleoside diphosphokinases contains only a single Mg2+. 1835 
Adenylate kinase catalyzes the reversible reactions AMP + ATP → 2 ADP or dAMP 1836 
+ ATP → dADP + ADP (203). The enzyme contains a loop, which closes upon 1837 
substrate binding, and, thus, prevents nucleophilic attack by water on the ATP 1838 
triphosphate chain. The structure of the E. coli enzyme has been probed with β,γ-1839 
imido ATP (PDB code 1ank). The phosphoryl group of AMP and the phosphate chain 1840 
of β,γ-imido ATP face one another in an almost co-linear arrangement. One oxygen of 1841 
the phosphoryl group of AMP is in close proximity to the γ-phosphorus of β,γ-imido 1842 
ATP, and, thus, ideally placed for an inline attack with the subsequent formation of 1843 
ADP (204). This collinear structure of the phosphoryl groups resembles the structure 1844 
of adenylate kinase ligated to the inhibitor di(adenosine-5’)pentaphosphate, except for 1845 
the presence of an additional phosphoryl group (205). Mg2+, which is necessary for 1846 
adenylate kinase activity, does not coordinate to side chains of the enzyme, but rather 1847 
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coordinates to two oxygens of di(adenosine-5’)pentaphosphate as well as to four 1848 
water molecules (206). This binding of Mg2+ to di(adenosine-5’)pentaphosphate is 1849 
consistent with β,γ-MgATP as the substrate for adenylate kinase (207), and Mg2+ 1850 
coordination to oxygens of both of the β-phosphates of two ADP molecules of M. 1851 
tuberculosis adenylate kinase, i.e. the reaction in the direction of ATP synthesis (PDB 1852 
code 2cdn) (208). Furthermore, in comparison with diphosphoryl and 1853 
nucleotidyltransfer reactions described above, adenylate kinase may represent an 1854 
alternative means of performing the function played by the second Mg2+ in other 1855 
phosphotransferases. The stabilizing and neutralizing effect of s second Mg2+ may be 1856 
replaced by one or more arginine and/or lysine residues such as those found near the 1857 
triphosphate chain and AMP in adenylate kinase (PDB codes 1ank and 2cdb) (204, 1858 
208). 1859 
 Catalytic strategies. The triphosphate chain of (deoxy)ribonucleoside 1860 
triphosphates is quite electron rich and, hence, negatively charged, so that chemical 1861 
reactions involving this chain require special conditions. In addition, an activated, i.e. 1862 
deprotonated, nucleophile may contribute additional negative charge to the transition-1863 
state. As described above, these difficulties are circumvented at least in part by the 1864 
presence of Mg2+ in the active site. Fig. 9 shows a schematic representation of part of 1865 
the active sites of enzymes or groups of enzymes that catalyze substitution reactions at 1866 
the α-, β- or γ-phosphates of (deoxy)ribonucleoside triphosphates and that contain two 1867 
Mg2+. The triphosphate chain, the coordination of each Mg2+, and the nucleophile are 1868 
shown for each enzyme. Additional amino acid residues may be involved in the 1869 
binding of the substrates but are not shown in Fig. 9. The two Mg2+ may have 1870 
multiple functions that include exact positioning of the substrates for transition-state 1871 
formation, electrostatic stabilization of the nucleophile and the transition-state, and 1872 
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electrostatic stabilization of the product(s) or leaving group(s). As described before 1873 
for PRPP synthase, one Mg2+ (MgB of Fig. 9) presumably is involved in the 1874 
stabilization of the nucleophile, i.e. the acceptor of the diphosphoryl group, the C1 1875 
hydroxyl of ribose 5-phosphate. Similarly, MgB of nucleotidyltransferases may 1876 
participate in stabilization of the nucleophiles, i.e. hexose phosphate (Fig. 9C) and 1877 
deprotonated DNA primer (Fig. 9D) (189). In contrast, no coordination is observed 1878 
between MgB and the γ-phosphate-attacking nucleophilic serine residue in protein 1879 
kinase A (Fig. 9A), and nucleophile positioning involves amino acid residues. As in 1880 
the case of MgB in PRPP synthase, MgB of nucleotidyltransferases binds the 1881 
nucleophile, and may stabilize the deprotonated nucleophile (Fig. 9C and D). 1882 
Interestingly, MgB of PRPP synthase and the nucleotidyltransferases coordinate both 1883 
of the substrates, i.e. ribose 5-phosphate and ATP in PRPP synthase (Fig. 9B), N-1884 
acetylglucosamine 1-phosphate and UTP in N-acetylglucosamine 1-phosphate 1885 
uridylyltransfrease (Fig. 9C), and the DNA template and deoxyribonucleoside 1886 
triphosphate in DNA polymerases (Fig. 9D). The γ-phosphate of nucleoside 1887 
triphoshphates carries two negative charges at physiologic pH, whereas the α- and β-1888 
phosphates carry one negative charge, each. These charges are neutralized by Mg2+. 1889 
The second Mg2+, MgA, in the enzymes under discussion typically binds the substrate 1890 
(deoxy)ribonucleoside triphosphate. Thus, the form bound to the enzyme in all the 1891 
cases shown appears to be the tridentate α,β,γ-MgATP. The MgA therefore not only 1892 
partly neutralizes the triphosphate chain, but also provides the proper conformation of 1893 
the substrate to the enzyme. The general belief is that the functioning of MgA includes 1894 
a stabilization of the transition state. It is noteworthy that the two MgA and MgB are 1895 
localized on both sides of the triphosphate chain except in the nucleic acid 1896 
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polymerases, where the two Mg2+ are located on the same side of the triphosphate 1897 
chain. 1898 
 1899 
UTILIZATION OF PRPP 1900 
The concentration of PRPP is approximately 0.5 mM in cells of S. enterica growing 1901 
exponentially in minimal salts medium with glucose as carbon source. This value may 1902 
be compared to the concentrations of ATP, GTP, UTP and CTP, which are 3, 0.9, 0.9, 1903 
and 0.5 mM, respectively (19). PRPP is utilized in nucleotide, amino acid and co-1904 
factor biosynthetic pathways. The relative consumption of PRPP for each of these 1905 
processes in E. coli has been estimated. Thus, purine and pyrimidine nucleotide 1906 
biosynthesis consumes 30-40% of the PRPP synthesized, each, whereas histidine and 1907 
tryptophan biosynthesis consumes 10-15% of the PRPP synthesized, each, and NAD, 1908 
NADP biosynthesis conumes approximately 1% of the PRPP synthesized (1). 1909 
 1910 
Reactions at the Anomeric Carbon of PRPP 1911 
The reactions occuring at the anomeric carbon of PRPP greatly outnumber the 1912 
reactions occurring af the diphosphoryl chain. The reactions at the anomeric carbon 1913 
are catalyzed by phosphoribosyltransferases, whereas hydrolases catalyze the 1914 
reactions at the diphosphoryl chain. Phosphoribosyltransferases catalyze reactions in 1915 
which N-, C- or O-glycosidic bonds are formed with the concomittant formation of 1916 
PPi (Fig. 1). We shall review first the reactions occurring at the anomeric carbon, and 1917 
then the reactions occurring af the diphosphate chain. 1918 
 Comparison of phosphoribosyltransferase and PRPP synthase structures. 1919 
The structure of phosphoribosyltransferases vary to some extent. The most 1920 
widespread structure, present in the so-called type I phosphoribosyltransferase, 1921 
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consists of a core of a five-stranded β-sheet surrounded by a number of helices, and, 1922 
additionally, a loop structure, the hood, which participates in the binding of the 1923 
nucleobase substrate, and a (catalytic) flexible loop, which remains unresolved until 1924 
the binding of PRPP, when it closes the active site for catalysis (209, 210). The type I 1925 
phosphoribosyltransferases utilize purine or pyrimidine bases or glutamine-derived 1926 
ammonia as the phosphoribosyl acceptor. Remarkably, in spite of only approximately 1927 
20 % amino acid sequence identity among type I phosphoribosyltransferases and 1928 
PRPP synthase, the three dimensional structures of type I phosphoribosyltransferases 1929 
strongly resemble that of each domain of PRPP synthase, as shown in Fig. 10A for T. 1930 
volcanium PRPP synthase and Toxoplasma gondii hypoxanthine-guanine 1931 
phosphoribosyltransferase. We shall use the T. gondii hypoxanthine-guanine 1932 
phosphoribosyltransferase as a structural “prototype” of type I 1933 
phosphoribosyltransferase, as many of the structural features of this enzyme apply to 1934 
most other type I phosphoribosyltransferases as well. The homology of the central 1935 
five-stranded β-sheet and the surrounding helices is evident in both structures, as is 1936 
also the homologous position of the catalytic flexible loop of PRPP synthase and the 1937 
flexible loop of the phosphoribosyltransferase. 1938 
 A comparison of amino acid residues of PRPP synthase and various type I 1939 
phosphoribosyltransferases reveals only a single conserved region, a series of 1940 
hydrophobic residues, usually three, followed by one or two aspartate residues, two or 1941 
three hydrophobic residues, and a four-residue sequence characteristic of sharp turns 1942 
in the polypeptide chain, such as Thr-Gly-Gly-Thr (44, 45, 211). This region in B. 1943 
subtilis PRPP synthase (216-Gly-Lys-Thr-Ala-Ile-Leu-Ile-Asp-Asp-Ile-Ile-Asp-Thr-1944 
Ala-Gly-Thr-232) is the ribose 5-phosphate binding loop described above (45), 1945 
whereas the corresponding region in T. gondii hypoxanthine-guanine 1946 
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phosphoribosyltransferase (139-Asp-Lys-His-Val-Leu-Ile-Val-Glu-Asp-Ile-Val-Asp-1947 
Thr-Gly-Phe-Thr-154) is the PRPP binding loop (212). Additionally, the PP loop 79-1948 
Lys-Glu-80 in T. gondii hypoxanthine-guanine phosphoribosyltransferase) and amino 1949 
acid residues of the flexible catalytic loop (residues 114 to 134 in in T. gondii 1950 
hypoxanthine-guanine phosphoribosyltransferase) are involved in the binding of 1951 
PRPP or MgPRPP in other phosphoribosyltransferases; collectively, these sequences 1952 
constitute the PRPP binding site (209, 210). The thee-dimensional structure of the 1953 
ribose 5-phosphate binding loop of PRPP synthase and the PRPP binding loop of 1954 
phosphoribosyltransferases are very much alike as shown in Fig. 10B, which shows a 1955 
superimposition of parts of the active site of B. subtilis PRPP synthase and T. gondii 1956 
hypoxanthine-guanine phosphoribosyltransferase: the binding of ribose 5-phosphate, 1957 
the β- and γ-phosphates of ATP and two Mg2+ at the active site of B. subtilis PRPP 1958 
synthase and the binding of PRPP and the Mg2+ at the active site of T. gondii 1959 
hypoxanthine-guanine phosphoribosyltransferase (54, 212). 1960 
 N-Glycosidic bond formation. By far the most abundant reactions involving 1961 
PRPP are formation of N-glycosidic bonds. The prototype of reactions involving 1962 
PRPP is shown in Fig. 1, and examples of the products containing carbons of PRPP 1963 
are shown in Fig. 11. A nitrogen-containing compound displaces the diphosphoryl 1964 
group of PRPP in a nucleophilic reaction with inversion of the anomeric carbon (for 1965 
example: adenine + PRPP → AMP + PPi). In general, the nitrogen-containing 1966 
compounds are aromatic bases. In purine and pyrimidine nucleotide biosynthesis the 1967 
ribosyl group of PRPP remains the ribosyl or deoxyribosyl group of the nucleotides. 1968 
Similarly, in co-factor (NAD and NADP) biosynthesis the ribosyl group of PRPP 1969 
remains the ribosyl groups of the co-factors. In contrast, in tryptophan and histidine 1970 
biosynthesis only some of the ribosyl carbons are built into the products. Thus, in 1971 
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tryptophan biosynthesis carbon two and three of the indolyl moiety originate from 1972 
carbon one and two, respectively, of the ribosyl moiety of PRPP, whereas five of the 1973 
six carbons of histidine originate from the ribosyl moiety of PRPP with the carboxyl 1974 
group originating from C5 of PRPP. The nitrogen-containing compounds utilized by 1975 
phosphoribosyltransferases may be the purine bases adenine, hypoxanthine, xanthine 1976 
or guanine, the pyrimidine bases may be orotate or uracil, the pyridine bases may be 1977 
quinolinate or nicotinate, or the bases may be anthranilate or ATP. A variant among 1978 
phosphoribosyltransferases, amidophosphoribosyltransferase, the first enzyme of de 1979 
nove purine biosynthesis, utilizes glutamine-derived ammonia. All together, 10 1980 
enzymes utilize PRPP for N-glycosidic bond formation with 11 products in organisms 1981 
such as E. coli or B. subtilis, Fig. 11. 1982 
 As we shall see below, PRPP is a very versatile compound for the delivery of 1983 
phosphoribosyl moieties. A large number of phosphoribosyltransferases have been 1984 
described. Although they all use PRPP as phosphoribosyl donor and, presumably, 1985 
they follow similar chemical mechanisms, they differ widely in three-dimensional 1986 
structure. The enzymes range from the type I phosphoribosyltransferases, which are 1987 
primarily involved in purine and pyrimidine nucleotide biosynthesis, type II 1988 
phosphoribosyltransferases, which are involved in pyridine nucleotide biosynthesis, to 1989 
type III and type IV phosphoribosyltransferasse, which are involved in histidine and 1990 
tryptophan biosynthesis, respectively. The three-dimensional structures of a large 1991 
number of phosphoribosyltransferases have been determined. Detailed reviews on the 1992 
biochemistry of phosphoribosyltransferases have been published previously (209, 1993 
210, 213). 1994 
 (i) Purine nucleotide biosynthesis. Nucleotide biosynthesis occurs via two sets 1995 
of reactions: de novo reactions in which nucleotides are generated by the addition of 1996 
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atoms one by one to the starting material, and the so-called salvage or auxillary 1997 
reactions by which preformed nucleobases are utilized for nucleotide biosynthesis. 1998 
 (a) Purine de novo synthesis. De novo purine nucleotide biosynthesis comences 1999 
with PRPP. The purine ring is built on the phosphoribosyl moiety atom by atom 2000 
begining with the the addition to C1 of the ribosyl moiety of the nitrogen of glutamine 2001 
derived NH3, which subsequently becomes N9 of the complete purine moiety. This 2002 
reaction is catalyzed by amidophosphoribosyltransferase (5-phospho-β-D-2003 
ribosylamine:diphosphate phospho-α-D-ribosyltransferase (glutamate-amidating), EC 2004 
2.4.2.14) encoded by purF in E. coli, glutamine + PRPP + H2O → glutamate + 5-2005 
phosphoribosyl 1-amine + PPi (Fig. 11, compound a) (214). 2006 
Amidophosphoribosyltransferase contains a domain that catalyzes the hydrolysis of 2007 
glutamine to form glutamate and ammonia. Subsequently, the ammonia is transferred 2008 
through a channel of 20 Å long to the phosphoribosyltransferase domain active site, 2009 
where PRPP is already postioned for further reaction (215). The process, ammonia 2010 
channeling in amidophosphoribosyltransferases, has been previously reviewed (216). 2011 
Although it is unusual for a phosphoribosyltransferase to have an additional enzyme 2012 
activity such as the glutaminase, amidophosphoribosyltransferase has a typical type I 2013 
phosphoribosyltransferase fold with the five-stranded β-sheets surrounded by two 2014 
helices on either side, a hood, a catalytic flexible loop as well as a MgPRPP binding 2015 
site consisting of the PRPP binding loop and a PP loop. The enzyme binds PRPP in a 2016 
manner similar to that described above for T. gondii hypoxanthine-guanine 2017 
phosphoribosyltransferase (Fig. 10B). 2018 
 (b) Purine salvage synthesis. The purine salvage or auxilliary reactions consists 2019 
of several enzymes that phosphoribosylate adenine, or the 6-oxopurines hypoxanthine, 2020 
xanthine or guanine. The products of these phosphoribosylations reactions are AMP, 2021 
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inosine 5’-monophosphate, xanthosine 5’-monophosphate, and GMP, respectively 2022 
(Fig. 11, compound f to i). In general, in most organisms there is a single 2023 
phosphoribosyltransferase that is specific for adenine, and at least one additional 2024 
phosphoribosyltransferase with specificity toward 6-oxopurine. E. coli and S. enterica 2025 
both contain apt-specified adenine phosphoribosyltransferase, hpt-specified 2026 
hypoxanthine phosphoribosyltransferase, and gpt-specified xanthine-guanine 2027 
phosphoribosyltransferase (19), whereas S. solfataricus contains pgT-1-specified 2028 
adenine phosphoribosyltransferase and pgT-2-specified 6-oxopurine 2029 
phosphoribosyltransferase with affinity for hypoxanthine, xanthine and guanine (217). 2030 
The purine phosphoribosyltransferase-catalyzed reactions are responsible for the 2031 
utilization of the purine compounds adenine, hypoxanthine, xanthine and guanine as 2032 
purine source by purine auxotrophic strains. 2033 
 The specificity of purine phosphoribosyltransferases are not readily deduced from 2034 
their amino acid sequences. The PRPP binding loop of adenine 2035 
phosphoribosyltransferase (EC 2.4.2.7) (adenine + PRPP → AMP + PPi) of E. coli is 2036 
126-Asp-Asp-Leu-Leu-Ala-Thr-131. The sequence Asp-Asp-hyd-hyd-Ala-Thr (hyd 2037 
indicating hydrophobic residues) is found in a large majority of adenine 2038 
phosphoribosyltransferases. An exception is S. solfataricus adenine 2039 
phosphoribosyltransferase, which has 95-Asp-Asp-Ile-Thr-Asp-Thr-100. On the other 2040 
hand, hypoxanthine and hypoxanthine-guanine phosphoribosyltransferases contain the 2041 
homologous sequence Glu-Asp-Ile-Ile-Asp-Thr/Ser. That is, a glutamate residue 2042 
replaces the first acidic residue of the Asp-Asp-dipeptide and the Asp typed in italic 2043 
replaces an alanine residue of adenine phosphoribosyltransferase, exemplified by 2044 
Ala130 of the E .coli adenine phosphoribosyltransferase. E. coli gpt-specified 2045 
xanthine-guanine phosphoribosyltransferase rather has the sequence 88-Asp-Asp-Leu-2046 
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Val-Asp-Thr-93, i.e. an Asp-Asp dipeptide as in adenine phosphoribosyltransferase 2047 
and Asp93 as in oxopurine phosphoribosyltransferase (217). 2048 
 The length of the adenine phosphoribosyltransferases shows some heterogeneity. 2049 
The enzyme has a basal size of approximately 180 amino acid residues, as seen in the 2050 
enzymes from E. coli, the purine de novo synthesis-lacking protozoan parasite 2051 
Giardia lamblia, S. cerevisiae and humans, whereas the enzymes from of the 2052 
protozoan parasite Leishmania donovani and the archeon S. solfataricus have 237 and 2053 
210 mino acid residue, respectively. Nevertheless all of them share the common core 2054 
structure of type I phosphoribosyltransferases (218-220). The additional amino acid 2055 
residues of S. solfataricus and L. donovani adenine phosphoribosyltransferases 2056 
protrude from both the N- and C-termini relative to the 180-amino acid adenine 2057 
phosphoribosyltransferases and may contribute to structural variations of the hood 2058 
(221, 222). The structures have been determined with the apo-forms or with adenine 2059 
or AMP bound in the active site. Particularly interesting is the structure of the G. 2060 
lamblia enzyme with the purine analog 9-deazaadenine and MgPRPP bound at the 2061 
active site. In this structure the hydroxyls of the ribose moiety coordinate to Mg2+ and 2062 
to the 124-Glu-Asp-125 acidic dipeptide, whereas the 5-phosphate is bound to the 2063 
128-Ala-Thr-Gly-Gly-Thr-132 subset of the PRPP binding loop, and the diphosphate 2064 
chain ligates to Mg2+ and to Arg63, which is part of the PP loop. Superimposition of 2065 
the 9-deazaadenine and MgPRPP-containing structure and an AMP-containing 2066 
structure revealed a 2.1 Å movement of the anomeric carbon during catalysis, whereas 2067 
the 5- or 5’-phosphate and adenine moieties essentially remained fixed (218). 2068 
 As already mentioned, the specificity of phosphoribosyltransferases with affinity 2069 
for 6-oxopurine varies depending on the organism. Any given 6-oxopurine 2070 
phosphoribosyltransferase has some affinity for all three 6-oxopurines (hypoxanthine, 2071 
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xanthine and guanine), but in general, has a preference for one or two of the 2072 
compounds. The descrimination between 6-amino and 6-oxo purines is based on 2073 
hydrogen bonding to the nitrogen and oxygen of the purine ring (209, 213). Thus, the 2074 
allocation of a phosphoribosyltransferase to the EC 2.4.2.8 (hypoxanthine 2075 
phosphoribosyltransferase) class as opposed to the EC 2.4.2.22 (xanthine 2076 
phosphoribosyltransferase) class may be a somewhat superficial and misleading 2077 
description. The binding of PRPP to the 6-oxypurine phosphoribosyltransferases is 2078 
similar to that described above for adenine phosphoribosyltransferase; that is, in 2079 
involves a PRPP binding site consisting of a PRPP binding loop with a carboxylate 2080 
dipeptide, Asp-Asp or Glu-Asp, a PP loop and a Thr/Ser-Gly-Glu-Thr consensus 2081 
sequence involved in the binding of the 5-phosphate moiety. 2082 
 (ii) Pyrimidine nucleotide biosynthesis. Unlike de novo purine nucleotide 2083 
biosynthesis, in de novo pyrimidine nucleotide biosynthesis the pyrimidine moiety is 2084 
first synthesized, and the product, orotate, and PRPP are assembled to form orotidine 2085 
5’-monophosphate (Fig. 11, compound b) in a reaction catalyzed by orotate 2086 
phosphoribosyltransferase (orotidine-5'-phosphate:diphosphate phospho-α-D-ribosyl-2087 
transferase, EC 2.4.2.10, orotate + PRPP → orotidine 5’-monophosphate + PPi). 2088 
Orotate phosphoribosyltransferase, a typical type I phosphoribosyltransferase, 2089 
contains the “usual” structural elements, a five-stranded β-sheet surrounded by a 2090 
number of helices, usually four, a hood structure involved in the binding of the 2091 
substrate orotate and a flexible catalytic loop, which closes the active site on catalysis. 2092 
The structures of orotate phosphoribosyltransferase from a variety of sources, 2093 
including S. enterica (223), E. coli (224), S. mutans (225), Plasmodium falciparum 2094 
(226) and L. donovani (227) have been published. 2095 
 86
 The three-dimensional structure of S. enterica orotate phosphoribosyltransferase 2096 
in complex with orotate and MgPRPP revealed an asymmetric structure of the dimer, 2097 
because both substrates bind to the active site of one subunit (B), whereas only orotate 2098 
was bound to the subunit A. The flexible catalytic loop of subunit A closes the active 2099 
site of subunit B, whose flexible catalytic loop remains unstructured and presumably 2100 
open. Orotate is bound by amino acids of the hood, and PRPP is bound in the PRPP 2101 
binding loop, which includes the 124-Asp-Asp-125 dipeptide (coordinating to 2102 
hydroxyls of ribose C2 and C3), the sequence 128-Thr-Ala-Gly-Thr-131 (binding the 2103 
5-phosphate), Tyr72 and Lys73 (the PP loop). A single Mg2+ coordinates the oxygens 2104 
of ribosyl C1, C2 and C3, an oxygen of the β-phosphate as well as two water 2105 
molecules. On catalytic flexible loop closure, lysine, arginine and histidine residues of 2106 
this loop bind to the diphosphate chain, and, together with the Mg2+, participate in 2107 
neutralizing the diphosphate chain during catalysis (228). The structure reveals the 2108 
presence of two shared active sites at the interface of the dimer, which has been also 2109 
demonstrated by formation of a heterodimer composed of one subunit defective in 2110 
PRPP binding and one subunit defective in the catalytic flexible loop (229). 2111 
 The structure of S. cerevisiae orotate phosphoribosyltransferase resembles that of 2112 
S. enterica (230). As mentioned, the dimeric structure is asymmetric. This asymmetry, 2113 
together with the movement of the catalytic flexible loops during (i.e. before and 2114 
after) catalysis, as well as kinetic analysis prompted the authors to suggest an 2115 
alternating active site catalytic mechanism, i.e. only one active site is functional at any 2116 
given time (230, 231). 2117 
 Unlike the purine salvage reactions, pyrimidine salvage involves the activity of 2118 
only a single phosphoribosyltransferase: uracil phosphoribosyltransferase 2119 
(UMP:diphosphate phospho-α-D-ribosyltransferase, EC 2.4.2.9), uracil + PRPP → 2120 
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UMP + PPi (Fig. 11, compound j). Uracil phosphoribosyltransferase allows organisms 2121 
to utilize uracil formed endogenously by nucleic acid catabolism or supplied by the 2122 
environment. Uracil phosphoribosyltransferase requires Mg2+ for activity. In general, 2123 
the activity of the enzyme is allosterically activated by GTP. GTP causes association 2124 
of subunits to tetramers, as observed for uracil phosphoribosyltransferase from E. coli 2125 
(232) and T. gondii (233). Alternatively, GTP functions as an allosteric activator of 2126 
the oligomeric uracil phosphoribosyltransferase of Sulfolobus species (234-237). The 2127 
enzyme from M. tuberculosis differs from the aforementioned in being unaffected by 2128 
GTP (238, 239), and the enzyme from G. intestinalis dimerizes in the presence of 2129 
GTP (240). 2130 
 The PRPP binding motif of uracil phosphoribosyltransferase differs markedly 2131 
from that of other phosphoribosyltransferases or PRPP synthase in that the typical 2132 
acidic dipeptide (Asp-Asp or Glu-Asp) is replaced by Asp-Pro (highlighted in bold), 2133 
as illustrated here with the E. coli uracil phosphoribosyltransferase amino acid 2134 
sequence: 123-Glu-Arg-Met-Ala-Leu-Ile-Val-Asp-Pro-Met-Leu-Ala-Thr-Gly-Gly-2135 
Ser-138 (241). The Asp-Pro dipeptide appears to be universal among uracil 2136 
phosphoribosyltransferase, as it is present in all the enzymes from the organisms 2137 
mentioned above as well as yeasts (242), bacilli (243, 244), and lactococci (245). 2138 
Analysis of a mutant variant that had this particular proline residue replaced by an 2139 
aspartate revealed a 100-fold increase in the KM value for uracil and a 50-fold 2140 
reduction in kcat. The KM value for PRPP was reduced in the mutant, whereas 2141 
kcat/KMPRPP was almost unchanged. It was therefore concluded that the proline residue 2142 
of the PRPP binding loop of uracil phosphoribosyltransferase “is of little importance 2143 
for binding of PRPP to the free enzyme, but is critical for binding of uracil to the 2144 
enzyme-PRPP complex and for the catalytic rate” (246). 2145 
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 Two variant forms of uracil phosphoribosyltransferase are found in Gram-2146 
positive organisms such as B. caldolyticus and B. subtilis. Both genes were shown to 2147 
complement E. coli upp lesions and therefore encode active enzymes. One of these 2148 
(upp) specified uracil phosphoribosyltransferase, whereas the other (pyrR) specified a 2149 
regulatory protein involved in regulation of pyrimidine gene expression, PyrR (247, 2150 
248). We shall return to PyrR in the section “PRPP as Mediator of Metabolic 2151 
Regulation”. 2152 
 Finally, a phosphoribosyltransferase activity for dioxotetrahydropyrimidine 2153 
(dioxotetrahydropyrimidine phosphoribosyltransferase, EC 2.4.2.20) has been 2154 
previously characterized (249). Whether it is a separate activity or a variant of other 2155 
pyrimidine phosphoribosyltransferases remains unresolved. 2156 
 (iii) NAD biosynthesis. The phosphoribosyltransferases of NAD biosynthesis are 2157 
members of the so-called type II phosphoribosyltransferases. De novo pyridine 2158 
nucleotide biosynthesis resembles de novo pyrimidine nucleotide biosynthesis in that 2159 
the aromatic base is synthesized prior to phosphoribosylation (250). The reaction with 2160 
PRPP and quinolinate is catalyzed by quinolinate phosphoribosyltransferase (β -2161 
nicotinate-D-ribonucleotide:diphosphate phospho-α-D-ribosyltransferase 2162 
(carboxylating), EC 2.4.2.19) encoded by nadC in E. coli: quinolinate + PRPP → 5’-2163 
phospho β-D-ribosylnicotinate + PPi + CO2. 5’-Phosphoribosylnicotinate is also 2164 
designated nicotinate mononucleotide (Fig. 11, compund c). The reaction is unusual 2165 
in producing carbon dioxide (251, 252). In pyridine co-factor salvage synthesis, 2166 
nicotinate phosphoribosyltransferase (5-phospho-α-D-ribose 1-diphosphate:nicotinate 2167 
ligase (ADP, diphosphate-forming), EC 6.3.4.21), encoded by pncB in E. coli, 2168 
catalyzes the reaction nicotinate + PRPP (+ ATP) → 5’-phospho-β-D-ribosyl-2169 
nicotinate + PPi (+ ADP + Pi). This reaction is unusual in that the enzyme is 2170 
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stimulated by ATP in a stoichiometric manner. That is, the enzyme is phosphorylated 2171 
by ATP at His219, which results in the formation of a high-affinity form, with KM 2172 
values for nicotinate and PRPP 200-fold lower than those of the unphosphorylated 2173 
enzyme. Also, the coupling of ATP hydrolysis to the phosphoribsyltransferase 2174 
reaction causes a change in the equilibrium value from 0.67 to 1100 (253-255). 2175 
Mutational replacement of His219 completely abbrogates phosphorylation and 2176 
stimulation by ATP (256). Mammalian organisms such as mice and humans contain 2177 
yet a different pyridine phosphoribosyltransferase, nicotinamide 2178 
phosphoribosyltransferase (nicotinamide-D-ribonucleotide:diphosphate phosphor-α-D-2179 
ribosyltransferase, E.C. 2.4.2.12), nicotinamide + PRPP → 5’-phospho-β-D-ribosyl-2180 
nicotinamide (nicotinamide mononucleotide, NMN) + PPi (257, 258). As with purine 2181 
and pyrimidine nucleotide biosynthesis, PRPP is used in both the de novo reactions of 2182 
NAD synthesis (quinolinate phosphoribosyltransferase) and in NAD salvage reactions 2183 
(nicotinate and nicotinamide phosphoribosyltransferases). 2184 
 (a) Quinolinate phosphoribosyltransferase. The structures of quinolinate 2185 
phosphoribosyltransferase from a number of sources have been determined. These 2186 
include M. tuberculosis (259), S. enterica (211), Helicobacter pylori (260), 2187 
Thermotoga maritima (261), and S. cerevisiae (262). The structures of these enzymes 2188 
resemble one another. The structure of the ternary complex of M. tuberculosis 2189 
quinolinate phosphoribosyltransferase with a quinolinate analog (phthalate) and a 2190 
PRPP analog (5-phosphoribosyl-1-[β-methylene]diphosphate, i.e. the two phosphorus 2191 
atoms are connected by a methylene moiety) reveals the binding of quinolinate and 2192 
PRPP together with two divalent metal ions (in this case Mn2+). In the ternary 2193 
complex the ribosyl moiety of PRPP is hydrogen bonded to Glu201 and Asp222 2194 
through the C2 and C3 hydroxyls, respectively. The two divalent metal ions 2195 
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coordinate to the same two hydroxyls, to the diphosphate chain or to water molecules; 2196 
the ions do not coordinate to enzyme amino acid residues. The diphosphate chain 2197 
forms hydrogen bonds to arginine, lysine and aspartate residues. The 5-phosphate is 2198 
hydrogen bonded, to among other residues Gly270 and Gly249. Thus, although the 2199 
fold of quinolinate phosphoribosyltransferase (a type II phosphoribosyltransferase) is 2200 
very different from the fold of type I phosphoribosyltransferases, some similarities are 2201 
evident. PRPP binding involves two acidic residues (Glu201 and Asp222) reminiscent 2202 
of the Asp-Asp dipeptide of type I phosphoribosyltransferases and of PRPP synthase; 2203 
the 5-phosphate binding involves glycine residues, and diphosphate binding involves 2204 
several basic residues. Although different in structures, similar arrangements have 2205 
evolved for the binding of the common substrate PRPP, which suggests a common 2206 
theme in the design of active sites. 2207 
 (b) Nicotinate phosphoribosyltransferase. The structure of nicotinate 2208 
phosphoribosyltransferase of the archaeon Thermoplasma acidophilum revealed a 2209 
three domain arrangement, where the structures of the N-terminal and central domains 2210 
resemble the two domains of quinolinate phosphoribosyltransferases, and a unique C-2211 
terminal domain is added. Only a few differences were observed in the number of β-2212 
strands beween nicotinate and quinolinate phosphoribosyltransferases. The phosphate 2213 
group of PRPP binds to T. acidophilum nicotinate phosphoribosyltransferase in a 2214 
mode similar to the binding of the PRPP analog to M. tuberculosis quinolinate 2215 
phosphoribosyltransferase, and the structures of the active sites of the two enzymes 2216 
are very similar in spite of little sequence conservation between them (263). 2217 
 The C-terminal domain, approximately 100 amino acid residues in length, is 2218 
composed of seven β-strands and one helix. Enzymological data for T. acidophilum 2219 
nicotinate phosphoribosyltransferase are not available, so it remains unknown if the 2220 
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activity of this enzyme is stimulated by ATP. It is possible that the C-terminal domain 2221 
participates in phosphorylation and ATP hydrolysis, and, by analogy, the 2222 
phosphorylation site may be present in the central domain, although a His219 2223 
homolog is not found in T. acidophilum nicotinate phosphoribosyltransferase. The C-2224 
terminal domain of S. enterica nicotinate phosphoribosyltransferase is exposed to the 2225 
solvent; trypsin treatment removed 24 C-terminal amino acid residues and inactivated 2226 
the ATPase activity. This inactivation was prevented by ATP binding, which provides 2227 
evidence for the involvement of the C-terminal domain in energy coupling (264). 2228 
 (c) Nicotinamide phosphoribosyltransferase. Vertebrates lack nicotinamide 2229 
deamidase and, thus, do not produce nicotinate from nicotinamide. Rather, they 2230 
salvage nicotinamide by means of nicotinamide phosphoribosyltransferase. 2231 
 The sandwich and α/β-barrel structure described above for M. tuberculosis 2232 
quinolinate phosphoribosyltransferase is repeated in human nicotinamide 2233 
phosphoribosyltransferase. The position of 5’- or 5-phosphate maps identically in 2234 
structures with 5’-phospho β-D-ribosylnicotinamide or with PRPP bound, whereas the 2235 
ribose moieties are dispalced relative to one another. The 5-phosphate of PRPP is 2236 
hydrogen bound to Gly383 and Gly384 (both of the A subunit), which are part of the 2237 
loop 381-Gly-Ser-Gly-Gly-Gly-385 that is similar to the corresponding loop of T. 2238 
acidophilum nicotinate phosphoribosyltransferase (263). The diphosphate of PRPP is 2239 
hydrogen bonded to Arg39 (B subunit), Arg40 (B subunit), Arg196 (A subunit) and 2240 
Lys400 (B subunit), and the C2 and C3 hydroxyls are hydrogen bonded to Arg311 2241 
and Asp313 (both of the A subunit). Thus, the binding of PRPP to human 2242 
nicotinamide phosphoribosyltransferase is homologous to the binding of PRPP to the 2243 
other type II phosphoribosyltransferases (265). 2244 
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 As expected, nicotinamide phosphoribosyltransferase from mouse and rat have 2245 
structures similar to that of the human enzyme (266, 267). There is extensive 2246 
structural resemblance between the type II phosphoribosyltransferases, namely, 2247 
quinolinate, nicotinate and nicotinamide phosphoribosyltransferases. Chappie and 2248 
coworkers offer a theory for the evolution of the type II phosphoribosyltransferases, in 2249 
which nicotinamide phosphoribosyltransferase evolved from nicotinate 2250 
phosphoribosyltransferase, which in turn evolved from quinolinate 2251 
phosphoribosyltransferase (268). 2252 
 Studies of human nicotinamide phosphoribosyltransferase have attracted interest, 2253 
because the enzyme has been identified as a growth factor for early stage B cells 2254 
(hence called “pre-B cell colony-enhancing factor”) and has been associated with 2255 
binding to and activation of the insulin receptor and has been also called “visfatin”. 2256 
For a review of the many apparent functions of human nicotinamide 2257 
phosphoribosyltransferase, consult the article by Garten and colleagues (269).. It is 2258 
unclear if the many functions may be ascribed simply to variations in the NAD pool. 2259 
However, because of the increased synthesis of nicotinamide 2260 
phosphoribosyltransferase in tumor tissues, studies have been directed toward the 2261 
isolation of inhibitors of the enzyme. Several of these inhibitors could be converted 2262 
enzymatically to phosphoribosylated derivatives. Analysis of the structure of a 2263 
ribosylated inhibitor bound to nicotinamide phosphoribosyltransferase confirmed the 2264 
binding of its 5-phosphoribosyl moity (270). 2265 
 (iv) Histidine biosynthesis. In histidine biosynthesis all of the five carbons of 2266 
PRPP are retained. The carboxylate, the Cα and the Cβ of the amino propanoic side 2267 
chain of histidine are generated from C5, C4 and C3, respectively of PRPP, whereas 2268 
C4 and C5 of the imidazole moiety are derived from C2 and C1 of PRPP. In the first 2269 
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step of histidine biosynthesis, PRPP and ATP react with the formation of PPi and N-2270 
(5’-phospho-β-D-ribosyl)-ATP, which has an N-glycosidic bond of C1 of the ribosyl 2271 
moiety to N1 of ATP (Fig. 11, compound d) (271). The reaction is catalyzed by ATP 2272 
phosphoribosyltransferase (ATP phosphoribosyltransferase, EC 2.4.2.17), which is 2273 
encoded by hisG in E. coli (272, 273). 2274 
 There are two subfamilies of ATP phosphoribosyltransferases. They have 2275 
different quaternary structures, hexa- or octameric (274-276), but similar molecular 2276 
architecture of their catalytic domains. The E. coli ATP phosphoribosyltransferase 2277 
polypeptide contains three domains. Domain I consists of four parallel and two 2278 
antiparallel β-strands flanked by two α-helices on each side; domain II is constructed 2279 
of four parallel and one antiparallel β-strand flanked by one helix on one side and two 2280 
helices on the other side. Domain III is a histidine binding domain (277). Domains I 2281 
and II constitute the catalytic fold of ATP phosphoribosyltransferase. Thus, although 2282 
this fold appears to be reminiscent of the type I phosphoribosyltransferase and PRPP 2283 
synthase domain fold, it represents a unique fold. Furthermore, ATP 2284 
phosphoribosyltransferases lack the hood and the catalytic flexible loop characteristic 2285 
of type I phosphoribosyltransferases. Additionally, the active form of both type of 2286 
enzymes are dimers or higher order oligomers. 2287 
 The active form of E. coli ATP phosphoribosyltransferase is a dimer of the three-2288 
domain polypeptide. Activity is inhibited by AMP, which prevents the binding of 2289 
ATP and PRPP. The binding of the inhibitors histidine and eventually also guanosine 2290 
3’-diphosphate 5’-diphosphate result in the formation of a hexameric, inactive 2291 
quaternary structure (277-279). There is only 27% sequence identity between E. coli 2292 
guanine-xanthine phosphoribosyltransferase and ATP phosphoribosyltransferase. A 2293 
PRPP binding loop located within domain II, however, is easily identified in the ATP 2294 
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phosphoribosyltransferase sequence: 162-Gly-Leu-Ala-Asp-Ala-Ile-Cys-Asp-Leu-2295 
Val-Ser-Thr-Gly-Ala-Thr-176 . The structure of ATP phosphoribosyltransferase from 2296 
M. tuberculosis is similar to that of E. coli; in this case, the PRPP binding loop was 2297 
identified as 147-Gly-Val-Ala-Asp-Ala-Ile-Ala-Asp-Val-Val-Gly-Arg-Thr-Leu-Ser-2298 
162 (280). ATP phosphoribosyltransferases such as those of E. coli and M. 2299 
tuberculosis are sometimes designated HisGL with L designating “long” form. This is 2300 
in contrast to the HisGS with S designating “short” form in for example L. lactis. 2301 
HisGS ATP phosphoribosyltransferases lack domain III, and instead associate with a 2302 
distinct polypeptide, HisZ, to form active octameric oligomers, whereas the isolated 2303 
HisG and HisZ polypeptides associate into inactives dimers. The catalytic fold of 2304 
HisGS ATP phosphoribosyltransferases is almost identical to that of HisGL ATP 2305 
phosphoribosyltransferases, and the active site is located, once again, in a cleft 2306 
between domain I and II. PRPP binding loops have been identified in ATP 2307 
phosphoribosyltransferases of L. lactis (148-Gly-Leu-Ala-Asp-Ala-Ile-Val-Asp-Ile-2308 
Val-Glu-Thr-Gly-Asn-Thr-162) (281), and of the hyperthermophilic bacterium T. 2309 
maritima (140-Gly-Leu-Ser-Asp-Leu-Ile-Val-Asp-Ile-Thr-Glu-Thr-Gly-Arg-Thr-155) 2310 
(282). Mutations that replaced Thr159 or Thr162 of L. lactis ATP 2311 
phosphoribosyltransferase confirmed the importance of this sequence in PRPP 2312 
binding (283). 2313 
 (v) Tryptophan biosynthesis. Contrary to the situation in histidine biosynthesis, 2314 
only two carbons of PRPP are retained in tryptophan. C2 and C3 of the indole moiety 2315 
of tryptophan originate from C1 and C2, respectively, of PRPP. The tryptophan 2316 
biosynthetic intermediate anthranilate reacts with PRPP in a reaction catalyzed by 2317 
anthranilate phosphoribosyltransferase (EC 2.4.2.18), encoded by trpD, which results 2318 
in the formation of N-(5-phospho-β-D-ribosyl)-anthranilate (Fig. 11, compound e) and 2319 
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PPi. The anthranilate phosphoribosyltransferase isolated from E. coli is bifunctional: it 2320 
also contains glutamine chorismate amidotransferase activity. Consequently, the E. 2321 
coli trpD gene product is considerably larger, a total of 531 amino acid residues, than 2322 
monofunctional anthranilate phosphoribosyltransferases, such as those from S. 2323 
solfataricus or M. tuberculosis, which have 345 or 370 amino acid residues, 2324 
respectively (284, 285). Other tryptophan biosynthetic enzymes from various species 2325 
have been shown to harbor two activities. 2326 
 The overall three-dimensional structure of anthranilate phosphoribosyltransferase 2327 
is similar among all of the species so far analyzed, i.e. the enterobacterium 2328 
Pectobacterium carotovorum (286), S. solfataricus (284), M. tuberculosis (285), 2329 
Xanthomonas campestris (PDB code 4hkm), the Gram-negative bacterium Thermus 2330 
thermophilus (PDB code 1v8g) and a cyanobacterial species (Nostoc sp.) (PDB code 2331 
1vqu). The two-domain structure consists of a smaller N-terminal domain of six 2332 
helices (the α-domain) and a larger C-terminal domain of six parallel β-sheets and one 2333 
antiparallel β-sheet as well as eight or more helices (the α/β-domain). Although the 2334 
five-stranded parallel β-sheet characteristic of type I phosphoribosyltransferases is 2335 
recognizable, anthranilate phosphoribosyltransferase contains additional structural 2336 
features, and, thus constitutes a separate fold sometimes designated as type IV 2337 
phosphoribosyltransferase (287). The enzyme is active as a homodimer; the α-domain 2338 
is responsible for the dimerization. Binding of PRPP and anthranilate is mediated in a 2339 
cleft of the α/β-domain. The binding of PRPP is promoted by two Mg2+ or Mn2+, 2340 
which accounts for a requirement of Mg2+ for activity (288). The binding of PRPP is 2341 
well mapped in the structures of S. solfataricus and M. tuberculosis anthranilate 2342 
phosphoribosyltransferase. The amino acid residues involved are the sequence 79-2343 
Gly-Thr-Gly-Gly-Asp-83, Lys106 and 223-Asp-Glu-224 of the S. solfataricus 2344 
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enzyme (107-Gly-Thr-Gly-Gly-Asp-111, Lys136 and 251-Asp-Glu-252, respectively, 2345 
of the M. tuberculosis enzyme). Remarkably, in spite of this sequence conservation, 2346 
the binding of PRPP in the two enzymes is very different. In common, one divalent 2347 
cation (MG1) coordinates to the α- and β-phosphates of PRPP. Another divalent 2348 
cation (MG2) coordinates to the two acidic residues (Asp-Glu). The Gly-Thr-Gly-2349 
Gly-Asp “wraps around” PRPP with the amino terminal glycine binding to the 2350 
diphosphate chain and the carboxy terminal aspartate or glycine binding to the 5-2351 
phosphate. Specifically, Gly79 forms hydrogen bond to the β-phosphate in the S. 2352 
solfataricus enzyme. Lys106 of the latter enzyme binds to the β-phosphate, whereas 2353 
Lys135 of the M. turbeculosis enzyme binds to the α-phosphate. Thus, this sequence 2354 
may be compared to the PPi loop of type I phosphoribosyltransferases and of PRPP 2355 
synthases. Among the differences in PRPP binding between the two enzymes are the 2356 
binding properties of Asp-Glu, which bind to MG2 and to the oxygen of C5 (Asp 2357 
residue only) in S. solfataricus anthranilate phosphoribosyltransferase. MG2 2358 
furthermore coordinates to the 5-phosphate and to the oxygens of C4 and C5 of ribose 2359 
5-phosphate (289). The corresponding aspartate and gluatmate residues of the M. 2360 
tuberculosis enzyme are coordinated to MG1 (Glu252) or to MG2 (Asp251). The 2361 
PRPP-divalent cation-coordinations of the latter enzyme are directed exclusively 2362 
toward the diphosphate chain (285). The conserved glycine-rich sequence 79-Gly-2363 
Thr-Gly-Gly-Asp-83 resembles the subsequence Asp-Asp-Xxx-Xxx-Thr-Gly-Gly-Thr 2364 
of several phosphoribosyltransferases and the glycine-containing subsequence of the 2365 
PRPP binding loop of PRPP synthase (228-Thr-Ala-Gly-Thr-232, 234-Ser-Gly-Gly-2366 
Thr-237 or 217-Thr-Gly-Gly-Thr-220 of B. subtilis, S. solfataricus or M. jannaschii 2367 
PRPP synthase, respectively). These sequences of phosphoribosyltransferases and 2368 
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PRPP synthases are involved in the binding of the 5-phosphate moiety of PRPP or 2369 
ribose 5-phosphate. 2370 
 Each subunit of anthranilate phosphoribosyltransferase binds two anthranilate 2371 
molecules in addition to one PRPP molecule and two Mg2+. Three sites for 2372 
anthranilate are responsible for tunnel movement of anthranilate with a concomitant 2373 
180° flipping of the compound toward MgPRPP, which at this point is presumably 2374 
already present. However, anthranilate may bind to the outer end of the tunnel before 2375 
MgPRPP is bound, and binding of the latter compound may participate in tunnel 2376 
formation (290). Interestingly, in S. solfataricus anthranilate 2377 
phosphoribosyltransferase Gly79 also forms a hydrogen bond to the anthranilate 2378 
nitrogen. Thus, this residue may be particularly important in positioning anthranilate 2379 
and PRPP for inline attack of anthranilate on C1 of PRPP (289). 2380 
 Tryptophan biosynthesis in M. tuberculosis has attracted much attention, as trp 2381 
strains of this organism are avirulent (291). Since the organism’s host, humans, are 2382 
unable to synthesize tryptophan a search for inhibitors of tryptophan biosynthetic 2383 
enzymes, including anthranilate phosphoribosyltransferase has been conducted in 2384 
hopes of identifying an antimicrobial agent (287, 290, 292). 2385 
 (vi) Phosphoribosyl transfer without participation of PRPP. For the sake of 2386 
completenes, the cobT encoded nicotinate nucleotide:5,6-dimethylbenzimidazole 2387 
phosphoribosyltransferase (EC 2.4.2.21) of S. enterica and E. coli should be 2388 
mentioned at this point. Altough this enzyme is a phosphoribosyltransferase, it does 2389 
not utilize PRPP as a substrate. Rather, the 5-phosphoribosyl moiety is detached from 2390 
the nicotinamide mononucleotide and added to the 5,6-dimethylbenzimidazole, and, 2391 
thus, one N-glycoside bond is replaced by a second N-glycoside bond (293, 294). A 2392 
variant of this enzyme (EC 2.4.2.55) has been characterized from the bacterium 2393 
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Sporomusa ovata. In contrast to nicotinate nucleotide:5,6-dimethylbenzimidazole 2394 
phosphoribosyltransferase, the S. ovata enzyme (EC 2.4.2.55) also utilizes phenol 2395 
derivatives as acceptors in the transfer of the 5-phosphoribosyl moiety (295). 2396 
 C-Glycosidic bond formation. 2397 
 (i) Tetrahydromethanopterin biosynthesis. Tetrahydromethanopterin is one of 2398 
a number of co-factors involved in the methanogenesis and sulfate-reduction in a 2399 
variety of archaeal species (296, 297), and methylotrophic bacteria (298, 299). The 2400 
pathway of tetrahydromethanopterin biosynthesis has been deduced from the 2401 
structures of a series of metabolites meticulously solved by White and colleagues (4, 2402 
300-303). The function of methanopterin is analogous to that of dihydrofolate, i.e. it is 2403 
a carrier of one-carbon molecules; formyl, methylene and methyl groups. Both 2404 
methanopterin and folic acid contain a substituted pteridyl moiety as well as an aryl 2405 
component apparently derived from 4-aminobenzoate. However, methanopterin 2406 
contains both deoxyribulosyl and phosphoribosyl moieties that are not present in 2407 
folate. Both of these pentose moieties are derived from PRPP. The two PRPP-utilizing 2408 
biochemical reactions of methanopterin biosynthesis are shown in Fig. 12A. Initially, 2409 
and regarded as the first committed step in tetrahydromethanopterin biosynthesis, 4-2410 
hydroxybenzoate condenses with PRPP with the formation of 5’-phospho-β-D-ribosyl 2411 
4-hydroxybenzene as well as PPi and carbon dioxide (Fig. 12A, reaction 1). The 2412 
product 5’-phospho-β-D-ribosyl 4-hydroxybenzene contains a carbon-carbon bond 2413 
between the ribosyl and aryl moieties (Fig. 12A, compound m). The enzyme 2414 
catalyzing this reaction has affinity for both 4-hydroxy- and 4-aminobenzoate (304, 2415 
305). In vitro and in vivo analyses used 4-aminobenzoate to elucidate the metabolic 2416 
pathway. The enzyme has been designated 4-(β-D-ribofuranosyl)aminobenzene-5'-2417 
phosphate synthase, and, in M. jannsachii, is encoded by the MJ1427 gene. Although 2418 
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4-hydroxybenzoate rather than 4-aminobenzoate appears to be the origin of the aryl 2419 
moiety of methanopterin, at least in M. jannaschii (304), we shall use the designation 2420 
aminobenzoate phosphoribosyltransferase for this enzyme, because most studies have 2421 
used 4-aminobenzoate as the substrate. Indeed, the product of the aminobenzoate 2422 
phosphoribosyltransferase-catalyzed reaction with 4-hydroxybenzoate as the 2423 
substrate, 5’-phospho-β-D-ribosyl 4-hydroxybenzene, is transformed in a subsequent 2424 
enzymic step to the amino-derivative 5’-phospho-β-D-ribosyl 4-aminobenzene (Fig. 2425 
12A, compound n). 2426 
 Aminobenzoate phosphoribosyltransferase of the methanogenic archaea 2427 
Methanosarcina thermophila, M. jannaschii and Methanothermobacter 2428 
thermautotrophicus as well as the hyperthermophilic, non-methanogenic (sulfate-2429 
reducing) archaeon A. fulgidus have been purified and studied. Edman degradation of 2430 
aminobenzoate phosphoribosyltransferase isolated from cell extracts of M. 2431 
thermophila strain TM-1 was used to establish the sequence of the 20 N-terminal 2432 
amino acid residues, which were then used to identify aminobenzoate 2433 
phosphoribosyltransferase-encoding genes in a variety of organisms (299). The 2434 
molecular mass of the native enzyme is 63.5 kDa, that of the subunit is 32.6 kDa, i.e. 2435 
the enzyme is a homodimer. PPi and 5’-phospho-β-D-ribosyl 4-aminobenzene have 2436 
been demonstrated as products of the reaction. The reaction requires Mg2+ or Mn2+, 2437 
the latter ion being the most efficient. The optimal pH is 4.8, the optimal temperature 2438 
50 °C. Some kinetic constants were determined; an apparent KM4-aminobenzoate was 58 2439 
μM and an apparent KMPRPP was 3.6 mM. Pyridoxal phosphate is suggested as 2440 
involved in the reaction, but data are inconclusive in this respect, and it is suggested 2441 
that pyridoxal phosphate may be involved in the reaction in a way that does not 2442 
require the carbonyl of pyridoxal phosphate (301, 305). 2443 
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 The M. jannaschii aminobenzoate phosphoribosyltransferase, encoded by the 2444 
gene MJ1427, resembles that of M. thermophila (306). Product inhibition studies 2445 
established the reaction as an ordered Bi-Ter mechanism with binding of PRPP 2446 
followed by 4-aminobenzoate, and release of CO2, then 4-(β-D-2447 
ribofuranosyl)aminobenzene-5'-phosphate and finally PPi. As with the enzyme from 2448 
M. thermophila, the affinity for PRPP is low (KMPRPP 1.5 mM), whereas that for 4-2449 
aminobenzoate was lower (KM4-aminobenzoate 0.15 mM). A kcat value was determined as 2450 
0.23 s-1. Phosphoribosyltransferase catalyzed reactions are thought to proceed with the 2451 
intermediate formation of a ribooxocarbenium ion as well as a negatively charged 2452 
nucleophile. Aminobenzoate phosphoribosyltransferase poses a special problem for 2453 
this generalization. How does the enzyme stabilize negative charge at C1 of the 2454 
nucleophile when the substrate already carries a negatively charged carboxyl group 2455 
(4-aminobenzoate or 4-hydrozybenzoate)? No prosthetic group, neither pyridoxal 5-2456 
phosphate nor a pyruvoyl moiety, appear to be present, indicating that enzyme side-2457 
chains only are involved in the catalytic process (306). 2458 
 In A. fulgidus the gene AF2089 encodes aminobenzoate 2459 
phosphoribosyltransferase. Following cloning and expression of the gene in E. coli, 2460 
the enzyme was partly purified. It has a temperature optimum at 70 °C, and maximal 2461 
activity at pH 5.3. Gel filtration revealed a molecular mass of 57 kDa, corresponding 2462 
to a homodimer, because the molecular mass of the subunit was established as 35.5 2463 
kDa (307). Finally, a procedure for the purification of aminobenzoate 2464 
phosphoribosyltransferase from M. thermautotrophicus has been published (307). 2465 
 Some archaeal species appear to contain two aminobenzoate 2466 
phosphoribosyltransferase-encoding genes. These are Pyrococcus abyssi, where the 2467 
aminobenzoate phosphoribosyltransferases (sequence designations PAB0141 and 2468 
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PAB1694) show 30% amino acid sequence identity, Pyrococcus horikoshii (sequence 2469 
designations PH0227 and PH1228) whose enzymes show 29% amino sequence 2470 
identity, and Aeropyrum pernix (sequence designations APE2425 and APE1512) 2471 
whose enzymes show 28% amino acid sequence identity (299). 2472 
 None of the aminobenzoate phosphoribosyltransferases contains a classical PRPP 2473 
binding site, as is the case for type II phosphoribosyltransferases. As mentioned, the 2474 
binding of PRPP to type II phosphoribosyltransferases occurs by interaction of a few 2475 
amino acid residues to the phosphate moieties of PRPP. Amino acid sequence 2476 
comparison of aminobenzoate phosphoribosyltransferases with M. tuberculosis or T. 2477 
acidophilum nicotinate and quinolinate phosphoribosyltransferases did not reveal 2478 
conserved amino acid residues between these phosphoribosyltransferases. 2479 
 O-Glycosidic bond formation. 2480 
 (i) Tetrahydromethanopterin biosynthesis. Another reaction of archaeal 2481 
methanopterin biosynthesis utilizes PRPP as a substrate; interestingly, this reaction 2482 
results in the formation of an O-glycosidic bond (Fig. 12A, reaction 2). The 2483 
phosphoribosyl acceptor substrate of this reaction is N-[(7,8-dihydropterin-6-2484 
yl)methyl]-4-(1-deoxy-D-ribulosyl)aminobenzene (Fig. 12A, compound o), and the 2485 
product is 1-(4-{N-[(7,8-dihydropterin-6-yl)methyl]amino}phenyl)-5-(5-phospho-α-D-2486 
ribulosyl)-1-deoxyribitol (Fig. 12A, compound p), i.e. C1 of the phosphoribosyl 2487 
moiety is attached to a hydroxyl group of the ribulosyl moiety of compound o, with 2488 
inversion of the anomeric carbon of the phosphoribosyl moiety, as usual (301). The 2489 
enzyme catalyzing this reaction has not been identified. One additional reaction is 2490 
necessary to convert compound p to the final cofactor as shown in Fig. 12A and is 2491 
described in the legend. 2492 
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 (ii) Arabinosyl monophosphodecaprenol biosynthesis. Arabinogalactan is an 2493 
important constituent of the cell wall of mycobacteria such as M. tuberculosis and M. 2494 
smegmatis. Arabinogalactan contains D-arabinosyl and D-galactosyl moieties. 2495 
Polymerization of the arabinosyl moieties is catalyzed by a number of 2496 
arabinosyltransferases, for which the donor is a lipid-linked arabinosyl donor, β-D-2497 
arabinosyl monophosphodecaprenol [reviewed previously (5, 308)]. Tracer 2498 
methodology applied to membrane preparation of M. smegmatis to study the origin of 2499 
the arabinosyl derivatives revealed that ribulose 5-phosphate was a precurser, but that 2500 
ribulose 5-phosphate was not converted directly to arabinose 5-phosphate (309). 2501 
Rather, the pentosyl phosphate donor was shown to be PRPP. Thus, following 2502 
incubation of M. smegmatis membrane preparations with [14C]PRPP, the production 2503 
of [14C]ribosyl phosphopolyprenol, [14C]arabinosyl phosphopolyprenol, 5-phospho-2504 
[14C]ribosyl phosphopolyprenol, and 5-phospo-[14C]arabinosyl phosphopolyprenol 2505 
was demonstrated, which showed the involvement of PRPP in the synthesis of 2506 
arabinose derivatives for cell wall formation in this organism, Fig. 12B (310). 2507 
Subsequently, an M. tuberculosis gene (Rv3806c) encoding an enzyme that 2508 
phosphoribosylates decaprenyl phosphate was identified, cloned and expressed in E. 2509 
coli. The enzyme is an integral membrane protein; membrane fractions of an E. coli 2510 
strain hosting Rv3806c were able to convert PRPP and decaprenyl phosphate into 5-2511 
phospho-β-D-ribosyl 1-phosphoryldecaprenol (311). The enzyme is designated 5-2512 
phospho-α-D-ribosyl-1-diphosphate:decaprenyl-phosphate 5-2513 
phosphoribosyltransferase. In analogy with other phosphoribosyltransferases, we shall 2514 
use the name decaprenyl phosphate phosphoribosyltransferase. 2515 
 Inspection of the amino acid sequence of decaprenyl phosphate 2516 
phosphoribosyltransferase does not reveal the classical PRPP binding site that is 2517 
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characteristic of PRPP synthases and type I phosphoribosyltransferases. As 2518 
mentioned, decaprenyl phosphate phosphoribosyltransferase is a membrane bound 2519 
enzyme, which is consistent with both a membrane soluble substrate (decaprenyl 2520 
phosphate) and a soluble substrate (PRPP). A topology with nine transmembrane 2521 
domains was suggested for the structure of M. tuberculosis decaprenyl phosphate 2522 
phosphoribosyltransferase by molecular modeling studies. According to this model, 2523 
the active site may involve the cytoplasmic loop II. From a search of amino acid 2524 
sequence alignments with other phosphoribosyltransferases, a sequence, 73-Asn-Asp-2525 
x-x-Asp-77 (where x indicates any amino acid), was suggested as important for PRPP 2526 
binding and enzymatic function (312). Indeed, the M. tuberculosis decaprenyl 2527 
phosphate phosphoribosyltransferase amino acid sequence 69-Val-Tyr-Leu-Val-Asn-2528 
Asp-Val-Arg-Asp-77 resembles a large part of the PRPP binding loop of E. coli 2529 
hypoxanthine-guanine phosphoribosyltransferase, 95-Val-Leu-Ile-Val-Glu-Asp-Ile-2530 
Ile-Asp-103, as well as the corresponding amino acid sequence of other 2531 
phosphoribosyltransferases (213, 313). These amino acids are located within the 2532 
cytoplasmic loop II and the junction of this loop and the transmembrane 2-domain. 2533 
Analysis of the decaprenyl phosphate phosphoribosyltransferase replacement mutants 2534 
Asn73Gln and Asp77Glu revealed significantly increased KM values for PRPP, 2535 
providing evidence that this sequence is involved in PRPP binding (312). 2536 
 (iii) Aminoglycoside antibiotic biosynthesis. A third reaction that forms an O-2537 
glycosidic bond with PRPP as the phosphoribosyl donor occurs in the biosynthesis of 2538 
the aminoglycoside antibiotic butirosin. The 26-ORF btr gene cluster specifies the 2539 
biosynthetic pathway for buritosin in Bacillus circulans (314, 315). The btrL cistron 2540 
encodes neamine phosphoribosyltransferase (neamine:5-phospho-α-D-ribose 1-2541 
diphosphate phosphoribosyltransferase, EC 2.4.2.49), which phosphoribosylates 2542 
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neamine with the formation of 5''-phosphoribostamycin, Fig. 12C (316). The B. 2543 
circulans neamine phosphoribosyltransferase contains a well-conserved PRPP binding 2544 
site 212-Asp-Ile-Val-Ile-Leu-Glu-Asp-Gln-Pro-His-Thr-Gly-Gly-Thr-225, which may 2545 
be compared to the E. coli hypoxanthine phosphoribosyltransferase sequence, 94-Asp-2546 
Val-Leu-Ile-Val-Glu-Asp-Ile-Ile-Asp-Ser-Gly-Asn-Thr-107. Neamine 2547 
phosphoribosyltransferase contains 604 amino acid residues and is much larger than 2548 
other type I phosphoribosyltransferases (316), such as E. coli hypoxanthine and 2549 
guanine-xanthine phosphoribosyltransferases, which contain 178 and 152 amino 2550 
acids, respectively. It is also larger than type II phosphoribosyltransferases such as E. 2551 
coli quinolinate and nicotinate phosphoribosyltransferases, which contain 297 and 400 2552 
amino acids, respectively. It is possible that the neamine phosphoribosyltransferase is 2553 
a bifunctional enzyme, although a second activity has not been discovered. This 2554 
putative second activity is not the phosphatase that hydrolyzes the phosphate ester of 2555 
5''-phosphoribostamycin to ribostamycin, as this activity is encoded by the btrP 2556 
cistron (316). 2557 
 In addition to butirosin, a number of other aminoglycoside antibiotics contain a 2558 
pseudo-disaccharide resembling that of butirosin as well as a ribosyl moiety. 2559 
Examples of these antibiotics are neomycin B, paromomycin, and lividomycin B. The 2560 
neomycin B biosynthesis-specifying gene cluster of Streptomyces fradiae contains the 2561 
neoL reading frame (accession CAF33322), whose deduced amino acid sequence 2562 
shows only 22% amino acid sequence identity with that of neamine 2563 
phosphoribosyltransferase. However, certain stretches of amino acids along the 2564 
sequences appears highly conserved, among these the PRPP binding site (317). 2565 
Similarly, a putative neamine phosphoribosyltransferase may be present in 2566 
Streptomyces lividus, because an ORF (accession CAG38706) of the lividomycin B 2567 
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biosynthetic cluster of S. lividus is 29% identical to the B. circulans neamine 2568 
phosphoribosyltransferase amino acid sequence. Details on the genetics of 2569 
aminoglycoside antibiotic biosynthesis have been previously reviewed (318). 2570 
 2571 
Reactions at the Diphosphoryl Moiety of PRPP 2572 
A few enzymes have been shown to hydrolyse the phosphoric anhydride bond of the 2573 
diphosphoryl moiety of PRPP: PRPP + H2O → ribosyl 1,5-bisphosphate + Pi. A 2574 
number of archaeal species, such as M. jannaschii, Methanosarcina acetivorans, A. 2575 
fulgidus, and T. kodakaraensis contain a form III ribulose 1,5-bisphosphate 2576 
carboxylase/oxygenase, which catalyzes the carboxylation of ribulose 1,5-2577 
bisphosphate. Usually ribulose 1,5-bisphosphate is formed by ATP-dependent 2578 
phosphorylation of ribulose 5-phosphate. However, in M. jannaschii and M. 2579 
acetivorans ribulose 1,5-bisphosphate originates from PRPP, and it was suggested 2580 
that PRPP was hydrolyzed to ribose 5-phosphate followed by NAD+-dependent 2581 
oxidation to ribulose 1,5-bisphosphate. Alternatively, PRPP may be transformed to 2582 
ribosyl 1,2-cyclic phosphate and then to ribulose 1,5-bisphosphate. The physiologic 2583 
function f this pathway remains to be established (319). In addition, certain 2584 
diphosphoryl (Nudix) hydrolases are able to hydrolyze PRPP with the formation of 2585 
ribosyl 1,5-bisphosphate and Pi (320). Finally, a PRPP pyrophosphatase activity has 2586 
been identified in macrophages exposed to hypoxia (321). 2587 
 2588 
Co-Factor Biosynthesis 2589 
Thiamine diphosphate. Thiamine diphosphate synthesis utilizes 5’-phosphoribosyl 2590 
5-aminoimidazole as a precursor. This compound is also a precursor of purine 2591 
nucleotide biosynthesis. 5’-Phosphoribosyl 5-aminoimidazole is converted to a 2592 
 106
pyrimidine moiety by thiC-encoded phosphomethylpyrimidine synthase. As such, 2593 
some of the carbons of PRPP end up in the pyrimidine moiety of thiamine 2594 
diphosphate. Thus, C2 of PRPP becomes the methyl group of the pyrimidine moiety, 2595 
C4 of PRPP becomes C5 of the pyrimidine moiety, whereas C5 of PRPP becomes the 2596 
methylene group that connects the pyrimidine and thiazole moieties of thiamine 2597 
diphosphate. C1 and C3 of PRPP are lost as formate and carbon dioxide (322). 2598 
 Flavins. The ribitol moiety of the flavin-containing co-factors FAD and FMN are 2599 
derived from the ribosyl moiety of GTP, and, thus, originally from PRPP (323, 324). 2600 
 Pterins. The pterin moiety of folate derivatives are synthesized from GTP. In 2601 
tetrahydrofolate, the C7, C6 and the methylene attached to C6 of the pterin moiety are 2602 
derived from C1, C2 and C3 of PRPP. C4 and C5 of PRPP are lost as glyoxylate. The 2603 
synthesis of pterin and methanopterin follow identical pathways at this stage (325, 2604 
326). Also, the molybdopterin is synthesized from GTP with similar utilization of 2605 
carbons of PRPP (327). 2606 
 2607 
Carbon-Phosphorus Lyase Pathway 2608 
As mentioned previously, PRPP can be synthesized in a reaction catalyzed by 2609 
phosphoribosyl bisphosphate phosphokinase. This reaction is part of the carbon-2610 
phosphorus lyase pathway, by which phosphonates are catabolized by means of a 2611 
radical-mediated process. This catabolic pathway is specified by the 14-cistron operon 2612 
phnCDEFGHIJKLMNOP found in numerous microorganisms including E. coli (154). 2613 
Phosphoribosyl bisphosphate phosphokinase is specified by the phnN cistron and 2614 
catalyzes the reaction ribosyl 1,5-bisphospate + ATP → PRPP + AMP, which is the 2615 
final chemical reaction specified by the phnC-D operon (151, 328). Thus, catabolism 2616 
of phosphonates by the carbon-phosphorus lyase pathway produces PRPP, in which 2617 
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the phosphorus of phosphonate is represented by the α-phosphate at the C1 position. 2618 
The utilization of phosphonate-derived phosphorus requires one or more of the above 2619 
described phosphoribosyltransferases, which produces PPi, which can by hydrolyzed 2620 
to Pi by diphosphatase (154, 329). 2621 
 2622 
PRPP AS MEDIATOR OF METABOLIC REGULATION 2623 
Until now this review has presented enzymes that produce PRPP and enzymes that 2624 
consume PRPP with the formation of N-, O- or C-glycosidic bonds. The following 2625 
section is dedicated to the regulatory functions played by PRPP. These functions 2626 
include binding to the PyrR regulator, which is involved in translational control of 2627 
pyrimidine biosynthesis gene expression; binding to the PRPP responsive PurR 2628 
regulator of Gram-positive organisms with low GC content; and allosteric activation 2629 
by PRPP of carbamoylphosphate synthetase. 2630 
 2631 
The Enigma of PRPP as a Regulator of Metabolic Activity 2632 
Bacterial enzymes that utilize PRPP generally have KM values at least one order of 2633 
magnitude lower than the normal intracellular PRPP concentration. Thus, the PRPP 2634 
concentration is unlikely to be a rate-determining factor for 2635 
phosphoribosyltransferases. No regulatory function, such as allosteric inhibition, of 2636 
phosphoribosyltransferase activity by PRPP at a metabolic level under normal growth 2637 
conditions has been identified experimentally. Traditionally, PRPP pool sizes are 2638 
expressed as millimol per gram dry weight; this unit is dependent on the cell 2639 
composition and is not directly translatable into intracellular molar concentration for 2640 
comparison between different species. However, it appears safe to state that the PRPP 2641 
concentration of bacterial cells is in the millimolar range (330, 331). Bacteria regulate 2642 
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their PRPP pools in response to exogenous purine sources. Thus, the PRPP pool of B. 2643 
subtilis, L. lactis, E. coli or S. enterica is reduced two to four-fold by the addition of 2644 
adenine or hypoxanthine (Table 5). This reduction in PRPP pool sizes may be caused 2645 
by allosteric and isosteric regulation of PRPP synthase by purine nucleotides, i.e. 2646 
ADP and GDP, as described above. 2647 
 The situation is different in mammals, where the PRPP concentration is rate-2648 
limiting for purine biosynthesis de novo and for salvage reactions (332), which 2649 
suggests that the rates of PRPP-utilizing enzymes may be determined by substrate 2650 
saturation kinetics. The PRPP concentration of mammalian cells is much lower than 2651 
that of bacteria, 5-30 µM, although with variation throughout the cell cycle (332, 2652 
333). 2653 
 We are therefore faced with the enigma of explaining how the high intracellular 2654 
PRPP levels of microbial organisms are sensed by regulator proteins, which 2655 
presumably should be saturated with PRPP under most physiological conditions. The 2656 
enigma is only partly resolved, and further research will be needed to fill in the 2657 
missing information. Details of the mechanism of PRPP-mediated regulation of 2658 
pyrimidine and purine nucleotide synthesis by the PyrR and PurR regulatory proteins 2659 
are described in the next section. 2660 
 2661 
Regulation of Pyrimidine Metabolism by the RNA Binding PyrR Protein 2662 
Pyrimidine biosynthetic genes are present in most organisms, and their expression is 2663 
subject to control by different mechanisms. Regulation of bacterial pyrimidine 2664 
metabolism has been extensively reviewed previously (334-336). Here we shall 2665 
concentrate on a description of the structure of PyrR and the involvement of PRPP in 2666 
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PyrR-mediated regulation of pyrimidine biosynthesis in the B. subtilis, B. caldolyticus 2667 
and L. lactis. 2668 
 Three-dimensional structure of PyrR. The three-dimensional structure of PyrR 2669 
from three microbial sources have be published: B. subtilis (337), B. caldolyticus 2670 
(338) and M. tuberculosis (339). The three-dimensional structure of T. thermophilus 2671 
PyrR has also been solved (PDB code 1ufr). The overall structure of the four PyrR 2672 
proteins is identical, and contains the typical type I phosphoribosyltransferase fold, a 2673 
five-stranded β-sheet surrounded by three helices, and the typical sequence elements 2674 
are easily identified: a PRPP binding site, i.e. a PRPP binding loop (100-Val-Ile-Leu-2675 
Val-Asp-Asp-Val-Leu-Phe-Thr-Gly-Arg-Thr-112 of B. caldolyticus PyrR), a PP loop 2676 
(37-Gly-Ile-Lys-Thr-Arg-41 of B. caldolyticus PyrR), a flexible loop (Thr71 to Asn83 2677 
of B. caldolyticus PyrR), and a hood structural element. The binding of UMP and 2678 
GMP to B. caldolyticus PyrR involves identical amino acid residues, Asp104, 2679 
Asp105, Thr109 and Arg137. The 104-Asp-Asp-105 dipeptide of the PRPP binding 2680 
loop binds to the nucleotide via Mg2+. Altogether, the binding of PRPP and 2681 
nucleotides to PyrR is similar to that of type I phosphoribosyltransferases. PyrR from 2682 
B. caldolyticus  has been proposed to exist as a dimer or tetramer (338, 340, 341), 2683 
although B. subtilis PyrR has been shown to exist in a hexameric state (342). The 2684 
dimerization pattern of PyrR is different from that of type I 2685 
phosphoribosyltransferases and the RNA binding activity of PyrR has been proposed 2686 
to be due to the exposure of a region of basic amino acid residues in the dimer. 2687 
Effectors of the quaternary structure are PRPP, uridine ribonucleotides, GTP and pyr 2688 
leader mRNA. A close resemblance of the crystal structure of GMP-bound B. 2689 
caldolyticus PyrR to an evolutionarily distant hypoxanthine-guanine 2690 
phosphoribosyltransferase suggests that the two proteins share ancestry (338). 2691 
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However, PyrR from both B. subtilis and B. caldolyticus have a low uracil 2692 
phosphoribosyltransferase activity that can support slow growth of a pyrimidine 2693 
requiring strain on uracil (248, 343). 2694 
 Mechanism of PRPP-mediated regulation by PyrR. The B. subtilis pyr gene 2695 
cluster encodes all of the enzymes required for the biosynthesis of UMP, a uracil 2696 
transporter, and the regulatory protein PyrR (343). Transcription is controlled by 2697 
pyrimidine availability through an attenuation mechanism. There are three terminator-2698 
antiterminator structures in pyr mRNA. PyrR binds to a conserved region in the pyr 2699 
operon leader resulting in disruption of an antiterminator that is the dominant RNA 2700 
structure in the absence of PyrR binding. The negative effect of PyrR is observed only 2701 
when pyrimidine precursors are available in the growth medium (342-344). 2702 
 The active RNA binding form of PyrR appears to be a dimer (Fig. 13A), which is 2703 
capable of recognizing and binding a specific RNA structure present in the leader of 2704 
mRNA transcripts of PyrR regulated genes (341). Dimer-formation and RNA binding 2705 
occurs when UMP, UTP, or PRPP is bound to PyrR, resulting in transcriptional 2706 
termination. GTP counteracts the binding of UTP (and possibly UMP), resulting in 2707 
multimer formation and presumably transcriptional read-through because the RNA 2708 
binding sites are sequestered in the tetramer. UMP, UTP, and GTP bind to PyrR at 2709 
physiological concentrations, while PRPP binding has an apparent dissociation 2710 
constant at sub-physiological concentrations, as discussed above (341). 2711 
 The physiological relevance of PRPP binding to L. lactis PyrR was demonstrated 2712 
by transcriptomic analysis of nucleotide metabolism. L. lactis pyr gene expression is 2713 
regulated by PyrR-dependent attenuation with a mechanism similar to that of B. 2714 
subtilis (345-347). The mRNA levels under PyrR attenuation control showed an 2715 
inverse correlation with the intracellular PRPP concentrations (348), in accordance 2716 
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with an increased RNA binding and attenuation upon PRPP binding to PyrR. It is 2717 
reasonable to suspect that PyrR from L. lactis also binds RNA as a dimer, and that 2718 
dimers are stabilized in relation to tetramers by binding of PRPP. An increase in 2719 
PRPP concentration is a consequence of purine shortage and hence a diminished 2720 
demand for pyrimidine synthesis; thus, the inverse correlation of PRPP and pyr gene 2721 
expression serves a valuable physiological function. 2722 
 Proteins with homology to PyrR are found among many bacterial species. With 2723 
few exceptions, PyrR is found among firmicutes, cyanobacteria and actinobacteria. 2724 
Apparently, PyrR is absent from the α-proteobacteria, but it is present in some orders 2725 
of the other classes of proteobacteria. PyrR is absent from enterobacteriales, but 2726 
present in the Pseudomonadales order. B. subtilis has two different enzymatic 2727 
activities that catalyze the formation of UMP from uracil and PRPP, PyrR and uracil 2728 
phosphoribosyltransferase encoded by upp (248). PyrR and uracil 2729 
phosphoribosyltransferase share 23% identity, which suggests that PyrR, aside from 2730 
its close ancestry to the hypoxanthine-guanine phosphoribosyltransferases, also shares 2731 
ancestry with uracil phosphoribosyltransferases. 2732 
 2733 
Regulation of Purine Metabolism by PRPP-Responsive, DNA Binding PurR 2734 
Proteins 2735 
PRPP responsive PurR transcriptional regulators are found only in Low-GC Gram-2736 
positive bacteria, but the members of this small protein family differ widely in their 2737 
mechanism of regulation. The B. subtilis PurR, hereafter designated PurRBs, is a 2738 
negative regulator, whereas the L. lactis PurR, hereafter designated PurRLl, is an 2739 
activator of purine metabolism gene expression. In contrast to the PRPP-responsive 2740 
PurR regulators from Gram-positive bacteria, a LacI-type PurR repressor protein is 2741 
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present in E. coli and a variety of other bacterial species. The LacI-type PurR proteins 2742 
do not respond to PRPP, but repress the transcription of purine genes when bound to 2743 
the co-repressors hypoxanthine or guanine (349, 350). In the following sections we 2744 
shall describe in more detail the structure and function of B. subtilis and L. lactis 2745 
PurR. 2746 
 Three-dimensional structure of B. subtilis PurR. B. subtilis PurR contains 285 2747 
amino acid residues and has a homodimeric quaternary structure (351). A C-terminal 2748 
domain of the subunit (residues 77 to 285) has the characteristic fold of type I 2749 
phosphoribosyltransferases and PRPP synthases described previously, a central 2750 
parallel β sheet flanked by α helices. Hood and flexible loop structural elements are 2751 
also present. The C-terminal domain of PurRBs also contains a PRPP binding site, i.e. 2752 
a PRPP binding loop (196-Gly-Ser-Asn-Val-Leu-Ile-Ile-Asp-Asp-Phe-Met-Lys-Ala-2753 
Gly-Gly-Thr-211) and a PP loop (139-Thr-Lys-Gly-Ile-142) (352). 2754 
 Gel mobility shift analysis showed that binding of PRPP to PurRBs changes its 2755 
affinity towards its DNA binding sites (351, 353). X-ray structural analysis of PurRBs 2756 
crystals containing the PRPP analog cPRPP revealed that the compound binds to the 2757 
PRPP and PP loops analogous to PRPP binding in type 1 phosphoribosyltransferases. 2758 
Contacting amino acid residues were Lys 140 and Asp203, Asp204 of the PP and 2759 
PRPP binding loop, respectively, as well as residues in the flexible loop (354). 2760 
Curiously, the binding of cPRPP occurred without the participation of Mg2+, which 2761 
may suggest relatively weak binding of cPRPP. DNA binding of two mutant variants 2762 
of PurRBs, Asp203Ala and Asp204Ala, could not be  inhibited by PRPP 2763 
in vitro, and the alterations caused a super-repression phenotype of pur gene 2764 
expression consistent with poor binding of PRPP to the altered PurRBs proteins (353). 2765 
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Altogether, binding of PRPP to PurRBs strongly resembles the binding of PRPP to 2766 
type I phosphoribosyltransferases. 2767 
 In spite of the high sequence similarity to type I phosphoribosyltransferases, 2768 
PurRBs is inactive as a phosphoribosyltransferase and does not even bind purine bases. 2769 
This deficiency is explained by the interactions of the large side chains of well-2770 
conserved Tyr102 and Phe205, which prevent the binding of a nucleophile in proper 2771 
position relative to C1 of PRPP. The presence of these bulky amino acid side chains 2772 
also explains the inability of compounds containing nucleobases to inhibit PurRBs-2773 
PurBox interactions (352). Interestingly, xanthine phosphoribosyltransferases contain 2774 
phenylalanine in the analogous position to Phe205, which indicates that the Phe205-2775 
Tyr102 interaction is crucial to blocking access of purines to the active site of PurR. 2776 
 The N-terminal domain (residues 1 to 74) of PurRBs forms a winged-helix 2777 
domain, a subdivision of the DNA binding helix-turn-helix domains (352), and is 2778 
attached to the C-terminal domain by a three-residue linker. This domain is 2779 
responsible for the binding of PurRBs to so-called PurBox sites located upstream of the 2780 
PurR regulated operons (354). Functionally, PurRBs may be regarded as a crippled 2781 
phosphoribosyltransferase, which has lost the catalytic activity but retained the PRPP 2782 
binding capability and has gained an N-terminal DNA binding domain. 2783 
 Mechanism of PRPP-mediated regulation of purine biosynthesis in B. 2784 
subtilis. The addition of adenine to cultures of B. subtilis causes repression of 2785 
transcription of a large number of operons including genes for purine nucleotide de 2786 
novo biosynthetic enzymes, genes specifying purine transport proteins, genes for 2787 
enzymes in purine nucleotide interconversion and certain co-factor biosynthetic genes 2788 
(351, 355, 356). Similar to the situation in enteric organisms (146), the addition of 2789 
adenine to cultures of B. subtilis causes depletion of the PRPP pool (357). Induction 2790 
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of expression of PurR regulated genes by PRPP binding has been evaluated by 2791 
PurRBs-DNA binding assays in vitro (351). PurRBs binds to a region 20 to 150 bp 2792 
upstream of the B. subtilis pur operon (358). This DNA region contains the operator 2793 
region: -81AAACACGAACATTA (PurBox1)-16 nucleotides-TATCGTTCGATAAT-2794 
38 (PurBox2), numbered relative to the transcription start site. PurBox1 and PurBox2 2795 
have similarity to the consensus PurBox (AWWWCCGAACWWT) although 2796 
PurBox2 is inverted (355, 359). Functional dissection has defined a minimal control 2797 
region and revealed the importance of the two PurBoxes in the overall regulatory 2798 
process. Based on the affinity of PurRBs for the PurBoxes, PurBox1 was designated 2799 
“strong”, and PurBox2 was designated “weak”. High-affinity binding of PurR to the 2800 
control region was shown to require at least one strong PurBox, whereas the induction 2801 
of PurRBs repression by PRPP requires at least one weak PurBox. The binding of 2802 
PurRBs to the operator is cooperative with a stoichiometry of two PurRBs dimers 2803 
binding to the operator, which suggests that one PurRBs dimer binds to PurBox1 and 2804 
another PurRBs dimer to PurBox2 with wrapping of the DNA around the two PurRBs 2805 
dimers (Fig. 13B) (354). 2806 
 In B. subtilis a guanine-responsive attenuation mechanism is superimposed on the 2807 
repression of transcription initiation by the PurR regulatory system, which results in a 2808 
complex regulatory pattern. Thus, the addition of guanine to cultures of B. subtilis 2809 
causes premature transcription termination in the mRNA leader region of purE (the 2810 
upstream cistron of the major 12-cistron pur operon) (360). This premature 2811 
transcription termination is caused by the purine riboswitch mechanism, which 2812 
regulates the pur, xpt, pbuG and yxjA operons (361). This riboswitch mechanism 2813 
involves the binding of guanine or hypoxanthine to the untranslated leader sequences 2814 
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but does not involve PRPP. Details of the mechanisms of riboswitches have been 2815 
previously reviewed (362, 363). 2816 
 Mechanism of PRPP-mediated regulation of purine biosynthesis in L. lactis. 2817 
Overall the effect of purine addition has the same effect on L. lactis as that on B. 2818 
subtilis: the PRPP level drops and the expression of genes of the PurR regulon is 2819 
lowered (364). However, a different mechanism of action became apparent when the 2820 
L. lactis purR gene was identified among purine auxotrophic strains obtained after 2821 
transposon mutagenesis. The purR insertion mutation caused a reduced transcription 2822 
of purD, which was complemented by purR+. These and other data showed that L. 2823 
lactis purR encodes an activator of purine gene expression. PurRLl contains 271 amino 2824 
acid residues, close to the length of PurRBs (285 amino acids). Remarkably, PurRLl 2825 
and PurRBs are 48% identical (69% similar), and yet their mechanisms are very 2826 
different. Like PurRBs, PurRLl contains a helix-turn-helix domain at the N-terminal 2827 
end. It also contains the typical type I phosphoribosyltransferase structural elements, a 2828 
PRPP binding site, i.e. a PRPP binding loop (194-Gly-Gln-Asn-Val-Leu-Ile-Val-Asp-2829 
Asp-Phe-Met-Lys-Gly-Ala-Gly-Thr-209), a PP loop (137-Thr-Lys-Gly-Ile-140), and 2830 
a flexible loop (359).  2831 
 PurRLl recognizes PurBox sequences similar to the consensus PurBox sequence 2832 
AWWWCCGAACWWT (365). PurRLl binds to PurBoxes under both activating (high 2833 
PRPP) and non-activating conditions. Activation of transcription requires that the 2834 
PurBox sequence is located at an exact position relative to the -10 promoter region, 2835 
presumably in order to bind and position RNA polymerase correctly for open complex 2836 
formation (359) (Fig. 13C). The standard -35 promoter elements of constitutive 2837 
promoters are usually absent from PurR activated promoters. In L. lactis different 2838 
topologies of PurBoxes have been identified in which the binding sites are located in 2839 
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tandem or head-to-head, which suggests that PurR may form different multimeric 2840 
conformations (364). 2841 
 In vivo kinetics of the PRPP-modulated activation of transcription by PurRLl was 2842 
studied by a combination of temporal mRNA and intracellular PRPP quantifications 2843 
during a metabolic downshift (348). Saturation curves for the coupled process of 2844 
PRPP binding to PurRLl and subsequent activation of mRNA synthesis were obtained 2845 
for all genes belonging to the PurR regulon in L. lactis. Interestingly, most saturation 2846 
curves appeared sigmoid, suggesting mechanisms employing cooperativity, but more 2847 
classical Michaelis-Menten curve forms were apparent for some PurR-activated genes 2848 
involved in purine salvage and folate metabolism (348). To our knowledge, this work 2849 
represents the first example of a kinetic analysis of the action of a regulatory protein 2850 
performed in a living organism. 2851 
 Evolution of PurR. PurR proteins from various organisms share extensive 2852 
sequence similarity, but the differences in regulatory mechanism between PurRBs and 2853 
PurRLl show that they have diverged considerably during evolution. Fig. 14 shows the 2854 
phylogenetic relationship among members of the PurR family. The branching pattern 2855 
of the PurR phylogeny resemble the branching pattern for the whole genome bacterial 2856 
phylogeny (366), indicating that the PurR protein was present during most of the 2857 
evolution of the low-GC branch of Gram-positive bacteria. The Bacillus branch and 2858 
the Streptococcus branch share a common ancestor, which is not shared by any other 2859 
species. It is apparent that the bacilli and streptococci use the B. subtilis type PurBox, 2860 
while all the others use the L. lactis type PurBox (Fig. 14A), except the clostridia, for 2861 
which no information is available. According to the unrooted phylogenetic tree, it is 2862 
likely that the activating PurRLl type evolved first and that the PurRBs type diverged 2863 
early in the evolution of the Low-GC Gram-positive bacteria. As a consequence, the 2864 
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L. lactis PurBox must simultaneously have evolved into the B. subtilis PurBox. When 2865 
the sequences in the logo plots for the two PurBox types are compared (Fig. 14B), it is 2866 
easily recognized that the B. subtilis PurBox consists of two L. lactis type PurBox 2867 
sequences located as inverted repeats with a spacing of 16 nucleotides, as previously 2868 
described (355). 2869 
 To further analyze the relationship of PurR with enzymes containing a type I 2870 
phosphoribosyltransferase fold, a phylogenetic analysis was performed for 2871 
homologues of B. subtilis class 1 phosphoribosyltransferases with all the major 2872 
bacterial lineages, spanning an evolution of at least three billion years. Included in the 2873 
analysis are also logo-plots of conserved amino acids in the PP loop and the PRPP 2874 
binding loop (Fig. 15). It is apparent that PurR and xanthine 2875 
phosphoribosyltransferase are close relatives (367), and that PyrR and hypoxanthine-2876 
guanine phosphoribosyltransferases are also closely related (338), and that they share 2877 
ancestry with uracil phosphoribosyltransferases (337). As noted in Fig. 15, PurR and 2878 
xanthine phosphoribosyltransferase homologues are only found in the low-GC-Gram-2879 
positive bacterial lineage. PurR and adenine phosphoribosyltransferase has previously 2880 
been inferred to be structurally related, based upon the common structure of the 2881 
flexible loop which forms a two-stranded antiparallel β-ribbon structure (210). A 2882 
similar structure is also present in the flexible loop of B. subtilis xanthine 2883 
phosphoribosyltransferase (367). Thus PurR, xanthine phosphoribosyltransferase and 2884 
adenine phosphoribosyltransferase are all structurally related. 2885 
 If PurR arose by evolution from a xanthine phosphoribosyltransferase, perhaps it 2886 
could have exploited some of the peculiarities of this enzyme. Of special interest is 2887 
the fact that the active form of xanthine phosphoribosyltransferase is a dimer, and that 2888 
binding of PRPP is necessary for stabilization of the dimeric conformation (367). 2889 
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Most other type I phosphoribosyltransferases have active tetrameric rather than 2890 
dimeric structures. Dimer formation could be important for PRPP modulation of 2891 
PurRLl as it is for PurRBs, perhaps by exposing interaction sites needed for RNA 2892 
polymerase capture. 2893 
 In search of a common mechanism for PRPP modulation of PurR 2894 
conformation. PurR is a family of proteins that share extensive similarity, but which 2895 
are divided into at least two phylogenetic branches with different PurR functionalities, 2896 
a B. subtilis-like branch and an L. lactis-like branch. Members of both branches 2897 
appear to have rigid DNA binding domains with hydrophobic cores that are not 2898 
readily modulated by PRPP binding, and both appear to harbor extensive positively 2899 
charged domains that may bind the DNA backbone and result in protection of large 2900 
DNA stretches. Yet regulators from one family represented by PurRLl appear to bind 2901 
to single PurBox motifs with unknown stoichiometry. Presumably the binding of 2902 
PRPP and closure of the flexible loop expose a binding site that is used to recruit 2903 
RNA polymerase. Regulators from the second family represented by PurRBs, 2904 
recognize two PurBoxes in a stoichiometry of one PurR dimer per PurBox and in a 2905 
conformation that involves formation of PurR tetramers (Fig. 13B and C). Occupancy 2906 
of the PRPP binding site reduces unspecific DNA binding and prevents PurR 2907 
repression of transcription initiation. It is likely that the closing of the flexible loop 2908 
upon PRPP binding, which is also shared by all type I phosphoribosyltransferases, is 2909 
the mechanistic basis for both effects. There is currently no evidence that all PurR 2910 
regulators in one family share a common mechanism, and it is not clear whether 2911 
PurRLl and PurRBs may substitute one another. However, B. subtilis-like tandem-2912 
PurBoxes are found only in the Bacillus and Staphylococcus branches and single 2913 
PurBoxes are found in the Lactococcus, Streptococcus and Lactobacillus branches. A 2914 
 119
search for evolutionary “cross-over” organisms with PurR proteins that possess both 2915 
repression and activation ability may be very useful in this respect. 2916 
 2917 
Allosteric Activation of Carbamoylphosphate Synthetase Activity by PRPP 2918 
Carbamoyl phosphate is a precursor for the synthesis of pyrimidine nucleotides and 2919 
the amino acid arginine. While bacterial species like E. coli and S. enterica contain 2920 
only a single carbamoyl phosphate synthetase, other bacterial species like B. subtilis 2921 
contain specific enzymes for each pathway, pyrimidine nucleotides and arginine. The 2922 
activity of pyrimidine nucleotide-specific enzyme was found to be stimulated by 2923 
PRPP (368, 369). 2924 
 In animals and fungi two or three of the six enzymes of de novo pyrimidine 2925 
nucleotide biosynthesis are grouped in di- or trifunctional enzymes. Animals contain 2926 
the trifunctional fusion of carbamoylphosphate synthase, aspartate transcarbamoylase 2927 
and dihydroororase activities, called CAD. CAD, thus, catalyzes the ATP-dependent 2928 
conversion of glutamine, bicarbonate and aspartate to dihydroorotate. CAD function 2929 
and structure have been previously reviewed (370, 371). Dihydroorotate in turn is 2930 
oxidized to orotate, which is then phosphoribosylated to orotidine 5’-monophosphate 2931 
catalyzed by orotate phosphoribosyltransferase. In the present context, the important 2932 
activity of CAD is carbamoyl phosphate synthase. The activity of this enzyme is 2933 
regulated by UTP and PRPP. UTP is a feedback inhibitor, whereas PRPP is an 2934 
allosteric activator of the enzyme, as found for the B. subtilis pyrimidine specific 2935 
carbamoyl phosphate synthetase (369, 372). CAD activity is modulated further by 2936 
protein phosphorylation mediated by the MAP kinase (373), cAMP dependent protein 2937 
kinase (373), and mTORC1 (374). The expression of the cad genes are also subject to 2938 
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regulation. Upon transition from G1 to S phase, the human cad mRNA level increased 2939 
approximately 10-fold, which is mediated by the global regulator c-MYC (374, 375). 2940 
 2941 
prs GENES, MUTANTS, AND GENE REGULATION 2942 
PRPP synthase is believed to be present in all free living organisms. A number of prs 2943 
mutants with alterations in the enzyme have been isolated and characterized. In 2944 
addition, a few knockout mutant alleles have been constructed in vitro, and, following 2945 
recombination, gene conversions have yielded null-alleles. Also mutant variants of 2946 
PRPP synthase have been characterized in a wide variety of organisms, including 2947 
humans. We review the properties of these mutant variants of bacterial origin in this 2948 
section. 2949 
 2950 
E. coli And S. enterica 2951 
E. coli, prs-1 and prs-2. A number of prs mutants have been isolated in E. coli. First, 2952 
the prs-1 allele appeared in a genetic selection designed to isolate mutants with 2953 
improved utilization of guanosine as purine source (28). Briefly, five mutants were 2954 
characterized; all of them had a lesion in the gsk gene as well as a lesion in a gene 2955 
specifying genes of an early part of the purine nucleotide biosynthesis de novo 2956 
pathway, i.e. mutants with the genotype purF gsk and purM gsk. The appearence of 2957 
the prs-1 gsk mutant strain may be explained along this line by extending the purine 2958 
nucleotide biosynthesis de novo pathway to include prs in addition to purF, purD, 2959 
purL etc. The prs-1 allele specifies Asp128Ala. This residue is only two residues 2960 
away from His130, equivalent to His135 of B. subtilis PRPP synthase. As described 2961 
before, His135 is important for the coordination of the MG2 site, i.e. maintaining the 2962 
α,β,γ-tridentate complex of MgATP. Consistent with this, PRPP synthase specified by 2963 
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prs-1 had a 27-fold increase in the KM for ATP, whereas the KM for ribose 5-2964 
phosphate was essentially unaltered (376). 2965 
 A temperature-labile PRPP synthase, specified by the prs-2 allele, was isolated by 2966 
localized mutagenesis of the hemA region (2). The prs-2 allele contained two 2967 
mutations, one responsible for a Gly8Ser alteration, the other, a cytidylate to 2968 
thymidylate transition that results in an alteration close to the Shine-Dalgarno 2969 
sequence. The latter mutation resulted in increased synthesis of PRPP synthase, and, 2970 
thus, in part compensated for a poorly-functioning enzyme. The Gly8Ser alteration 2971 
was responsible for the temperature-labile PRPP synthase (377). 2972 
 In vitro generated knockout prs alleles. A prs knockout mutation would render 2973 
the strain prototrophic for purine, pyrimidine and pyridine nucleotides as well as 2974 
histidine and tryptophan. Any scheme to isolate such a strain must included the 2975 
following considerations. NAD, or its metabolite nicotinamide mononucleotide, may 2976 
be utilized intact without catabolism to satisfy the pyridine nucleotide requirement 2977 
(378). The requirement of PRPP for tryptophan and histidine synthesis can be 2978 
eliminated by the addition of these two amino acids to the growth medium. In 2979 
contrast, PRPP is normally essential for both de novo and salvage purine and 2980 
pyrimidine nucleotide reactions. PRPP consumption in de novo synthesis of purine 2981 
and pyrimidine nucleotides is mediated by purF-specified 2982 
amidophosphoribosyltransferase and pyrE-specified orotate 2983 
phosphoribosyltransferase, whereas the salvage reactions of purine and pyrimidine 2984 
nucleotides are mediated by adenine, hypoxanthine, xanthine, guanine and uracil 2985 
phosphoribosyltransferases. Some organisms, such as E. coli and S. enterica also 2986 
contain nucleoside kinases, which phosphorylate nucleosides auch as inosine, 2987 
guanosine and uridine to inosine 5’-monophosphate, GMP and UMP, respectively. 2988 
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Uptake of these nucleosides via these kinase reactions would eliminate the requirment 2989 
for PRPP. However, nucleosides are predominantly phosphorolyzed by nucleoside 2990 
phosphorylases such as purine nucleoside phosphorylase I (deoD) with specificity for 2991 
adenosine, inosine and guanosine, purine nucleoside phosphorylase II (xapA) with 2992 
specificity for inosine, xanthosine and guanosine, and uridine phosphorylase (udp) 2993 
with specificity for uridine (19). Thus, knockout of deoD and udp is necessary to 2994 
permit the salvage of nucleosides by phosphorylation of guanosine by guanosine 2995 
kinase (gsk) and uridine by uridine kinase (udk). With respect to guanosine utilization, 2996 
yet another genetic lesion was necessary to permit isolation of a Δprs strain. This 2997 
lesion, for example gsk-3, improved the activity of guanosine kinase by rendering the 2998 
enzyme insensitive to feedback inhibition by GTP and presumably GDP (379, 380). 2999 
Altogether, a background strain deoD udp gsk-3 was used for the succesful 3000 
recombination of in vitro generated, plasmid-borne Δprs allele into the chromosome 3001 
of E. coli. (The growth medium included guanosine, uridine, histidine, tryptohan and 3002 
NAD.) Two alleles Δprs-3::Kanr and Δprs-4::Kanr were recombined into the 3003 
chromosome (3). Also the temperature sensitivity of the prs-2 allele could be rescued 3004 
in the deoD udp gsk-3 genetic background (2). 3005 
 dnaR. PRPP synthase has been shown to be involved in DNA replication, but it is 3006 
unclear whether the effect is direct or indirect. A genetic lesion of E. coli, dnaR130, 3007 
was shown to be an allele of the prs gene, hereafter designated prs-130. A strain 3008 
harboring prs-130 was temperature sensitive for initiation of DNA replication, 3009 
whereas elongation was unaffected. Only replication initiating at chromosome-borne 3010 
chromosomal origin of replication, oriC, was affected by prs-130. Thus, replication of 3011 
an oriC-harboring plasmid, stable DNA synthesis, i.e. replication independent of 3012 
RNase HI (specified by rnhA), and replication of bacteriophage λ were all unaffected 3013 
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by prs-130. The fact that bacteriophage λ DNA replication was unaffected by 3014 
temperature and that identical bacteriophage λ burst sizes of prs-130 and prs+ strains 3015 
was observed, prompted the author to suggest that the temperature-sensitive DNA 3016 
replication of the prs-130 strain was not caused by lack of precursors for nucleic acids 3017 
or proteins. Also the decline in PRPP synthase activity specified by prs-130 paralled 3018 
the decline in DNA replication upon temperature shift. The prs-130 lesion is located 3019 
within a 274 bp HindIII-AvaII DNA fragment of the prs coding sequence. The entire 3020 
prs-130 allele has been sequenced, but the sequence cannot be found in the available 3021 
data bases (381, 382). 3022 
 A number of mutant alleles of genes other then prs were able to suppress the 3023 
temperature sensitivity caused by the prs-130 allele. These extragenic suppressors of 3024 
prs-130 include dnaA (383), certain rpoB alleles specifying rifampicin resistant 3025 
variants of the β-subunit of RNA polymerase (384), rpe specifying D-ribulose 5-3026 
phosphate 3-epimerase. Suppression of prs-130 by mutations in the dnaA gene 3027 
prompted the author to suggest a direct physical interaction of DnaA and PRPP 3028 
synthase, whereas the appearance of prs-130 suppressors in RNA polymerase 3029 
suggested an involvement of PRPP synthase in a transcriptional event in DNA 3030 
replication at oriC. Remarkably, D-ribulose 5-phosphate 3-epimerase (specified by the 3031 
rpe gene) also suppressed the temperature sensitive phenotype of the prs-130 strain 3032 
(385). Ribulose phosphate epimerase catalyzes the interconversion of ribulose 5-3033 
phosphate and xylulose 5-phosphate and the enzyme is part of the non-oxidative 3034 
pentose phosphate pathway (386), which involves ribose 5-phosphate, the precursor 3035 
of PRPP. This fact leads us to ask whether a knock-out of rpe results in an increase of 3036 
ribose 5-phosphate isomerase activity? This activity catalyzes the interconversion of 3037 
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ribulose 5-phosphate and ribose 5-phosphate, which might lead to improved PRPP 3038 
synthesis. 3039 
 Altogether, these various observations demonstrate an involvement of PRPP 3040 
synthase in some aspects of DNA synthesis in E. coli, but the detailed biochemistry of 3041 
this effect remains unclear. 3042 
 ssrA. The ssrA gene specifies the SsrA-RNA, which together with the SmpB 3043 
protein is involved in rescuing stalled ribosomes. SsrA-RNA functions both as a 3044 
tRNA and as an mRNA molecule, SsrA-RNA function results in the synthesis of an 3045 
Ssr-polypeptide fusion that is destined for degradation and the liberation of the stalled 3046 
ribosome (387, 388). Two temperature-sensitive mutants were isolated in a ΔssrA 3047 
genetic background. Both mutations mapped within the prs gene, one of which 3048 
specified Cys215Tyr. The temperature-sensitive phenotype was suppressed by 3049 
reinsertion of a wild-type ssrA gene (389). Similar mutants were isolated in the thyA 3050 
gene (390), and, thus the restoration of activity of SsrA is not restricted to 3051 
misexpression of the prs gene (388). 3052 
 However, using SmpB as bait in pull-down assays, SsrA-RNA and a number of 3053 
polypeptides were copurified. One of these polypeptides was PRPP synthase. Half 3054 
maximal binding of PRPP synthase to SsrA-RNA was obtained at 1-2 μM PRPP 3055 
synthase; this is compared to half maximal binding of ribosomal protein S1 to SsrA-3056 
RNA at 0.030 μM, which indicates relatively poor binding of PRPP synthase to SsrA-3057 
RNA. The binding of PRPP synthase was therefore relatively unspecific, so that 3058 
physiologically significant binding of PRPP synthase to an SsrA-RNA particle, if it 3059 
occurs at all, may require additional protein factors (391). 3060 
 S. enterica, prs-100. The prs-100 allele, previously designated prsB (392), was 3061 
isolated by combined screening of ethyl methanesulfonate-mutagenized cells for 3062 
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temperature-sensitive growth and lack of PRPP synthase activity (392). The prs-100 3063 
lesion causes an Arg78Cys alteration, and is located within a stretch of amino acid 3064 
residues that are involved in the formation of the bent dimer (Table 3 amino acid 3065 
residues Leu76 and Ile77). This supports the conclusion of the authors “that the 3066 
mutation alters the enzyme’s kinetic properties through substantial structural 3067 
alterations rather than by specific perturbation of substrate binding or catalysis” (27). 3068 
 Thiamine biosynthesis. A genetic screen for mutants of S. enterica with 3069 
improved biosynthesis of thiamine was conducted in a strain with purF and gnd 3070 
lesions, i.e. a strain lacking amidophosphoribosyltransferase and glucose 6-phosphate 3071 
dehydrogenase activities. Normally, amidophosphoribosyltransferase (specified by 3072 
purF) is essential for thiamine diphosphate synthesis, but six thiamine-prototrophic 3073 
mutants lacking amidophosphoribosyltransferase arose at a low frequency 3074 
(approximately 4 x 10-8). All of the mutants had decreased activity of PRPP synthase, 3075 
which presumably resulted in an increase in the ribose 5-phosphate pool, and, thus, a 3076 
stimulation of the amidophosphoribosyltransferase-independent, spontaneous (i.e. 3077 
nonenzymic) amination of ribose 5-phosphate to 5-phosphoribosyl 1-amine, and 3078 
subsequent thiamine diphosphate synthesis. One mutation mapped within the Shine-3079 
Dalgarno sequence whereas the remaining five mapped within the prs coding region. 3080 
The in vitro PRPP synthase activity of these latter mutants was 20-60 % of the wild-3081 
type activity. Interestingly, one PRPP synthase variant, Asp224Ala, i.e. an alteration 3082 
within the PRPP binding loop, retained approximately 30% of the wild-type PRPP 3083 
synthase activity. As pointed out by the authors, the selection procedure yielded only 3084 
mutants with residual activity of PRPP synthase. Because the mutations were acquired 3085 
by positive selection (growth in the absence of thiamine) and all of the mutations 3086 
negatively affected the activity of PRPP synthase, this procedure could be valuable in 3087 
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a screen for mutations that test the importance of various amino acid residues in PRPP 3088 
synthase activity (393). 3089 
 3090 
prs Gene Organization and Regulation of prs Gene Expression 3091 
E. coli and S. enterica. The prs gene is a member of the purine regulon, because prs 3092 
gene expression is under the control of the purR gene product (a LacI-type). The Pur 3093 
box sequence of the prs gene is identical and located at identical positions in E. coli 3094 
and S. enterica: -56AAGAAAACGTTTTCGC-41 (with the first cytidylate residue of 3095 
the transcript numbered as +1). Four nucleotides separate the Pur box and the -35 3096 
region. PurR caused a three-fold repression of prs gene expression in vivo in 3097 
experiments that measured expression of prs-lacZ operon fusions with or without the 3098 
presence of purR. Furthermore, electrophoretic mobility shift analysis of PurR 3099 
binding to DNA containing the prs Pur box demonstrated that PurR bound to the 3100 
DNA. Finally, protection of the prs Pur box by PurR was demonstrated by DNase I 3101 
footprinting (394). The synthesis of PRPP synthase is derepressed approximately 10 3102 
fold during pyrimidine starvation (395), and uridine derivatives specifically cause 3103 
repression of PRPP synthase synthesis (396). 3104 
 The genetic organization of the prs region in E. coli and S. enterica is identical. 3105 
The prs gene is located downstream of the lolB gene (encoding outer membrane 3106 
lipoprotein required for localization of lipoproteins) (397), and ispE (encoding 4-3107 
diphosphocytidyl 2-C-methylerythritol kinase) (398). The prs gene is transcribed from 3108 
two promotors. A larger transcript is initiated two genes upstream of prs and 3109 
comprises lolB-ispE-prs. A smaller transcript initiates within the ispE coding 3110 
sequence and contains the last 152 nucleotides of the ispE coding sequence in both 3111 
organisms. The transcription start site of the smaller transcript and a rho-independent 3112 
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termination site downstream of the prs coding sequence have been mapped (45, 399). 3113 
The smaller transcript is 20-fold more abundant than the larger transcript. Pyrimidine-3114 
mediated prs gene regulation occurs by increase of the amount of the smaller 3115 
transcript (399). The coding region of the prs gene is preceeded by a leader sequence 3116 
302 nucleotides long in E. coli, 417 nucleotides long in S. enterica (45, 399, 400). 3117 
Comparison of the two leader sequences reveals 149 almost identical nucleotides of 3118 
the 5’-end of the transcripts of the two organisms, followed by 115 nucleotides in the 3119 
S. enterica prs leader, which are not present in the E. coli prs leader, and 152 3120 
nucleotides, which are almost identical in the leaders of the two transcripts, i.e. an a-3121 
b-c arrangement i S. enterica and an a-c arrangement in E. coli. 3122 
 Altogether, the expression of the prs gene of E. coli and S. enterica is controlled 3123 
by both purine and pyrimidine compounds. Purine-mediated regulation occurs by 3124 
means of the PurR repressor binding to the Pur box located within the upstream ispE 3125 
gene. Several lines of experimental results provide evidence for the involvement of 3126 
the prs leader in regulation of the synthesis of PRPP synthase. First, two prs-galK 3127 
operon fusions were analyzed for production of galactokinase activity. The first gene 3128 
fusion contained the prs promoter as well as 24 of the 5’-nucleotides of the prs 3129 
transcript, the second contained the prs promoter, the entire prs leader and 13 3130 
nucleotides of the prs coding sequence. Cells containing gene fusion one contained 3131 
five times as much galactokinase activity as cells containing gene fusion two. Thus, 3132 
nucleotides of the prs leader contain structure(s) that reduce the production of 3133 
galactokinase of the gene fusion, and, presumably of PRPP synthase under native 3134 
conditions (401). In another study a mutant variant of RNA polymerase (rpoBC) of S. 3135 
enterica that had been selected as resistant to pyrimidine fluoroanalogs was constitive 3136 
in expression of the pyrE gene specifying orotate phosphoribosyltransferase. The 3137 
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activity of orotate phosphoribosyltransferase was elevated 40 fold, but the activity of 3138 
PRPP synthase was also elevated more than two fold (402). The defective RNA 3139 
polymerase was shown to increase the coupling of transcription and translation at the 3140 
pyrE attenuator (403). It is possible therefore that the increase in prs gene expression 3141 
is also caused by increased coupling of transcription and translation within the prs 3142 
leader. In other experiments, whole transcriptome shotgun sequencing has revealed a 3143 
short transcript originating from the E. coli prs promotor. Although the ends of this 3144 
transcript have not been mapped, the analysis provides additional evidence for the 3145 
existence of a prematurely terminated prs transcript (M. A. Sørensen, University of 3146 
Copenhagen, personal communication). Indeed, a number of potential leaders may be 3147 
formed from the prs leader, and quite a number of secondary structures, including 3148 
hairpins and loops, are predicted from the nucleotide sequence. One possible 3149 
secondary structure of the S. enterica prs leader is shown in Fig. 16. Unlike the pyrE 3150 
attenuator, which is followed by eight uridylate residues and has been shown to be 3151 
regulated by premature transcription termination in the leader sequence (404), the 3152 
putative E. coli prs leader stem loops are followed by none or a few uridylate 3153 
residues. This may explain the difference in fold of pyrimidine-mediated regulation of 3154 
the two operons: 40 fold in pyrE gene expression, 2.3 fold in prs gene expression. 3155 
 Gram-positive organisms. Genetic mapping and nucleotide sequencing showed 3156 
that the prs gene of B. subtilis is located between the gcaD (tms-26) and ctc genes (43, 3157 
405). The former gene encodes the bifunctional enzyme α-D-glucosamine 1-phosphate 3158 
acetyltransferase, N-acetylglucosamine 1-phosphate uridyltransferase (406), whereas 3159 
the latter gene encodes a general stress protein similar to E. coli ribosomal protein 3160 
L25 (407). In vegetative cells of B. subtilis gcaD, prs, and ctc are expressed as a 3161 
tricistronic operon from a promoter immediately upstream of gcaD (408). Similar 3162 
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arrangements of gcaD-prs-cts are found in other Gram-positive organisms, 3163 
Clostridiaceae, Corynebacteriaceae, Listeriaceae, Staphylococcaceae species. On the 3164 
other hand, Streptococcaceae such as Streptococcus pyogenes, Enterococcus faecalis 3165 
and L. lactis have other more heterogeneous genetic organizations of prs genes. 3166 
Streptococcaceae generally contain two prs genes, as described previously for L. 3167 
lactis. In contrast to the situation in enterobacteria, the regulation of prs gene 3168 
expression in Gram-positive organisms is essentially unknown. 3169 
 3170 
FUTURE PERSPECTIVES 3171 
Although extensive efforts have been spent on elucidation of the various aspects of 3172 
PRPP metabolism, a number of important aspects remain to be disclosed. Perhaps 3173 
most important is the function or functions of the NHR found in many eukaryotic 3174 
PRPP synthases, and the functions of the PAPs in human and rat PRPP synthases. For 3175 
example purification of PRPP synthase from crude extracts of wild-type S. cerevisiae 3176 
should be possible and would elucidate the quaternary structure of the native enzyme 3177 
or enzymes. Additionally, the fact that S. cerevisiae PRPP synthase is a multimeric 3178 
enzyme consisting of different subunits, such as Prs1 and Prs3 and possibly higher 3179 
order structures, makes possible studies of mutants with alteration of various amino 3180 
acid residues in one subunit, while the other subunit(s) retain(s) their wild-type 3181 
phenotype. Candidates for such an analysis are, with amino acid numbers referring to 3182 
B. subtilis PRPP synthase, His135, Asp174 and Lys197 residues. Similar experiments 3183 
may be possible with mammalian PRPP synthase(s). As mentioned previously, there 3184 
is compelling evidence for the involvement of yeast PRPP synthase-polypeptides in a 3185 
variety of cellular processes other than amino acid and nucleotide synthesis, and there 3186 
is some evidence that NHRs play roles in this involvement. PAPs may also be 3187 
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involved in cellular processes other than nucleotide synthesis, and studies in 3188 
mammalian cell lines might reveal roles of the PAPs in such other physiological 3189 
processes and cross-regulation. Studies of mouse cell lines (and live animals) with the 3190 
PAPs knocked out, individually and together, could be of very great interest in this 3191 
respect. As described above, a specific role for human PRPP synthase isozyme 2 in 3192 
cancer cells has been documented (125). Although PAPs were not implicated, they 3193 
could very well participate in mediating the effects. 3194 
 Another aspect of interest is the three-dimensional structure of class II PRPP 3195 
synthases. The available data on their quaternary structure is conflicting. On one hand, 3196 
circular dichroism and gel filtration analyses predict the structure of sugarcane PRPP 3197 
synthase to be hexameric similar to that of B. subtilis PRPP synthase (129), whereas 3198 
recombinant spinach PRPP synthase isozymes 3 and 4 eluted as trimers in gel 3199 
filtration chromatography (47). 3200 
 Furthermore, the three-dimensional structure of PRPP-utilizing enzymes other 3201 
than those of purine, pyrimidine, pyridine, histidine and tryptophan biosynthesis, i.e. 3202 
enzymes catalyzing the formation of O- and C-glycosidic bonds is worth solving as 3203 
they may contribute additional information regarding the versatility of PRPP in 3204 
intermediary metabolism. 3205 
 Regulation of PRPP synthase activity in vivo is presently poorly understood. In 3206 
vitro, the activity is intricately regulated by the energy charge with ATP being a 3207 
substrate, AMP a product, and ADP a potent negative, allosteric and isosteric (i.e. 3208 
competitive at the ATP site) regulator of PRPP synthase activity. Understanding how 3209 
these properties contribute to physiological in vivo regulation requires further 3210 
investigation. 3211 
 3212 
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(Figure legends) 4720 
FIG 1 Biochemical function of PRPP. The β,γ-diphosphoryl group of ATP is 4721 
transferred to ribose 5-phosphate with the generation of PRPP in a reaction catalyzed 4722 
by PRPP synthase, encoded by a prs gene. PRPP is a substrate in a number of 4723 
substitution reactions most of which involve a nitrogen-containing compound. The 4724 
reaction occurs at C1 of the ribosyl moiety and proceeds with inversion of the 4725 
configuration of this carbon and with PPi as a leaving group. 4726 
 4727 
FIG 2 Alignment of amino acid sequences of PRPP synthases from B. subtilis (B.s.), 4728 
S. oleracea (isozyme 4) (S.o.) and M. jannaschii (M.j.) The B. subtilis PRPP synthase 4729 
amino acid sequence is numbered from the N-terminal serine, as the original N-4730 
terminal methionine is removed in the mature protein. Functional elements of the B. 4731 
subtilis PRPP synthase is indicated by bars above the B. subtilis amino acid sequence. 4732 
Amino acid residues identical in all three sequences are indicated by asterisks below 4733 
the M. jannascii PRPP synthase amino acid sequence, whereas conserved amino acid 4734 
residues are indicated by a dot. Conserved amino acids are valine, leucine and 4735 
isoleucine; phenylalanine and tyrosine; aspartate and glutamate; arginine and lysine; 4736 
serine and threonine; glycine and alanine. The division of the N- and C-terminal 4737 
domains (150-Leu-Met-151) of B. subtilis PRPP synthase is indicated by a vertical 4738 
line. B. subtilis PRPP synthase amino acid residues, which are located at the active 4739 
site are typed in red, those which are located at the allosteric, regulatory site are typed 4740 
in blue, whereas those involved in subunit-subunit interactions are typed in green. 4741 
Amino acid residues involved in formation of the bent dimer are typed in bold, 4742 
whereas those involved in formation of the parallel dimer are typed in italic. 4743 
Whenever amino acid residues of PRPP synthase of S. oleracea or M. jannaschii are 4744 
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identical to those of the B. subtilis enzyme, the color code of the latter enzyme is 4745 
applied to the S. oleracea and M. jannaschii residues as well. The underlined amino 4746 
acid residues, Val178-Asp196, Arg198, and Asn209-Val211 are involved in the 4747 
formation of a tightly packed interface necessary for allosteric inhibition. Amino acid 4748 
residues were selected on the basis of the three-dimensional structures previously 4749 
published (49, 50, 54). Vertical arrow heads point to B. subtilis PRPP synthase amino 4750 
acids, which are homologous to amino acids altered in the human PRPP synthase 4751 
isozyme 1 due to point mutations in the PRSP1 gene. Red arrow heads point to amino 4752 
acid alterations resulting in increased PRPP synthase activity, whereas blue arrow 4753 
heads point to amino acid alterations resulting in decreased PRPP synthase activity. 4754 
The amino acid alterations and properties of the human PRPP synthase variants are 4755 
described further in the text and summarized in Table 4. 4756 
 4757 
FIG 3 Three-dimensional structure of B. subtilis PRPP synthase. (A) Monomer drawn 4758 
on the basis of the SO42--PRPP synthase structure (PDB code 1dkr) (49). The N-4759 
terminal domain is at the top. Shown are the five-stranded parallel β-sheets (red), 4760 
helices (blue), the flag region (green), the regulatory flexible (RF) loop, the ribose 5-4761 
phosphate (R5P) loop, and the PP loop (yellow). The unresolved catalytic flexible 4762 
(CF) loop is shown as a dotted line. (B) Bent and parallel dimers drawn on the basis 4763 
of the Cd2+-PRPP synthase structure (PDB code 1ibs) (50). Subunit A is colored as 4764 
the monomer in (A). Shown are Cd2+ (black), AMP of the active site (red), sulfate 4765 
bound at the position of the phosphate moiety of ribose 5-phosphate and at the 4766 
position of the α-phosphate of ADP of the allosteric site (red). (C) Hexameric 4767 
propeller structure drawn on the basis of the mADP-PRPP synthase structure (PDB 4768 
code 1dku) (49). Subunit A (as well as subunit C and E) is colored as the monomer in 4769 
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(A). Shown are the positions of the methylene ADP moieties (red) and methylene 4770 
ADP molecules (green), both modeled to only AMP, of the ATP binding sites and the 4771 
allosteric sites, respectively. 4772 
 4773 
FIG 4 Allosteric site of B. subtilis PRPP synthase. Stereo view based on the mADP-4774 
PRPP synthase structure (PDB code 1dku) (49). The site is occupied by methylene 4775 
ADP. Amino acid residues contributing to methylene ADP binding are provide by 4776 
three subunits labelled A, B and D as in Fig. 3. Amino acid residues of subunit A are 4777 
shown in blue, amino acid residues of subunit B in light gray and amino acid residues 4778 
of subunit D are shown in dark gray. 4779 
 4780 
FIG 5 Positions of non-homologous regions. Each line of bars represents polypeptides 4781 
of a PRPP synthase with the amino-terminus at the left-hand end. S.c.1, S. cerevisiae 4782 
Prs1; S.c.3, S. cerevisiae Prs3; S.c.5, S. cerevisiae Prs5; S.p.1, S. pombe Prs1; S.p.2, S. 4783 
pombe Prs2; S.p.3, S. pombe Prs3; PAP39, human PRPP synthase-associated protein 4784 
39; PAP41, human PRPP synthase-associated protein 41. S. cerevisiae and S. pombe 4785 
Prs3 are shown at the top as a bar consisting of three segments (I, II and III) 4786 
represented by different blue shadings. This bar could represent most class I PRPP 4787 
synthases. The left- and right-hand ends of segment II are located within the 4788 
regulatory and catalytic flexible loops, respectively. A non-homologous region (NHR) 4789 
is shown in red shading. The number of amino acid residues of each NHR is shown 4790 
below the bars. The three NHRs of S. cerevisiae Prs1 and 5 are designated NHR1, 4791 
NHR5-1 and NHR5-2. According to this nomenclature S. cervisiae Prs1 has the 4792 
structure segment 1-segment 2-NHR1-segment 3, S. cervisiae Prs5 has the structure 4793 
segment 1-NHR5-1-segment 2-NHR1-segment 3, S. pombe PRPP synthase 1 has the 4794 
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structure segment I-segment II-NHR-segment III, S. pombe PRPP synthase 2 has the 4795 
structure segment I-NHR-segment II-segment III, and human PAP39 and 41 have the 4796 
structure segment I-segment II-NHR-segment III. 4797 
 4798 
FIG 6 Catalytic mechanism of PRPP synthase. (A) Closure of the catalytic flexible 4799 
loop of T. volcanium PRPP synthase by superimposition of the open and closed 4800 
structures (PDB code 3lrt and 3mbi, respectively). Structural elements are colored as 4801 
in Fig. 3A. A 17 Å movement of the flexible catalytic loop, consisting of the β10 and 4802 
β11 strands, results in the closed conformation necessary for catalysis. (B) Close up of 4803 
the binding of substrates at the active site of T. volcanium PRPP synthase with open 4804 
and closed catalytic flexible loop. In the open conformation the triphosphate chain of 4805 
ATP, modeled here to only ADP, forms a more or less linear arrangement. In the 4806 
closed conformation the triphosphate chain, again modeled to only ADP, bends with 4807 
the β-phosphate obtaining a position ideal for attack of O1 of ribose 5-phosphate on 4808 
the β-phosphorus. An Mg2+ of the closed conformation is shown as a black sphere 4809 
(138). (C) Stereo view of the binding of ribose 5-phosphate, Mg2+ ions and the 4810 
transition state analog AlF3 to the active site of B. subtilis PRPP synthase, AlF3-PRPP 4811 
synthase (54). α indicates the α-phosphate of ATP provided by an AMP molecule, β 4812 
indicates the β-phosphate of ATP provided by Al3+ (bound to three F-), γ indicates the 4813 
γ-phosphate of ATP provided by the phosphate of a second AMP molecule. The two 4814 
Mg2+ are indicated by MG1 and MG2. Relevant amino acid residues, His135, 4815 
Asp174, Lys197 and Arg199 are included as well. Reprinted with permission (54). 4816 
(D) Stereo view of the binding of ribose 5-phosphate, α,β-methylene ATP, Mg2+ and 4817 
Ca2+ ions to the active site of B. subtilis PRPP synthase in the GDP-PRPP synthase 4818 
complex. Ca2+ (designated CA1) coordinates to the hydroxyls at C1, C2 and C3 of 4819 
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ribose 5-phosphate, oxygen of the β- and γ-phosphates of α,β-methylene ATP, 4820 
Asp174 as well as a water molecule. The Mg2+ (designated MG2) coordinates to the 4821 
oxygen of C2’ of the ribosyl moiety as well as oxygen of the α- and γ-phosphates of 4822 
α,β-methylene ATP, as well as to three water molecules. Thus, there is no 4823 
coordination to oxygen of the β-phosphate of α,β-methylene ATP. Reprinted with 4824 
permission (54). 4825 
 4826 
FIG 7 Reactions catalyzed by diphosphoryltransferases and alternative biosynthesis of 4827 
PRPP. In some cases ATP may be replaced by dATP. The diphosphoryl and 4828 
phosphoryl moieties of the products are shown in red and blue, respectively. (A) 4829 
Reaction catalyzed by phosphoribosyl bisphosphate phosphokinase. The substrate is 4830 
ribosyl 1,5-bisphosphate, the product is PRPP; (B) reaction catalyzed by PRPP 4831 
synthase. The substrate is ribose 5-phosphate, the product is PRPP; (C) 2-amino-4-4832 
hydroxy-6-hydroxymethyldihydropterin diphosphokinase. The substrate is 2-amino-4-4833 
hydroxy-6-hydroxymethyldihydropterin, the product is 2-amino-4-hydroxy-6-4834 
hydroxymethyldihydropterin diphosphate; (D) GTP/GDP 3’-diphosphokinase 4835 
(stringent factor). R may be a hydrogen or a phosphoryl group, i.e. the substrate is 4836 
GDP or GTP, respectively, and the product is guanosine 3’-diphosphate 5’-4837 
diphosphate (ppGpp) or guanosine 3’-diphosphate 5’-triphosphate (pppGpp), 4838 
respectively; (E) nucleotide diphosphokinase. R1 may be an adenyl, a guanyl or a 4839 
hypoxanthyl univalent radical, whereas R2 may be a hydrogen, a phosphoryl or a 4840 
diphosphoryl moiety; (F) thiamine diphosphokinase. The substrate is thiamine, the 4841 
product is thiamine diphosphate. 4842 
 4843 
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FIG 8 Diphosphoryl-, nucleotidyl- and phosphoryltransfer reactions. Water molecules 4844 
are indicated by Wat. (A) The active site of the ternary complex of E. coli 4845 
hydroxymethyldihydropterin diphosphokinase. AMPCPP, α,β-methylene ATP; HP; 4846 
hydroxydihydropterin (PDB code 1q0n) (164). (B) The active site of DNA 4847 
polymerase β (PDB code 1bpy) (176). (C) The active site of cAMP protein kinase A. 4848 
AMPPNP, β,γ-imido ATP (PDB code 4hpu) (201). 4849 
 4850 
FIG 9 Catalytic strategies. The coordination of Mg2+ (shown as blue spheres) of the 4851 
active site to the substrates, to amino acid residues and to water molecules (shown as 4852 
red spheres) is schematically illustrated by blue lines. (A) cAMP-dependent protein 4853 
kinase A (PDB code 4hpu) (201). (B) PRPP synthase. R5P, ribose 5-phosphate. MgA 4854 
was designated MG2, and MgB was designated MG1 before (54). (C) Hexose 1-4855 
phosphate nucleotidyltransfrease based on the structure of N-acetylglucosamine 1-4856 
phosphate uridylyltransferase (PDB code 4g87). MgB coordinates to aspartate and 4857 
asparagine residues (192). (D) DNA polymerase based on the structure of DNA 4858 
polymerase β (PDB code 1bpy) (176). The three acidic residues are usually aspartates, 4859 
but occasionally one aspartate is substituted by glutamate (185, 186). The structure is 4860 
valid also for RNA polymerases (187). 4861 
 4862 
FIG 10 Similarity of the folds of the PRPP synthase domain and type I 4863 
phosphoribosyltransferases. (A) Superimposition of the C-terminal domain (amino 4864 
acids 151 to 286) of T. volcanium PRPP synthase (blue, PDB code 3mbi) (138) and T. 4865 
gondii hypoxanthine-guanine phosphoribosyltransferase (green, PDB code 1fsg) 4866 
(212). The PP, ribose 5-phosphate (R5P) and catalytic flexible (CF) loops are 4867 
indicated. (B) Substrate binding at the active sites of B. subtilis PRPP synthase and T. 4868 
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gondii hypoxanthine-guanine phosphoribosyltransferase. The B. subtilis PRPP 4869 
synthase transition state analog (cf Fig. 6C) consisting of the phosphoryl moiety of 4870 
AMP (indicated by α), AlF3 (indicated by β), the phosphoryl moiety of a second AMP 4871 
molecule (indicated by γ) and ribose 5-phosphate as well as Asp223 and Asp224 are 4872 
shown as thick lines, and the two Mg2+ as green spheres (54). Residues from the 4873 
structure of T. gondii hypoxanthine-guanine phosphoribosyltransferase in complex 4874 
with 9-deazaguanine (not shown), PRPP and Mg2+ as well as Glu146 and Asp147 4875 
(PDB code 1fsg) (212), is shown as thin yellow lines or spheres superimposed on the 4876 
AlF3-PRPP synthase structure. Reprinted with permission (54). 4877 
 4878 
FIG 11 N-glycosidic bond formation with PRPP. PRPP and atoms of the products 4879 
derived from PRPP are shown in red. Each reaction produces an N-glycosidic 5’-4880 
phosphoribosyl compound and PPi. The reaction with quinolinate also produces 4881 
carbon dioxide. The compounds a to e are products of de novo reactions: a, 5-4882 
phosphoribosyl 1-amine; b, orotidine 5’-monophosphate; c, 5’-4883 
phosphoribosylnicotinate; d, 5’-phosphoribosyl-ATP; e, 5’-4884 
phosphoribosylanthranilate. The compounds f to k are products of salvage reactions: 4885 
f, AMP; g, inosine 5’-monophosphate; h, xanthosine 5’-monophosphate; i, GMP; j, 4886 
UMP; k, 5’-phosphoribosylnicotinate. 4887 
 4888 
FIG 12 C- and O-glycosidic bond formation with PRPP. The phosphoribosyl donor 4889 
PRPP is shown in red, and atoms derived from PRPP in the intermediates and 4890 
products are also shown in red. (A) Biosynthesis of tetrahydromethanopterin. 4891 
Compounds: l, 4-hydroxybenzoate; m, 5’-phosphate-β-D-ribosyl 4-hydroxybenzene; 4892 
n, 5’-phosphate-β-D-ribosyl 4-aminobenzene; o, N-[(7,8-dihydropterin-6-yl)methyl]-4893 
 202
4-(1-deoxy-D-ribulosyl)aminobenzene; p, 1-(4-{N-[(7,8-dihydropterin-6-4894 
yl)methyl]amino}phenyl)-5-(5-phospho-α-D-ribulosyl)-1-deoxyribitol. Enzyme 1, 4-4895 
aminobenzoate phosphoribosyltransferase (5-phospho-α-D-ribose 1-diphosphate:4-4896 
aminobenzoate 5-phospho-β-D-ribofuranosyltransferase (decarboxylating), EC 4897 
2.4.2.54); enzyme 2, 1-(4-{N-[(7,8-dihydropterin-6-yl)methyl]amino}phenyl)-5-(5-4898 
phospho-α-D-ribulosyl)-1-deoxyribitol synthase. This enzyme activity has not been 4899 
identified. The four reactions leading from compound m to compound n in effect 4900 
convert a hydroxy group to an amino group and involve the the formation of 4901 
phosphate ester and the addition of an aspartyl residue, the removal of Pi and fumarate 4902 
(304). The three reactions leading from compound n to compound o involve the 4903 
attachment of a pterin derivative (R = N-[7,8-dihydropterin-6-yl]methyl) to the 4904 
nitrogen of compound n followed by opening of the ribosyl moiety and isomerization 4905 
to a ribulose derivative and dephosphorylation to form compound o. The boxed 4906 
compound is the product of the pathway, 5,6,7,8-tetrahydromethanopterin (with a 4907 
complete structure of the pteridyl moiety), the active co-factor in transformation of 4908 
carbon dioxide to methane in methanogenic Archaea (301), and is formed form 4909 
compound p by attachment of a glutamyl moiety to the phosphate group followed by 4910 
dehydrogenation of the pteridyl moiety. (B) Biosynthesis of arabinosyl 4911 
monophosphodecaprenol. Compounds: q, decaprenyl phosphate; r, 5-phospho-β-D-4912 
ribosyl 1-O-monophosphodecaprenol (decaprenylphospho-β-D-ribosyl 5-phosphate). 4913 
Enzyme 3: decaprenyl phosphate phosphoribosyltransferase (5-phospho-α-D-ribosyl 4914 
1-diphosphate:decaprenyl-phosphate 5-phosphoribosyltransferase, EC 2.4.2.45). The 4915 
boxed compound is the arabinosyl donor arabinosyl monophosphodecaprenol, which 4916 
is formed from compound r by dephosphorylation of the ester at C5 of the ribosyl 4917 
moiety followed by epimerization. The latter two reactions occur on the outside of the 4918 
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cell (5). (C) Biosynthesis of butirosin. Compounds: s, neamine; t, 5''-4919 
phosphoribostamycin. Enzyme 4: neamine phosphoribosyltransferase. The boxed 4920 
compound is butirosin. Two isomers are synthesized, one contains a ribosyl moiety 4921 
(shown) a second contains an arabinosyl moiety (not shown). Other aminoglycoside 4922 
antibiotics derived from neamine, i.e. neomycin B, paromomycin, and lividomycin B, 4923 
lack the 4-amino-2-hydroxybutyryl side chain but contain an N-acetylaminoglucosyl 4924 
moiety attached to C3’’ of the ribosyl moiety, and the pseudo-disaccharides of the 4925 
three compounds are differently decorated with hydroxyl and amino groups (318). 4926 
 4927 
FIG 13 Mechanism of PRPP-mediated regulation of transcription by PyrR and PurR. 4928 
PyrR and Pur R are shown as orange spheres. (A) Model of PyrR regulation based on 4929 
the combined data from B. subtilis and B. caldolyticus. RNA (green hairpin) binds to 4930 
dimeric PyrR, which is stabilized by UMP, UTP or PRPP. The tetrameric 4931 
conformation is stabilized by GMP, and does not bind RNA. See text for details. (B) 4932 
Model of PurRBs repression. DNA (blue line) containing one strong (solid green line) 4933 
and one weak (green punctuated line) PurBox binds to two PurRBs dimers (forming a 4934 
weak tetramer) in the absence of PRPP. In the presence of PRPP the DNA binding is 4935 
prevented, and the tetramerization is lost. (C) Model of PurRLl activation. PurRLl binds 4936 
to PurBox sequences, irrespectively of PRPP binding, presumably as a dimer. Binding 4937 
of PRPP is hypothesized to expose a binding site for RNA polymerase. RNA 4938 
polymerase is positioned correctly relative to the -10 region of the promoter. 4939 
 4940 
FIG 14 Phylogenetic analysis of PurR from low-GC Gram-positive bacteria. (A) PurR 4941 
sequences from representatives of the major bacterial lineages in the low-GC Gram-4942 
positive bacteria were aligned using the Clustal Omega program, and a phylogenetic 4943 
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tree was constructed using the ClustalW2 Phylogeny program. (B) The type of 4944 
PurBox used by each species was identified at the RegPrecise website 4945 
(http://regprecise.lbl.gov/RegPrecise/collection_tffam.jsp?tffamily_id=53), and the 4946 
two types of logo-plots were constructed from the PurBox sequences presented for the 4947 
Streptococcaleses and Bacciliales, respectively, using the weblogo service 4948 
(http://weblogo.berkeley.edu/logo.cgi). 4949 
 4950 
FIG 15 Common phylogeny of PyrR, PurR, type 1 phosphoribosyltransferases and 4951 
class I PRPP synthases in all major bacterial lineages. Homologous protein sequences 4952 
were deduced and identified from representative genome sequences of all major 4953 
bacterial lineages, for the following proteins: adenine phosphoribosyltransferase 4954 
(APRTase); hypoxanthine-guanine phosphoribosyltransferase (HPRTase); orotate 4955 
phosphoribosyltransferase (OPRTase); uracil phosphoribosyltransferase (UPRTase); 4956 
xanthine phosphoribosyltransferase (XPRTase). The collected sequences were aligned 4957 
using the Clustal Omega program, and a phylogenetic tree was constructed using the 4958 
ClustalW2 Phylogeny program. Left panel, phylogenetic tree with protein sequences 4959 
belonging to same enzyme families grouped together as triangles, starting at the point 4960 
of the first branching of the individual protein sequences and labeled with the enzyme 4961 
abbreviations shown above. The triangle marked OPRTase* is a group of orotate 4962 
phosphoribosyltransferase sequences that appears to form a separate branch with a 4963 
destinct set of amino acid sequences in the PP and PRPP binding loops. Sequences 4964 
with homology to the xanthine phosphoribosyltransferase and PurR proteins were 4965 
only found among the low-GC Gram-positive bacteria, as indicated. Middle panel, 4966 
logo plot of the frequency of amino acids in the PP loop identified in the Clustal 4967 
Omega alignment and constructed using the weblogo service 4968 
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(http://weblogo.berkeley.edu/logo.cgi). Right panel, logo plot of the frequency of 4969 
amino acids in the PRPP binding loop identified in the Clustal Omega alignment and 4970 
constructed using the weblogo service. 4971 
 4972 
FIG 16 Possible secondary structure of the S. enterica prs leader. The sequence ranges 4973 
from nucleotide one, indicated by 5’, to nucleotide 417, which is immediately 4974 
followed by the initiator codon-specifying guanylate-uridylate-guanylate triplet and 4975 
indicated by 3’ (45). The ΔG of the structure is -540 kJ mol-1. The leader prs 4976 
sequences of S. enterica and E. coli are identical except for the framed sequence, 4977 
which is present only in the S. enterica prs leader. The nucleotides circled in red 4978 
represent the coding of a possible leader peptide, the red arrows points to the 4979 
nucleotides of a possible Shine-Dalgarno sequence. Possible leader peptide amino 4980 
sequences are indicated for E. coli and S. enterica. Identical amino acid residues of 4981 
the two possible leader peptides are underlined. 4982 
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TABLE 1 Crystal forms of PRPP synthase and PRPP synthase-associated proteins     4984 
  Resolution  PDB  4985 
Organism Designation Å Ligands code  Reference 4986 
B. subtilis SO42- 2.3 Two SO42- (phosphate of ribose 5-phosphate, α-phosphate of ADP) 1dkr (49) 4987 
 mADP 2.2 AMP (active site), methylene ADP (allosteric site) 1dku (49) 4988 
 Cd2+ 2.8 Two Cd2+ (Mg2+ sites), AMP (active site), SO42- (phosphate of 1ibs (50) 4989 
   ribose 5-phosphate)  4990 
 AlF3 2.0 Two AMP, AlF3, two Mg2+, SO42- (positioned at the α-phosphate  (54) 4991 
   of ADP in the allosteric site). The ATP analog at the active site is 4992 
   pieced together by three molecules: AMP (α-phosphate)-AlF3  4993 
   (β-phosphate)-AMP (γ-phosphate),with the adenosyl moiety  4994 
   protruding into the space between subunits 4995 
 mADP/R5P 2.1 methylene ADP and ribose 5-phosphate (active site), two Mg2+,  (54) 4996 
   SO42- (α-phosphate of ADP in allosteric site) 4997 
 GDP 1.8 Four Mg2+, Ca2+, GDP, GTP, two α,β-methylene ATP, two ribose  (54) 4998 
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   5-phosphate, glycerol 4999 
 mGDP 1.9 Five Mg2+, methylene GDP, three α,β-methylene ATP, two  (54) 5000 
   ribose 5-phosphate, two glycerol 5001 
B. pseudomallei  2.3 None 3dah (53) 5002 
E. coli E. coli PRPPS 2.7 Mg2+ 4s2u (52, 409) 5003 
M. jannaschii Apo 2.7 None 1u9y (48) 5004 
 Ternary 2.9 AMP, ribose 5-phosphate 1u9z (48) 5005 
S. solfataricus  2.8 AMP 4twb (139) 5006 
T. volcanium ADP/SO4 1.5 ADP, SO42- 3lrt (138) 5007 
 ADP/SO4 1.8 ADP, SO42- 3nag (138) 5008 
 mATP/SO4 1.9 mATP, SO42- 3lpn (138) 5009 
 ADP-Mg2+ 1.9 ADP, Mg2+, Pi, ribose 5-phosphate 3mbi (138) 5010 
Human hPRS1wild-typea 2.6 SO42- 2h06 (51) 5011 
 hPRS1ATPSO42-Cda 2.2 AMP, SO42-, Cd2+ 2hcr (51) 5012 
 hPRS1S132Ab 2.2 SO42- 2h07 (51) 5013 
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 hPRS1Y146Mc 2.5 SO42- 2h08 (51) 5014 
 -a 2.6 SO42- 3efh 5015 
 -a 2.0 SO42- 3s5j 5016 
 -d 2.3 Mg2+, SO42- 4f8e (124) 5017 
 PRS1a 2.0 SO42- 3s5j (118) 5018 
 E43Te 3.0 SO42- 4lyg (118) 5019 
 D65Nf 2.1 SO42- 4lzn (118) 5020 
 A87Tg 3.3 SO42- 4LZO (118) 5021 
 M115Th 2.1 SO42- 4M0P (118) 5022 
 Q133Pi 2.7 SO42- 4M0U (118) 5023 
 PAP39j 2.7 SO42- 2c4k 5024 
 PAP41k 2.6  2ji4   5025 
a PRPP synthase isozyme 1. 5026 
b Ser132Ala mutant variant of PRPP synthase isozyme 1. 5027 
c Tyr146Met mutant variant of PRPP synthase isozyme 1. 5028 
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d Asp52His mutant variant of PRPP synthase isozyme 1. 5029 
e Glu43Thr mutant variant of PRPP synthase isozyme 1. 5030 
f Asp65Asn mutant variant of PRPP synthase isozyme 1. 5031 
g Ala87Thr mutant variant of PRPP synthase isozyme 1. 5032 
h Met115Thr mutant variant of PRPP synthase isozyme 1. 5033 
i Gln133Pro mutant variant of PRPP synthase isozyme 1. 5034 
j PRPP synthase-associated protein 39 5035 
k PRPP synthase-associated protein 41 5036 
  5037 
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TABLE 2 Kinetic parameters of PRPP synthases of various organisms  5038 
 PRPP synthase KM (μM)      Vmax or specific activity 5039 
Organism class R5P ATP dATP GTP CTP UTP μmol (min × mg protein)-1 References  5040 
B. subtilis I 480 660     190 (70) 5041 
B. caldolyticus I 530 310     400 (55) 5042 
S. enterica I 160 50     130 (56) 5043 
E. coli I 203 113     181 (57) 5044 
M. tuberculosis I 8.2-71 1-25     1.4-530 (77-79) 5045 
B. amyloliquefaciens I 105 50     37 (149) 5046 
Human isozyme 1 I 52 21     25 (73) 5047 
Human isozyme 2 I 83 70a     36 (73) 5048 
Rat isozyme 1 I 40 44     39 (71) 5049 
Rat isozyme 2 I 73 60     35 (71) 5050 
Rat, liver enzyme I 64 49     16 (143) 5051 
S. oleracea, isozyme 3 II 110 170 233 650 116 137 13.1b (46) 5052 
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S. oleracea, isozyme 4 II 48 7 84 490 680 500 16.2c (47) 5053 
M jannaschii Archaea 2800 2600     2200 (48) 5054 
T. kodakaraensis Archaea       182 (140)  5055 
a S0.5 value. 5056 
b Values varied between 1.2 and 6.9 with GTP, CTP or UTP as the diphosphoryl donor. 5057 
c Values varied between 4.2 and 6.6 with GTP, CTP or UTP as the diphosphoryl donor. 5058 
 5059 
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TABLE 3 Comparison of amino acid residues involved in dimer association of B. 5060 
subtilis PRPP synthase with amino acids of PRPP synthase of other organismsa  5061 
  M. tuber- Spinach M. janna- T. volca- S. solfa- 5062 
B. subtilis E. coli culosis isozyme 4 schii nium taricus  5063 
Bent dimer (B. subtilis PRPP synthase, N-terminal domain interactions) 5064 
N69 N64 N72 I73 N60 E61 D61 5065 
E70 D65 R73 F74 D61 V62 K62 5066 
I72 L67 L75 Q76 I63 E64 L64 5067 
M73 M68 M76 L77 V64 M65 I65 5068 
L76 L70 L79 I80 I67 T68 F68 5069 
I77 V72 I80 Y81 L68 L69 L69 5070 
L116 V112 L119 L122 A107 I106 T108 5071 
L120 F116 L123 V127 I111 I110 I112 5072 
 5073 
Parallel dimer (B. subtilis PRPP synthase, N- and C-terminal domain interactions) 5074 
K115 K111 R118 R120 R106 Q105 K107 5075 
Q138 Q134 Q141 Q144 H128 T128 E130 5076 
I139 I135 I142 E145 I129 L129 E131 5077 
F142 F138 F145 F139 F132 S132 Y134 5078 
D144 D140 D147 S150 T134 V144 K136 5079 
V178 V174 V182 G185 V167 L165 L169 5080 
D186 K182 D190 Q183 K175 A173 E177 5081 
I192 M189 L197 M199 Y181 H179 Y183 5082 
A193 A190 A198 V200 D182 F180 S184 5083 
I194 I192 F199 V201 Y183 F181 Y185 5084 
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R198 R195 R201 V205 T187 K185 E189 5085 
V211 I208 V218 E207 T200 N198 A202  5086 
        5087 
a The annotated amino acid residues involved in the formation of the two types of 5088 
dimer (bent and parallel, see text for details) of B. subtilis PRPP synthase are listed at 5089 
the left-hand column according to the previously published three-dimensional 5090 
structure (49). The B. subtilis PRPP synthase amino acid sequence was then aligned 5091 
pairwise with the amino acid sequences of PRPP synthases of E. coli (accession 5092 
U00096) (313); M. tuberculosis (accession AL123456) (410); S. oleracea isozyme 4 5093 
(15); M. jannaschii (accession L77117) (411); T. volcanium GSS1 (accession 5094 
BA000011) (412) and S. solfataricus P2 (accession AE006641) (413), and amino acid 5095 
residues at similar positions of PRPP synthases of these latter six organisms are listed 5096 
in the other columns. Amino acid residues that are identical or conserved relative to 5097 
the B. subtilis enzyme are shown in bold, whereas non-conserved residues are shown 5098 
in red. 5099 
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TABLE 4 Human PRPP synthase isozyme 1 variantsa   5101 
Amino acid Homologous position in  Reference 5102 
alteration B. subtilis PRPP synthase Enzyme property   5103 
Increased activityb 5104 
Asp51His Asp57 Reduced inhibition by ADP, increased stimulation by Pi (72) 5105 
Asn113Ser Asn119 Reduced inhibition by ADP, increased stimulation by Pi (72) 5106 
Leu128Ile Leu134 Reduced inhibition by ADP, increased stimulation by Pi (72) 5107 
Asp182His Asp186 Reduced inhibition by ADP, increased stimulation by Pi (72) 5108 
Ala189Val Ala193 Reduced inhibition by ADP, increased stimulation by Pi (72) 5109 
His192Leu Asp196 Reduced inhibition by ADP, increased stimulation by Pi, reduced stability (72, 123) 5110 
 5111 
Reduced activity 5112 
Glu42Asp Asn48 Not characterized (120) 5113 
Asp64Asn Glu70 Reduced specific activity in crude erythrocyte extract (121) 5114 
Ala86Thr Ile92 Reduced specific activity in crude erythrocyte extract (121) 5115 
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Met114Thr L119 Reduced specific actitivy in crude fibroblast extract (120) 5116 
Gln132Pro Gln138 Reduced specific activity in crude erythrocyte and fibroblast extracts (122) 5117 
Val141Leu Ile147 Reduced activation by Pi (414) 5118 
Leu151Pro Leu156 Reduced specific activity in crude erythrocyte and fibroblast extracts (122) 5119 
Ile289Thr Ser293 Reduced specific activity in crude erythrocyte extract (121) 5120 
Gly305Arg Gln308 Reduced specific activity in crude erythrocyte extract (121) 5121 
 5122 
Acute lumphoblastic leukemia relapse-specificc 5123 
Val52Ala Cys58  (148) 5124 
Ile71Val Ile77  (148) 5125 
Cys76Ser Leu82  (148) 5126 
Ser102Asn Ser108  (148) 5127 
Asn113Asp Asn119  (148) 5128 
Asp138Gly Asp144  (148) 5129 
Asn143Ser Asp148  (148) 5130 
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Gly173Glu Gly177  (148) 5131 
Lys175Asn Thr179  (148) 5132 
Asp182Glu Asp186  (148) 5133 
Ala189Thr/Val Ala193  (148) 5134 
Leu190Ile Ile194  (148) 5135 
Thr302Ser Val305  (148) 5136 
Tyr310Cys Tyr313  (148) 5137 
a Amino acid residues are numbered from the N-terminal proline residue, as the original N-terminal methionine is removed in the mature protein 5138 
(72). 5139 
b A comprehensive review of the various deseases caused by mutations in the human PRPP synthase isozyme 1-encoding gene has been 5140 
published previously (415). 5141 
c Relapse-specific PRPP synthase variants have not been characterized enzymatically. 5142 
 5143 
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 5144 
TABLE 5 PRPP pool sizes in various bacterial species   5145 
   PRPP pool size 5146 
Bacterial species Purine added (mmol [g dry weight]-1) Reference 5147 
B. subtilis None 1.1 ±0.1 (357) 5148 
  Adenine 0.6a (357) 5149 
L. lactis None 2.6 ±0.6 (416) 5150 
  Hypoxanthine 0.7 ±0.2 (416) 5151 
E. coli None 4.4 (417) 5152 
  Hypoxanthine 1.2 (417) 5153 
S. enterica None 1.2 (36) 5154 
  Hypoxanthine 0.3 (36)  5155 
a No repression observed by hypoxanthine. 5156 
 5157 
















